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High HIV viral diversity, even within a particular subtype, makes vaccine design 
strategies an enormously challenging task.  Furthermore, host responses that define 
correlates of protection are poorly understood. Through the characterization of full-length 
viral genomes from individuals recently infected with subtype C, this thesis investigates 
the potential effect of viral diversity on vaccine effectiveness.  In addition, through 
characterizing the transmitted virus and its early evolution we shed light on early events 
associated with control of viral replication. 
HIV-1 subtype C accounts for 50% of all HIV-1 infections world-wide and for 
approximately 95% of infections in South Africa.  In this study we characterized samples 
from the CAPRISA acute infection study which recruits individuals within 3 months of 
infection and monitors their disease progression.  Characterisation of near full-length 
subtype C genomes from 23 individuals with primary infection showed that there was no 
evidence of a primary infection transmission network, however a comprehensive analysis 
of all sequences available from South Africa showed for the first time a number of 
supported clusters indicative of epidemiological linkage.   We determined the potential of 
candidate vaccines tested in South Africa (Merck/Ad5, SAAVI-C and the mosaic 
candidate immunogens) to induce cytotoxic T cell responses against primary infection 
strains using a tool which determines the epitope coverage. As expected, the subtype C 
consensus-based SAAVI immunogen provided 4 – 20% better epitope coverage than the 
subtype B derived Merck immunogen. However the recombination-derived mosaic 
immunogens were markedly better compared to the other vaccine candidates providing 
20-30% increased coverage. 
It is unresolved whether recently transmitted HIV has genetic features that 
specifically favour transmissibility. To identify potential “transmission signatures”, we 
compared 20 full-length HIV-1 subtype C genomes from primary infections, with 66 
sampled from ethnically and geographically matched individuals with chronic infections.  
Controlling for recombination and phylogenetic relatedness, we identified 39 sites at 












sites were predominantly located within Env, Pol and Gag (14/39, 9/39 and 6/39 
respectively) and were significantly clustered (33/39) within known immunoreactive 
peptides.  Within 6 months of infection we detected reversion-to-consensus mutations at 
14 of the sites and potential CTL escape mutations at seven sites.  Here we provide 
evidence that frequent reversion mutations probably allows the virus to recover 
replicative fitness which, together with immune escape driven by the HLA alleles of the 
new hosts, differentiate sequences from chronic infections from those sampled shortly 
after transmission. 
Finally, we investigated the role of the adaptive immune responses on viral 
evolution during early infection. For 11 participants we had at least three full-length 
genomes derived longitudinally within the first six months of infection. We showed that 
early CTL escape across the proteome is not associated disease progression. However, 
viral diversification (p = 0.0239), reversion (p = 0.0084) and APOBEC-induced (p = 
0.0011) mutations were significantly associated with lower CD4+ T cell counts. A more 
detailed analysis of a slow and rapid progressor showed that viruses from the rapid 
progressor experienced more positive selective pressure, and more frequent early CTL 
escape compared to the slow progressor.  In the rapid progressor, escape was associated 
with a complex or shuffling escape patterns in 50% of epitopes.  
In conclusion, this study elucidated characteristics of subtype C viruses from the 
primary infection phase and the role of early viral evolution and adaptive immune 
responses in the initial viral control. We show that genetic features of viruses in early 
infection are defined by HLA-associated immune adaptation and that regaining of 
replicative fitness through reversion to wild-type amino acids is the key driver of early 
viral evolution. We also showed that the candidate SAAVI-C immunogen are predicted to 
provide better CTL epitope coverage against subtype C infections than the subtype-
mismatched subtype B Merck/Ad5 immunogen. However, the mosaic immunogens in 
preclinical development is superior in predicted epitope coverage to both the 
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ADCC    Antibody-dependent cellular cytotoxicity 
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1.1 HISTORY ON THE ORIGIN OF HIV/AIDS 
 
Acquired Immunodeficiency Syndrome (AIDS) was first described in 1981 after 
the identification of Pneumocystis carinii pneumonia in previously healthy homosexual 
men in the United States of America (USA) (MMWR 30, 1981; MMWR 31, 1981; 
Gottlieb et al., 1981; Masur et al., 1982).  Human immunodeficiency Virus type 1 (HIV-
1), initially called Lymphadenopathy-associated virus (LAV) or Human T lymphotropic 
virus type III (HTLV-III), was subsequently identified as the aetiologic agent of AIDS by 
two independent research groups in France and the USA in 1983 and 1984 respectively 
(Barre-Sinoussi et al., 1983; Groopman et al., 1984). 
 
The earliest clinical evidence of HIV-1 infection comes from samples collected in 
1959 (Kinshasa male, Zhu et al., 1998) and 1971 to 1976 (Norwegian sailor, Froland et 
al., 1988).  The identification of the second HIV-1 positive sample from Kinshasa 
collected in 1960 whose viruses differed by as much as 11.7% in the env gene from the 
1959 strain suggested that HIV had already been diversifying in humans for a number of 
years before 1960 (Gao et al., 2001; Worobey et al., 2008).  Based on this data, the latest 
introduction of HIV into humans was dated to around 1900 (1902 to 1921), 20 years 
earlier than previously estimated (Korber et al., 2000; Worobey et al., 2008).  Although 
the origin of HIV-1 has been a topic of extensive debate in the past (Gao et al., 1999; 
Poinar et al., 2001; Worobey et al., 2004), recent studies have provided substantial 
evidence to show that HIV originated in chimpanzees (Keele et al., 2006).  The zoonotic 
transfer of a SIVcpz strain is thought to have occurred through blood from non-human 
primates during hunting, butchering and handling of uncooked contaminated meat (Gao 
et al., 1999; Courgnaud et al., 2002; Peeters et al., 2002; Bibollet-Ruche et al., 2004).  












in the HIV-1 M, N and O groups (Figure 1.1) (Keele et al., 2006, Sharp et al., 2001; 
Yang et al. 2000; Roques et al., 2004).  Interestingly, the N group virus YBF30 displays 
characteristics of recombination between SIVcpz and HIV-1 which further support a 
common ancestral origin (Yang et al., 2000; Roques et al., 2004).  Investigators have 
found evidence of an O-like virus in gorillas (SIVgor) suggesting that either gorillas were 
the origin of Group O in humans or that both humans or gorillas were infected from a 
common chimpanzee source (van Heuverswyn et al., 2006; Takehisa et al., 2009).  
However, recently a virus from a Cameroonian women was identified which grouped 
with the SIVgor sequences suggesting a fourth zoonotic transmission.  It is proposed that 
this fourth lineage is called the HIV-1 P group, pending identification of further evidence 







Figure 1.1 A phylogenetic tree of partial Pol amino acid sequences showing evolutionary relationships 
between M, N, O group HIV-1 viruses infecting humans and SIV strains from chimpanzees and gorillas, as 













1.2 HIV-1 VIRION STRUCTURE AND GENOMIC ORGANIZATION 
 
The HIV virion is about 110-145 nanometers (nm) in diameter and has a roughly 
spherical host cell-derived membrane studded with the transmembrane (TM, gp41) and 
surface units (SU, gp120) of the envelope glycoprotein translated as the gp160 precursor.  
The envelope also contains other cellular proteins derived from the host during budding 
(Haseltine et al., 1991; Briggs et al., 2003).  Below the host-derived membrane is a dense 
protein layer formed by the matrix protein (Gag p17) which surrounds the complex 
capsid (p24) that are either cone-shaped or cylindrical with the ends in close contact with 
the membrane (Briggs et al., 2003).  Inside the capsid the nucleocapsid (p7) enfolds 2 
copies of the viral single stranded (ss) positive sense RNA genome (Haseltine et al., 
1991; Cohen et al., 2008).  Viral enzymes encoded by the pol gene include integrase (IN) 
and reverse transcriptase (RT) and protease (PR) is encoded by the pro gene 
(http://phene.cpmc.columbia.edu/7thReport/7th Report of ICTV/ sites/descriptions/ 
Retroviridae/lentivirus.htm).  The positive strand RNA genome has untranslated regions 
called R-U5 and U3-R at the 5’- and 3’-ends respectively.  The complete HIV-1 provirus 
genome organization is shown in Figure 1.2 and a comprehensive list of the encoded viral 






Figure 1.2 Genomic organization of HIV-1 with genes and the open reading frames (Frame 1, 2 and 3) 

















Table 1.1 HIV-1 encoded proteins and their functions 
Protein Size (kDa) Function and properties 
Gag p24 Structural capsid protein 
Gag p17 Myristoylated matrix protein 
Gag p7 Nucleocapsid protein, helps in reverse transcription 
Gag p6 L domain involved in budding 
Pro p10 (PR) Posttranslational processing of viral proteins, Gag/Pol cleavage and maturation 
Pol p66, p51 (RT) Reverse transcription 
Pol  p15 (RNase H) RNase H activity, removes RNA from DNA-RNA hybrids 
Pol  p32 (IN) DNA provirus integration requires integrase (IN) 
Env gp120 Envelope surface protein (SU : surface unit) 
Env gp41 Envelope transmembrane (TM) protein 
Tat  p14 Transactivation, not virion-associated 
Rev p19 Regulation of viral mRNA expression, not virion-associated 
Nef p27 Can increase or decrease virus replication, MHC and CD4 down regulation 
Vif  p23 Increases virus infectivity and cell-to-cell transmission, helps in proviral DNA synthesis 
and/or in virion assembly 
Vpr p15 Helps in virus replication, transactivation 
Vpu p16 Helps in virus release, disrupts gp160-CD4 complexes, not virion-associated 
Adapted from Cohen et al., 2008 
1.3 GENETIC DIVERSITY OF HIV-1 
High genetic diversity is a well recognized characteristic of HIV with intra-person 
variation in long-term nonprogressors with chronic infection differing by as much as 15% 
in env (Shankarappa et al., 1999).  This diversity of viral populations within an individual 
is described by the term quasispecies.  A quasispecies describes a large and complex 
population of genetically diverse but related genomes that act as a whole (Goodenow et 
al., 1989).  Each individual genome only has a short-lived existence which is subject to 
natural selection.  A quasispecies (swarm) is inherently unstable and although variant 
genomes may at any one moment be at equilibrium with respect to selective pressures, it 
can easily shift if more advantageous mutants appear (Goodenow et al., 1989; Novak et 
al., 1990).  However, the most-fit variant is not always favored but is subjected to the 
properties of the rest of the swarm and the host environment (Nowak et al., 1990). 
Reverse transcription, mediated by the viral reverse transcriptase, results in the 
generation of double stranded (ds) DNA from the viral RNA genome.   Characteristic of 














Figure 1.3 Schematic diagrams for reverse transcription of HIV-1 genomic RNA for integration into 
cellular DNA (proviruses) (Kostrikis et al., 2002). 
 
switching steps that ultimately result in a DNA provirus with two direct repeats called the 
long terminal repeat  (LTR) regions (van Wamel & Berkhout, 1998).  The first copy 
DNA (cDNA) strand transfer process can involve the first strand from the duplicate RNA 
copy (termed intra-molecular strand transfer) or the first strand from another viral RNA 
genome (inter-molecular strand transfer) which would result in a recombinant genome 
during dual infections (van Wamel & Berkhout, 1998).  The high degree of genetic 












proofreading ability and its ability to extend a mismatched primer on a DNA or RNA 
template.  Reverse transcriptase has an estimated error rate of 2.16 x 10-5 (Mansky & 
Temin, 1995).  Given that the estimated HIV generation time is approximately 2 days 
(Markowitz et al., 2003), and with a reproductive ratio of 6 (Stafford et al., 2000), the 
virus has a great ability to diversify over time.  Thus high replication rates coupled with 
the error prone nature of the RT results in massive viral diversification over time.  HIV-1 
env gene diversifies at an estimated rate of approximately 1% per year (Shankarappa et 
al., 1999; Herbeck et al., 2006). 
 
A second major mechanism that the virus uses to diversify is through 
recombination (Figure 1.4).  A key feature of HIV-1 replication is strand-switching 
(Figure 1.3) which results in recombination between the two viral RNA copies from 
different variants infecting the same cell (Figure 1.4) (Haseltine, 1991; van Wamel & 
Berkhout, 1998; Katzenstein, 2006).  Recombination allows the virus to make shifts in 
viral sequence by acquiring large pieces of sequences from other viruses co-infecting the 
same cell.  HIV recombination occurs frequently during replication and some studies 
have suggested that there can be as many as 9 recombination events per virus replication 
cycle in T cells and up to ~30 in macrophages (Levy et al., 2004).  The error-prone nature 
of reverse transcriptase together with recombination enables the virus to rapidly respond 
to selective pressures within the host. 
 
Cellular apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G 
(APOBEC3G) activity was identified as another mechanism that increases viral diversity 
and  has  also  been  implicated  in  the  development  of   antiretroviral  drug  resistance 
mutations (Jern et al., 2009) as well as CTL escape (Wood et al., 2009).  APOBEC3G is 
a cytidine deaminase which is effective at limiting retroviral infections (Harris et al., 
2003; Zhang et al., 2003).  Through this mechanism cytosines (C) from newly 
synthesized minus-strand viral DNA are modified to uracils (U) and presents as G>A 
transitions present in high frequency in the viral genome (G>A hypermutation) (Harris et 
al., 2003; Zhang et al., 2003, Yu et al., 2003).  However HIV-1 like all other primate 












forms an ubiquitin-ligase complex with cellular proteins which then bind to APOBEC3G 
and thereby target it for degradation (Sheehy et al., 2003; Yu et al., 2003; 2004). 
A recent study showed that APOBEC3G–induced mutations are found at a 
frequency of 73% in proviral DNA, 17% in intracellular viral RNA and 5% in viral RNA. 
The low frequency in viral RNA is thought to be the result of strong selection against the 
incorporation of defective genomes (hypermutated genomes) into virus progeny (Russell 
et al., 2009).  Proviral DNA hypermutation was recently shown to be associated with 
higher CD4 counts (Land et al., 2008). 
Figure 1.4 Schematic diagram showing dual infection of a single cell with 2 distinct HIV-1 variants 
followed by viral replication and packaging of 2 distinct vRNA copies per virion and subsequent 












1.4 THE GLOBAL DISTRIBUTION OF HIV-1 STRAINS 
 
HIV-1 is classified into Group M, N and O with the Group M viruses responsible 
for the global pandemic (Figure 1.5) as well as the recently described group P (see 1.1).  
Based on phylogenetic relationships Group M sequences have been classified into 9 
subtypes with 6 sub-subtypes (subtypes A-D, F-H, J and K; sub-subtypes A1-A4, F1 and 






Figure 1.5 Unrooted Maximum Likelihood trees for the gag, pol and env genes showing the phylogenetic 













strains have recombined to form mosaic viruses that are successfully transmitted at high 
frequency and those reported in at least three epidemiologically unlinked cases are called 
circulating recombinant forms (CRFs). 
   
There has been a dramatic increase in the number of CRFs described from 16 in 
2005/ 2006 (Lal et al., 2005; McCutchan, 2006) to 43 in 2009 (Table 1.2) (http:// 
www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/nomenclature/Nomen.html, Taylor 
et al., 2008; http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes.html).  The 
importance of CRFs in the global HIV-1 epidemic is highlighted by its association with 
epidemics in intraveneous drug users (IDUs) in Asia (CRF01_AE, CRF07_BC and 
CRF08_BC), the former Soviet Union (CRF03_AB), Spain and Portugal (CRF14_BG) 
and in Afghanistan and Iran (CRF35_AD) (Thomson et al., 2002; Taylor et al., 2008).  In 
addition, CRF02_AG is responsible for the majority of infections in Nigeria, and 
dominates in the West African region (Figure 1.6). 
 
All the different HIV-1 subtypes (M group) and CRFs (excluding those associated 
with sentinel IDU epidemics) as well as N and O group viruses are found in Africa.  At 
least six strains account for the majority of HIV-1 infections world-wide namely subtypes 
A, B, C, D, CRF01_AE and CRF02_AG;  and in  most  geographic  regions outside  
Africa  only  one  or  two  HIV-1  subtypes co-circulates with one usually dominating the 
epidemic (Figure 1.6) (Thomson et al., 2002; Lal et al., 2005; McCutchan, 2006).  The 
most prevalent subtypes circulating in West Africa are subtypes A, G, CRF02_AG as 
well as other recombinant forms.  Subtypes A and D, as well as multiple recombinant 
forms are also found at high frequency in East Africa. 
 
Subtype B is responsible for most of the epidemics in the developed world 
including the Americas, Western Europe and Australia, while HIV-1 subtype A is highly 
prevalent in former Soviet Republics.  The CRF01_AE circulates predominantly in 
Southeast  Asia as  well  as  subtype C which  accounts  for more  than 50%  of all HIV-1 
infections world-wide.  This subtype is found at high prevalence in Southern Africa 












Table 1.2 List of circulating recombinant forms (CRFs) documented in June 2009 (from 
http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes.html). 
 
Name Reference strain Subtypes Author 
CRF01_AE CM240 A, E J.K. Carr 
CRF02_AG IbNG A, G J.K. Carr 
CRF03_AB Kal153 A, B K. Liitsola 
CRF04_cpx 94CY032 A, G, H, K, U D. Paraskevis 
CRF05_DF VI1310 D, F T. Laukkanen 
CRF06_cpx BFP90 A, G, J, K R. B. Oelrichs 
CRF07_BC CN54 B', C R. Wagner 
CRF08_BC GX-6F B', C F.E. McCutchan 
CRF09_cpx 96GH2911 A, G, U F.E. McCutchan 
CRF10_CD TZBF061 C, D I.N. Koulinska 
CRF11_cpx GR17 A, CRF01, G, J M. Peeters 
CRF12_BF ARMA159 B, F J.K. Carr 
CRF13_cpx 96CM-1849 A, CRF01, G, J, U K. Wilbe 
CRF14_BG X397 B, G R. Najera 
CRF15_01B 99TH.MU2079 CRF01, B F.E. McCutchan 
CRF16_A2D 97KR004 A2, D U. Visawapoka 
CRF17_BF ARMA038 B, F J.K. Carr 
CRF18_cpx CU76 A1, F, G, H, K, U M. Thomson 
CRF19_cpx CU7 A1, D, G M. Thomson 
CRF20_BG Cu103 B, G M. Thomson 
CRF21_A2D 99KE_KER2003 A2, D F.E. McCutchan 
CRF22_01A1 CM001BBY CRF01, A1 J.K. Carr 
CRF23_BG CB118 B, G M. Thomson 
CRF24_BG CB378 B, G M. Thomson 
CRF25_cpx 02CM_1918LE A, G, U J.K. Carr 
CRF26_AU MBTB047 A, U M. Peeters 
CRF27_cpx 04FR-KZS A, E, G, H, J, K, U M. Peeters 
CRF28_BF BREPM12609 B, F R. Diaz 
CRF29_BF BREPM16704 B, F R. Diaz 
CRF30_0206 NE36 CRF02, CRF06 M. Peeters 
CRF31_BC 04BR142 B, C M. Soares 
CRF32_06A1 EE0369 CRF06, A1 M. Adojaan 
CRF33_01B 05MYKL007 CRF01, B K.P. Ng & K.K. Tee 
CRF34_01B OUR2275P CRF01, B F.E. McCutchan 
CRF35_AD AF095 A, D F.E. McCutchan 
CRF36_cpx NYU830 A, G, CRF01, CRF02 R. Powell 
CRF37_cpx NYU926 A, G, CRF01, CRF02, U R. Powell 
CRF38_BF GDJE B, F C. Lopez-Galindez 
CRF39_BF 03BRRJ103 B, F M.G. Morgado 
CRF40_BF 05BRRJ055 B, F M.G. Morgado 
CRF41_CD CO6650V1 C, D S. Tovanabutra 
CRF42_BF luBF_13_05 B, F1 J-C. Schmit 












Figure 1.6 The global distribution of HIV-1 subtypes, circulating recombinant forms (CRFs, are numbered) 
and other recombinant forms (RFs) (Woodman & Williamson, 2009). 
1.5 THE HIV-1 EPIDEMIC IN SOUTH AFRICA 
The first cases of AIDS in South Africa were reported in 1983 and involved two 
homosexual male flight attendants who visited the USA during the course of their duty 
(Ras et al., 1983).  In the early 1990s, HIV started to increase in prevalence in the 
heterosexual population.  In 1990 there was a prevalence of 0.7% in women attending 
antenatal clinics which increased to 29.4% in 2007, making South Africa one of the 
hardest hit countries globally (National HIV and Syphilis Prevalence survey, South 
Africa, 2007; Dorrington & Bourne, 2008).  Studies showed that the early epidemic 












while the later heterosexual epidemic was associated with subtype C (Dietrich et al., 
1993; Engelbrecht et al., 1995; Williamson et al., 1995; van Harmelen et al., 1997; 
Bredell et al., 1998; van Harmelen et al., 1999).  HIV-1 subtype C is responsible for over 
95% of infections in South Africa (van Harmelen et al., 1999; Bredell et al. 2007).  A low 
frequency of subtypes like A, D, B, G and F1 and even some recombinants has also been 
reported (van Harmelen et al., 1997; Papathanasopoulos et al., 2002; Bredell et al., 2002; 
Engelbrecht et al., 2005; Loxton et al., 2005; Wilkinson & Engelbrecht, 2009). 
 
 
1.6 HIV-1 INFECTION AND PATHOGENESIS 
 
1.6.1 Natural History of Disease 
 
Early studies based on large HIV-1 subtype B infected cohorts showed that CD4 
T cell counts were predictive of disease progression (Mellors et al., 1997; de Wolf et al., 
1997).  They subsequently showed that viral loads were also highly predictive of disease 
outcome (Vlahov et al., 1998; Lyles et al., 2000; Arduino et al. 2001, Giorgi et al., 2002). 
The disease profile of HIV-1 infection can be divided into three stages namely: (i) 
primary infection, (ii) asymptomatic infection, and (iii) AIDS.  The nomenclature of the 
early stage following infection has not been standardized.   For the purpose of this thesis 
we will be use the term primary infection to describe the first 3 months following 
infection, and acute infection phase will be used to refer to the earliest stage of primary 
infection prior to the development of virus specific antibody responses. 
  
HIV primary infection is often accompanied by a flu-like illness however it may 
also be completely asymptomatic.  The severity of symptomatic primary infection has 
been associated with higher viral loads both during primary infection and at 12 months 
post infection (Schacker et al., 1998; Kelley et al., 2007).  High plasma viral loads and a 
decline in CD4 T cells are characteristic of this stage.  During primary infection, the 
decline in viral load occurs at the same time as the increase in HIV-specific cellular 












set-point.  This decrease in viral load heralds the beginning of the asymptomatic or 
“clinical latency” stage which can last for as long as ten years or more.  AIDS refers to 
the stage whereby there is an appearance of symptomatic disease and is associated with a 
loss in CD4 T lymphocytes to a critical level of <200 cells/mm3 with a concomitant 
increase in viral load levels (Gange et al., 2001). 
   
There is great variation in the rate of disease progression between individuals 
(Figure 1.7).  Factors affecting the rate of disease progression include Gag-specific T 
helper and cytotoxic T cell responses, the virus inoculum, viral fitness as well as host 
genetic factors (Saah et al., 1998; Ioannidis et al., 1999; Edwards et al., 2002; Troyer et 
al., 2005, Brumme et al., 2008; Muira et al., 2009a; Muira et al., 2009b).  About 10% of 
adults develop AIDS within 2 to 3 years of infection and are referred to as rapid 
progressors (Wang et al., 2000).  A small proportion of HIV-1 infected adults (5%-10%) 
remains asymptomatic for more than ten years and is called nonprogressors (NPs) or 
long-term nonprogressors (LTNPs).  These LTNPs have stable CD4 T cell counts and 
low (controllers) or undetectable (elite controllers) viral loads (Figure 1.7) (Wang et al., 
2000; Kaur & Mehra, 2009).  The majority of HIV-infected individuals have a clinical 
course that is highly variable.  Most studies describing the rates of disease progression 
were determined before highly active antiretroviral treatment (HAART) became readily 
available (Kaur & Mehra, 2009).  Anti-retroviral treatment is now widely available across 
the world to interrupt or slow disease progression.  At the time of this study, the 
recommended treatment criteria in South Africa requires CD4 counts below 200 





Successful infection of a new host through sexual contact is estimated to occur at 
a frequency of approximately 1 in 1000 exposures although risk factors such as ulcerative 
genital  disease and  HIV disease  stage can  increase  this to as  high  as 3 in 100  and in 












Figure 1.7 Shows variability in disease progression after HIV-1 infection (from Kaur & Mehra, 2009). 
Transmission has been associated with a viral load in the donor of over 1500 viral RNA 
copies/ml of blood (Quinn et al., 2000). 
The mucosal barrier is an important mechanical barrier that the virus needs to 
bypass to establish infection.  It has long been known that there is a viral population 
bottleneck associated with transmission with recently infected individuals usually 
harbouring a highly homogeneous viral population (McNearney et al., 1992; Wolfs et al., 
1992; Delwart et al., 2002).  Recent studies using single genome amplification (SGA) 
have more accurately characterized this bottleneck through predicting the sequence of the 
founder virus(es) and quantitating the number of infecting variants (Keele et al., 2008; 
Abrahams et al., 2009; Haaland et al., 2009).  SGA enables representative sampling, as 
well as reducing the chances of in vitro recombination through template switching. 
Direct sequencing instead of cloning also reduces the sequence errors due to Taq 
polymerase induced substitutions.  Sequences generated from SGAs thus give a true 
reflection of quasispecies present in vivo (Salazar-Gonzalez et al., 2008). 
Studies based predominantly on subtype B and subtype C sexual transmissions 












(homogeneous infection) (Keele et al., 2008; Abrahams et al., 2009; Haaland et al., 
2009).  However questions remain on the possible clonal outgrowth of a more fit viral 
variant during the first few days post infection as animal studies had shown the 
establishment of infection by multiple genetic variants and subsequent outgrowth of a 
single variant (Miller et al., 2005; Zhang et al., 1999).  Prior infection with other 
pathogens, especially those causing ulcerative lesions, has been associated with a higher 
frequency of multiple HIV-1 variant, suggesting that mucosal inflammation compromises 
the mucosal barrier which in turns affects the genetic bottleneck (Kampinga et al., 1997; 
Long et al., 2000; Sagar et al., 2003; Haaland et al., 2009).  This implies that the mucosal 
barrier is in part responsible for this bottleneck.  In addition, it is clinically important as 
high diversity following transmission has been associated with more rapid disease 
progression (Sagar et al., 2003; Grobler et al., 2004; Gottlieb et al., 2004). 
 
HIV-1 is thought to cross the mucosal barrier in several ways:  particles may be 
captured by dendritic cells (DCs); may directly cross by transcytosis; or by infecting 
intraepithelial lymphocytes (Figure 1.8) (Haase & Pope, 2003).  After crossing the 
mucosal barrier, HIV-1 infects resting and activated CD4 T cells, DCs and macrophages 
in the submucosa.  Following local replication, it is thought that the virus seeds the 
lymphatic system from  where it migrates to the  gut-associated T  lymphocytes (GALT) 
where it rapidly replicates and destroy CD4 T cells (Brenchley et al., 2004; Mehandru et 
al., 2004).  From the GALT, the virus disseminates to the lymphoid organs which also 
serve as viral reservoirs during clinical latency (Guadalupe et al., 2003; Mehandru et al., 
2004;  Haase & Pope, 2003). 
 
During this time of viral dissemination the latent viral reservoirs are established. 
The virus enters cells by firstly binding the CD4 receptor with its envelope glycoprotein 
which induces a structural transformation in the viral envelope to expose the binding site 
for the second receptor.  At the mucosal membranes HIV-1 variants that preferentially 
use the CCR5 chemokine coreceptor (R5 tropic viruses) infect DCs, T lymphocytes and 
macrophages.  These cells  express  both  the  CD4 receptor and the CCR5 coreceptor on 













Figure 1.8 Diagram showing HIV-1 infection through the mucosal membrane using (1) dendritic cells, (2) 
transcytosis and (3) intraepithelial lymphocytes followed by local replication, systemic dissemination and 
establishing the lymphatic tissue reservoir (adapted from Haase & Pope, 2003). 
 
 
chemokine receptor being the major alternative receptor which is often associated with 
viruses in late disease stage (X4 tropic viruses).  Binding to the second receptor is needed 
to complete envelope transformation and membrane fusion to internalize the virus (Kozak 
et al., 1997; Rizzuto et al., 1998). 
 
 
1.7 THE TRANSMITTED VIRUS 
 
The primate model of SIV infection demonstrated that the virus, after localized 
replication in the submucosa, spread to the GALT where it establishes productive 
infection within days after transmission to a new host (Veazey et al., 1998).  Thus the 
best opportunity to prevent infection through vaccination or other prevention 
technologies will be within the first few days post infection before spread to the lymphoid 












& Shattock, 2008). 
 
As vaccines and microbicides need to protect against the transmitted virus, there 
is great interest by researchers to identify and characterize the earliest transmitted HIV-1 
variants.  Some of the first reports suggested that there are specific signatures associated 
with transmission.  The first characteristic is the predominant selection of CCR5-tropic 
variants (Deng et al., 1996); these are almost always associated with transmission, even if 
the donor harbored predominantly X4 viruses (Wolinsky et al., 1992; van’t Wout et al., 
1994).  Further evidence of the role of CCR5 in transmission is that individuals who do 
not have functional CCR5 receptors are largely resistant to infection (Liu et al., 1996, 
Huang et al., 1996; Lucotte, 2002).  A study of primary infection viral envelope 
glycoproteins sampled from a subtype C acute infection cohort showed different selection 
pressures in acute infection compared to those from chronic infection viruses (Bandawe 
et al., 2008).  Furthermore, studies of donor recipient transmission pairs have shown that 
biological  properties differ:  subtype C viruses in  recently   infected   individuals  were 
shown to have a shorter variable loops in envelope and were more neutralization sensitive 





Figure 1.9 This diagram shows the time course of HIV-1 infection and indicating the window of 












subtype A envelope sequences  also  suggested  that  subtype  A viruses  from  early 
infection had shorter V1V2loops and fewer N-linked glycosylation sites than those from 
chronic infection (Chohan et al., 2005).  Furthermore, envelope glycoprotein variable 
loop lengths have been shown to increase over time and this increase has been associated 
with escape from neutralizing antibody responses (Sagar et al., 2006; Rong et al., 2007). 
Potent autologous neutralizing responses were reported in early infection with HIV-1 
subtype C and the magnitude of these responses were dependent on variable loop length 
and number of potential N-linked glycosylation sites (Derdeyn et al., 2004; Gray et al., 
2007). Thus understanding the functional characteristics of the envelope glycoproteins is 
important in the design of vaccines that aim to induce neutralizing antibody responses. 
1.8 HOST IMMUNE RESPONSES AND DISEASE PROGRESSION 
1.8.1 Innate immune responses 
The innate immune system is the first line of defense and exerts control of HIV-1 
replication through cellular, extracellular and intracellular components.  The cellular 
component involve DCs, natural killer (NK) cells, γδ T cells and regulatory T cells; 
whereas the extracellular component are made up of various cytokines and chemokines 
(Figure 1.10); and lastly the intracellular component represent the antiviral cellular 
proteins namely APOBEC3G, TRIM5α and the defensins (Lehner et al., 2008). 
Evidence for the role of cellular components of innate immunity are shown in a 
study of highly exposed persistently seronegative sexworkers from Kenya where 
resistance to HIV-1 infection was associated with the genotype A1*010301 of the human 
leucocyte antigen-DP, that presents antigen to CD4 T cells (Hardie et al., 2008). 
Furthermore, natural killer cells that express the NK cell receptor, the killer 
immunoglobulin-like receptor 3DS1 (KIR3DS1) and its ligand (HLA-B Bw4-801) can 
effectively control HIV-1 replication and has been associated with slower disease 













Co-expression of protective HLA alleles (B*57) and NK cells with the KIR3DS1 
phenotype are strongly associated with slower progression to AIDS (Boulet et al., 2008).  
Recently, strong HIV-1 specific NK cell responses have been associated with protection 
against HIV-1 infection in infants from mother-to-child transmission pairs (Tiemessen et 
al., 2009).  A large cohort study on host determinants for control of HIV-1 infection, 
identified polymorphisms in host genes like HLA (B*5701, HLA-C), ring finger protein 
39 (RNF39) and zinc ribbon domain-containing1 (ZNRD1) (Fellay et al., 2007). 
 
 
Figure 1.10 Diagram shows the kinetics of early immune responses to viral infections  which begin with 
the release of IFN-α  followed by the production of IL-15 that induce rapid proliferation of NK cells which 




First evidence of the role of the extracellular component in innate defenses was 
the demonstration that the β-chemokines macrophage inhibitory protein (MIP)-1α, MIP-
1β and RANTES which is the natural ligand for the CCR5 coreceptor, inhibit entry of 
R5-tropic viruses (Cocchi et al., 1995).  HIV acute infection is associated with a 
“cytokine storm” where rapid increases in IL-15 and IFN-α at peak viraemia may be 












effects (Stacey et al., 2009). 
 
Two important intracellular factors that restrict HIV-1 entry into target cells are 
APOBEC3G and TRIM5α (Harris et al., 2003; Zhang et al., 2003; Stremlau et al., 2004).  
TRIM5α, a tripartite motif bearing protein, is induced by IFN-α and affects the uncoating 
of the HIV-1 capsid during infection (Stremlau et al., 2004; reviewed by Towers, 2007).  
Increased levels of TRIM5α mRNA expression have been associated with reduced risk of 
infection (Sewram et al., 2009). 
 
 
1.8.2 Cytotoxic T cell responses 
 
Cytotoxic immune responses are induced in response to the presentation of 
processed antigen by the HLA type 1 molecules on the surface of infected cells.  CD8 
(cytotoxic) T cell-mediated immune responses are thought to be important in the initial 
control of peak viraemia in primary HIV-1 infection (Koup et al., 1994; Borrow et al., 
1994; Pontesilli et al., 1998; Goulder & Watkins, 2004).  CD8 depletion experiments in 
SIV infection in the macaque animal model confirmed the essential role of CD8 T cell 
(CTL) responses in the control of virus replication (Schmitz et al., 1999; Jin et al., 1999). 
 
Further evidence of the importance of CTL in controlling disease progression is 
the association between HLA and disease progression.  HLA class I alleles differ in their 
ability to control HIV-1 replication and the protective HLA types B*13, B*27, B*51, 
B*57, B*5801, and B*8101 have been associated with better prognosis (slow or long-
term nonprogression) (Saah et al., 1998; Ioannidis et al., 1999; Costello et al., 1999; 
Fellay et al., 2007; Goulder & Watkins, 2008).  These protective HLA types target CTL 
epitopes in functionally constrained regions of especially the Gag protein and highly 
conserved residues in the HIV-1 proteome (Martinez-Picado et al., 2006; Boutwell et al., 
2009; Wang et al., 2009).  Overall increased numbers of predicted HLA-associated CTL 
epitopes were associated with lower viral loads and higher CD4 counts whereas increased 












in individuals carrying protective HLA-I alleles (Rousseau et al., 2008; Rolland et al., 
2008). 
 
Studies on HIV-1 infected individuals from various ethnic origins shows that 
predominant responses against the Gag and Nef proteins are localized in specific 
immunodominant regions in Gag and Nef (Frahm et al., 2004; Masemola et al., 2004; 
Geldmacher et al., 2007; Gray et al., 2009).  Gag-specific cytotoxic immune responses 
against an increased number of epitopes (increased breadth), together with CTL escape 
mutations in functionally constrained regions of Gag which reduced fitness, have both 
been  associated with decreased viral loads  (Martinez-Picado et al., 2006; Kiepiela et al.,  
2007; Boutwell et al., 2009; Miura et al., 2009; Wang et al., 2009). 
 
However, T cell-mediated immune targeting of Env has been associated with 
increased viral loads (Kiepiela et al., 2007; Ngumbela et al., 2008; Troyer et al., 2009).  
Recently, Gray et al. (2009) reported that in a HIV-1 subtype C acute infection cohort, 
the HIV-1-specific T cell responses during primary infection were a poor predictor of 
viral set point and disease progression.  Contradictory to this observation, Streeck et al. 
(2009) found that increased early immunodominant HIV-1-specific CD8 T cell responses 
are associated with lower viral set point and slower CD4 T cell loss in a large cohort of 
individuals infected with subtype B. 
 
 
1.8.2.1 CTL escape and reversion to wild-type 
 
HIV-1 overcomes control by CTLs through a mechanism of variation in amino 
acid residues that affect CTL epitope processing, binding or recognition by HLA alleles, 
resulting in non-recognition (Couillin et al., 1994; Jamieson et al., 2003; Yokomaku et 
al., 2004).  Viral escape from cytotoxic T cell mediated responses (CTL escape) has been 
associated with loss of immune control and subsequent disease progression (Kelleher et 
al., 2001; Goulder et al., 1997; Karlsson et al., 2007; Kemal et al., 2008).  However, CTL 












virus progeny with decreased fitness and have been associated with control of viral 
replication and slow or long-term nonprogression (Wagner et al., 1999; Leslie et al., 
2004; Martinez-Picado et al., 2006; Boutwell et al., 2009; Miura et al., 2009a; Miura et
al., 2009c). 
Reversion of transmitted CTL escape mutations to wild-type are often seen after 
transmission and may result in restoration of replicative fitness (Friedrich et al., 2004; 
Leslie et al., 2004; Li et al., 2007).  Some of these attenuating mutations do not revert 
after transmission to an HLA-mismatched recipient because the virus evolved to acquire 
additional mutations, called compensatory mutations which alleviates or restores the 
fitness cost induced by the original escape mutation (Brockman et al., 2007; Crawford et 
al., 2007; Schneidewind et al., 2009). 
1.8.3 Neutralizing antibody responses 
Antibody responses are usually the first line of defense against viral infections as 
they target viral entry processes.  However in HIV infection, although HIV-1-specific 
IgG and IgM antibody responses are detectable from 8 days post infection, it is clear that 
the majority of envelope-specific antibody responses are non-neutralizing and do not 
reduce the viral load in acute infection (Tomaras et al., 2008).  Some non-neutralizing 
antibodies were found to be effective in inducing antibody dependent cellular cytotoxicity 
(ADCC), an immune mechanism that had been associated with virus control by Natural 
Killer cells (NK cells, Ahmad & Menezes, 1995; Weber et al., 2000, Stratov et al., 2008). 
Other mechanisms of antibody-mediated viral clearance are through antibody-virus 
aggregation and phagocytosis followed by virus killing or through complement-mediated 
ADCC (Srivastava et al., 2005). 
Neutralizing antibodies only emerge some weeks or months after control of acute 
phase viraemia (Wei et al., 2003; Gray et al., 2007).  Neutralization sensitivity of HIV-1 












can evade neutralizing antibody responses by changing the variable loop length or its 
glycosylation profile (Wei et al., 2003; Derdeyn et al., 2004; Rong et al., 2007; Gray et 
al., 2007).  HIV-1 can mutate to change the variable loop lengths without affecting the 
functional envelope structure and it had been shown that deletions in the variable loops 
are associated with positive selection pressures (Wood et al., 2009).  A few neutralizing 
antibodies that effectively neutralize a broad range of HIV-1 strains have been identified 
from individuals with HIV-1 subtype B infections namely: 2F5, 4E10, IgG1b12 and 
2G12 (Trkola et al., 1996; Zwick et al., 2001; Binley et al., 2004).  IgG1b12 targets the 
CD4 binding site whereas 2G12 targets a cluster of oligomannose sugars on gp120 
(Scanlan et al., 2002; Srivastava et al., 2005). The 2F5 and 4E10 broadly neutralizing 
antibodies target the membrane-proximal external region of gp41 where it interferes with 
membrane fusion.  
 
 
1.9 VACCINE DESIGN STRATEGIES AND HIV-1 DIVERSITY  
 
Current vaccine design strategies against HIV-1 aim to either prevent productive 
infection or to reduce the viral load set point following infection with good predicted 
clinical outcome (Figure 1.11) (reviewed by Barouch, 2008). 
 
1.9.1 Antibody-based vaccine design strategies 
 
A vaccine that can induce neutralizing antibodies remains one of the biggest 
challenges of HIV vaccine research.  In the early 1980’s the identification of HIV-1 as 
the eatiologic agent for AIDS raised the hopes that an effective vaccine based on the 
surface or envelope glycoprotein would provide protection (Srivastava et al., 2005).  
However, the complex trimeric structure of HIV makes eliciting relevant antibodies 
through vaccines difficult:  for example the HIV-1 V3 region of the surface unit of the 
envelope glycoprotein (Gp120) was found to be a potent inducer of neutralizing 
antibodies  against  tissue  culture  adapted  strains  of  HIV-1  but not  primary  isolates 












monomeric gp120 subunit vaccines (Flynn et al., 2005; Pitisuttithum et al., 2006) the 
field focused on the development of a more natural (trimeric) envelope vaccine that 
elicits broadly neutralizing antibodies (Srivastava et al., 2003; 2005).  However 
developing such a vaccine immunogen is a major challenge. HIV-1 infected individuals 
take weeks but usually months to develop neutralizing antibodies against their own virus 





Figure 1.11 The expected effect of HIV-1 vaccines on potential infection indicated by longitudinal viral 
load trajectories. The black lines on the graphs show the normal longitudinal viral load in the absence of 
intervention. The red lines show the expected longitudinal viral load (a) with a successful (gold standard) 
vaccine inducing sterilizing immunity and (b) with a sub-optimal or therapeutic vaccine with a reduced 
viral load peak and lower set point after break-through infection (from Barouch, 2008). 
 
 
 The membrane proximal region (MPER) of gp41 also serves as a target for 
therapeutic and vaccine-based interventions.  Massanella et al. (2009) demonstrated that 
anti-gp41 specific neutralizing antibodies (2F5, 4E10) prevent cell to cell spread of HIV-
1.  However mimics of the 4E10 epitope for vaccine design failed to induce the expected 
immune responses. More recently Li et al. (2008) found that deletion of the gp41 fusion 
peptide or destabilization of the fusion core enhanced the antigenicity and 
immunogenicity of 4E10 and this strategy may improve vaccine designs aimed at the 












Newer targets for inducing neutralizing antibodies with improved antiviral 
properties include inducing antibodies against tertiary structures also called quarternary 
neutralizing epitopes (QNE).  These include the cross-neutralizing antibody, 2G12 
(Scanlan et al., 2002; Binley et al., 2004; Stamatatos et al., 2009).  Recently the first non-
subtype B induced broadly neutralizing antibodies (PG9 and PG16) were isolated from an 
African donor infected with subtype A (Walker et al., 2009). These two monoclonal 
antibodies seems to also target the QNEs on HIV-1 virus neutralization is dependent on 
the V1, V2 and V3 loops and the presence of glycans (Walker et al., 2009). 
 
Strategies to design effective antibody-based vaccines to induce effective 
neutralizing antibodies with sufficient breath focus on (i) the CD4 binding site (including 
CD4  inducible  conformational  epitopes),  (ii)  the  coreceptor  binding  site and (iii) the 
membrane proximal external region (MPER) of gp41 (Zwick et al., 2001; Binley et al., 
2004; Stamatatos et al., 2009).  However, Korber & Gnanakaran (2009) showed by using 
a structure-based evaluation of sequence variation in gp120 from subtype B that only 
20% of potential antibody epitopes will be recognized by a subtype B strain and only 
12% by a subtype C strain which demonstrates the low level of potential cross-
neutralizing antibody responses predicted to be induced by potential envelope-based 
vaccines (Figure 1.12).  Similarly Haynes et al. (2006) showed that subtype B consensus 
like V3 loop immunogens induced neutralizing antibodies in less than 50% of subtype B 
primary isolates with limited cross-neutralization potential against unrelated subtypes. 
 
 
1.9.2 T cell based vaccine design strategies 
 
Following the failure of the first Env-based vaccines to induce protective 
neutralizing antibody  responses,  focus  had shifted  to induce cytotoxic T cell responses 
induced against HIV-1 by using naked DNA or vectors that express whole protein 
(Moore & Burton, 2004; Duerr et al., 2006).  As CTL based vaccines target linear 
epitopes it is likely that these types of vaccines will be particularly susceptible to the 












Figure 1.12 Showing epitope mismatches in clusters comparing a consencus B envelope against (a) acute 
subtype B viruses and (b) against acute subtype C viruses, whereas epitope coverage of a subtype C 
consensus envelope is shown in (c) against acute subtype C viruses and (d) against acute subtype B viruses 












called centralized immunogens) reduce diversity between the vaccines and the circulating 
viruses (further details provided in Chapter 2). 
 
More recently an immunogen design strategy that also strives to reduce diversity 
as well as account for as much of the high frequency mutations as possible  were  used to 
design T cell-based vaccines.  This strategy involves the design of mosaic or recombinant 
proteins generated through artificial recombination of HIV-1 genes with each 
recombinant selected retaining all the required functional properties of native proteins 
(Figure 1.13) (Fischer et al., 2007).  The final immunogen is comprised of multiple 
recombinant proteins or peptides which contain an optimal number of ninemers (9-mers/ 
linear epitopes) as targets for a wide range of HLA alleles (Fischer et al., 2007; Kong et 
al., 2009). 
  
The Merck Adenovirus vector type 5 (Ad5) Gag/Pol/Nef vaccines were the first 
promising vaccines aimed at the induction of cellular immune responses against HIV-1.  














Figure 1.13 Diagram showing the processes of virtual HIV-1 recombination using computer-based 













during safety and immunogenicity trials, but failed to protect against infection and also 
did not lower the viral loads following break-through infection in a proof-of-concept trial 
(Priddy et al., 2008; McElrath et al, 2008; Buchbinder et al., 2008).  The vaccines will 
also be discussed in chapter 2. 
 
 
1.10 STUDY SCOPE AND RATIONALE 
 
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 
was established by five institutions namely University of KwaZulu-Natal, University of 
Cape Town, University of the Western Cape, National Institute for Communicable 
Diseases and Columbia University in New York, USA in 2002 
(http://www.caprisa.org/joomla/ ). The large CAPRISA 002 Acute Infection study funded 
by the Comprehensive International Programme of Research on AIDS (CIPRA) through 
the National Institute of Allergies and Infectious Diseases (NIAID) of the National 
Institute of Health, USA (http://www3.niaid.nih.gov/news/newsreleases/2002/ 
sacipraawrd.htm; http://www.caprisa.org/joomla/) with Dr. Salim Abdool Karim as 
principal investigator and Drs. Carolyn Williamson and Koleka Mlisana as protocol 
chairs was established in 2002. The study aimed to define prognostic markers of disease 
progression in HIV-1 subtype C infection, and to investigate the impact of cellular and 
antibody immune responses in acute and early infection on disease progression.  More 
specifically the study was entitled: “Viral set point and clinical progression in HIV-1 
subtype C infection: The role of immunological and viral factors during acute and early 
infection”. Primary study objectives were: (i) to determine whether viral load at 12 
months post infection is related to the subsequent progression of HIV disease as defined 
by CD4+T count below 350 cells/mm3 or AIDS defining illnesses or initiation of 
antiretroviral therapy, (ii) to determine whether the magnitude and breadth of HIV-1 
specific CD8+ T cell responses at three months post infection correlates with viral load at 













Our research under leadership of Dr. Carolyn Williamson focused on the 
following specific objectives of CAPRISA 002: (i) to describe the dynamics of viral 
evolution in subtype C infection and to determine if viral genetic changes associated with 
neutralizing antibody and cellular immune responses are associated with increased viral 
load, (ii) to determine if dual infection with two genotypically distinct HIV strains is 
associated with changes in viral load and disease progression.  
 
The purpose of this study was to characterize full-length HIV-1 genomes from 
HIV-1 subtype C primary infection to gain further insights into HIV transmission and 
early viral evolution.   
 
The aims of this study were: 
(i) To characterize near full-length HIV-1 subtype C viruses from recent primary 
infections  
(ii) To identify genetic features characteristic of recently transmitted HIV-1 
subtype C viruses that distinguish them from viruses from chronic infection 
(iii) To describe the effects of immune selective pressures in primary infection on 
viral evolution  
 
South Africa has the most severe HIV epidemics globally and the development of 
a vaccine effective against variants circulating in South Africa is a national priority.  HIV 
is continually evolving within individuals and at a population level.  While there are more 
than 400 near full-length HIV-1 subtype C virus sequences in the HIV sequence database, 
only ~14 were obtained from individuals during primary infection 
(http://www.hiv.lanl.gov/; Lole et al., 1999; van Harmelen et al., 2001; Salazar-Gonzalez 
et al., 2009; Fernãndez-Garcia et al., 2009), with 3 from South Africa.  As diversity may 
affect vaccine efficacy we were interested in characterizing viruses from primary 
infection as these represent currently circulating strains.  Furthermore, we wanted to 
determine the predictive effectiveness of candidate HIV vaccines that are tested in South 













  Biomedical interventions such as vaccines and microbicides target the 
transmitted virus and studies have shown that these viruses may have features different 
from viruses in chronic infection.  It is therefore of interest to further elucidate genotypic 
features of viruses from acute infection which may differentiate them from those in 
chronic infection.  Furthermore, as events in acute infection are thought to play an 
important role in determining subsequent disease progression, it is also important to 
understand the immune selective pressures responsible for initial control of virus 














FULL-LENGTH SOUTH AFRICAN PRIMARY INFECTION 






High genetic diversity is a characteristic of HIV-1 and is one of the hurdles to 
developing an effective vaccine.  The genetic distance in the envelope (Env) 
glycoprotein, for example, ranges from 25% to 35% between subtypes or clades, and up 
to 20% within a subtype (Gao et al., 2001; Gaschen et al., 2002).  Most vaccines 
currently in development focus on the induction of T cell immunity (Moore & Burton, 
2004; Duerr et al., 2006).  As T cell-based vaccines target linear epitopes, it is likely that 
these vaccines will be vulnerable to the effects of genetic diversity. 
 
To combat this problem of viral diversity, vaccine developers have devised 
different strategies to reduce the distance between the vaccine immunogen and the 
circulating viruses.  As one approach, immunogens were developed based on sequences 
from primary infection and selected to be closest to the consensus of the dominant 
circulating subtype (Wagner et al., 1992; Williamson et al., 2003; Kothe et al., 2006).  
Such immunogens were included in the modified vaccinia Ankara (MVA) and subtype C 
DNA vaccines developed by the University of Cape Town and the South African AIDS 
Vaccine Initiative (SAAVI) (Burgers et al., 2006; 2008; 2009; Shephard et al., 2008). 
 
A second approach involved the synthesis of immunogens based on the consensus 
(Wagner et al., 1992; Kothe et al., 2007; Santra et al., 2008), ancestral (Kothe et al., 
2006) or closest to the center of the tree (COT, Nickle et al., 2007; Rolland et al., 2007; 












diversity by half for p17, p24 and gp160 (Gaschen et al., 2002, reviewed by Korber et al., 
2009).  Consensus sequences represent the most common amino acid at each position 
whereas the ancestral state includes mutational changes associated with recent 
evolutionary events and lastly the COT algorithm combines the benefits of both the 
aforementioned (Nickle et al., 2007; Rolland et al., 2007). 
 
A third strategy is to include immunogens representative of different subtypes.  
This approach has been used by the Vaccine Research Centre (NIAID, NIH) who 
developed a DNA prime, adenovirus type 5 (Ad5) boost vaccine which included 
representative env genes from subtypes A, B and C (Catanzaro et al., 2006; 2007).  A 
fourth approach, not yet in clinical trials, is mosaic immunogens designed to closely 
mimic natural sequences.  Each immunogen consists of computationally derived multiple 
recombinant proteins that together constitute an optimal number of ninemers (9-mers/ 
linear epitopes) as targets for a wide range of HLA alleles (Fischer et al., 2007; Kong et 
al., 2009) (as discussed in Chapter 1, section 1.9.2; see Figure 1.13). 
 
We were interested in characterizing full-length HIV genomes from recently 
infected individuals from South Africa.  These genomes reflect the viral strains that are 
currently responsible for new infections and spread – therefore representing the viruses 
against which candidate vaccines need to show effectiveness.  Although amplification of 
full-length genomes directly from plasma viral RNA was described more than ten years 
ago (Fang et al., 1996), this method was not widely used due to limited reproducibility.  
The development of reverse transcriptases capable of generating longer cDNAs and new 
heat-stable high fidelity polymerases produced amplicons of up to 40 kilobases (kb), 
leading to reliable amplification of full-length HIV-1 genomes from plasma viral RNA 
(Rousseau et al., 2006).  In this study we used the method developed by Rousseau et al., 
(2006) to generate full-length sequences of HIV-1 subtype C strains from 23 participants 
recruited during primary infection. 
 
The first vaccines tested in South Africa were the subtype C-based vaccine called 












vaccine sponsored by the International AIDS Vaccine Initiative (IAVI) 
(http://www.iavireport.org/trials-db/).   More recently South Africa was involved in a 
phase IIb vaccine trial (HVTN 503/ Phambili trial) to evaluate the Merck, MRKAd5 
HIV-1 Gag/Pol/Nef replication-defective trivalent vaccine (Priddy et al., 2008, 
http://www.iavireport.org/trials-db/).  This vaccine was based on HIV-1 subtype B 
consensus sequences. 
 
The Phambili trial was prematurely terminated when the sister trial, STEP-HVTN 
502 test-of-concept trial failed to prevent infection.  One possible reason for the failure of 
the Merck trial includes the induction of insufficient breath of T cell responses, since 
each vaccine recipient showed responses to only one or two vaccine-derived epitopes 
(Korber et al., 2009), that may easily have been mismatched with respect to the infecting 
virus.  Studies are currently underway to determine the reactive epitopes and the 
sequences of the infecting viral sequences in the vaccinees to investigate this hypothesis. 
 
HIV-1 subtype C DNA and MVA candidate vaccines are currently being tested in 
phase I clinical trials in the USA and South Africa (SAAVI102/HVTN073).  This vaccine 
incorporates South African HIV-1 subtype C consensus sequences for the gag, pol [RT], 
tat and nef genes, and env gene fragments from South African subtype C isolates sampled 
in 1998, chosen on the basis of their proximity to consensus sequences circulating at the 
time (Williamson et al., 2003).  The construction of these candidate vaccines has been 
described (Burgers et al., 2006; 2008) and the constructs were shown to be immunogenic 
in animal models (Shephard et al., 2008; Burgers et al., 2009). 
 
In this chapter we characterized the full-length genomes of HIV-1 amplified from 
23 recently infected women.  To determine the potential of candidate vaccines to induce 
CD8 T cell responses against primary infection strains, we compared these sequences to 















2.2 MATERIALS AND METHODS 
2.2.1 Cohorts 
2.2.1.1 CAPRISA 002 
The CAPRISA 002 acute infection study participants (n = 23, Table 2.1.) were 
recruited as recent seroconverters from a  prospective cohort  of  mainly high-risk  HIV-1 
negative women established in 2004 (as well as other seroincidence cohorts) in Durban, 
KwaZulu-Natal, South Africa.  Previous studies focusing on heterosexual HIV-1 
transmissions in South African cities including Durban showed that the subtype C viruses 
from South Africa are genetically spread throughout the global distribution of subtype C 
viruses and follows a star-like phylogeny (Gordon et al., 2003; Williamson et al., 2003). 
Thus sampling from Durban only would represent the overall distribution of subtype C 
strains in South Africa. The CAPRISA 002 acute infection study cohort has been 
described in detail by van Loggerenberg et al., 2008.  Recent seroconverters were defined 
as those participants who had a reactive HIV-1 antibody test within 3 months of a 
previous negative test or had a positive HIV-1 RNA test in the absence of HIV-1 specific 
antibodies.  Clinical assessment and sample collection were done at enrolment and 
weekly for the first month, then fortnightly for up to 3 months, then monthly until 12 
months and thereafter quarterly. 
Classification of HIV-1 infection stages (Table 2.1) was carried out using viral 
and antibody markers as previously reported (Fiebig et al., 2003; Keele et al. 2008). 
Briefly, individuals in HIV stages; I, were HIV RNA positive but p24 antigen negative, 
II, were HIV RNA and p24 antigen positive, III, were antibody-enzyme immuno assay 
(EIA) positive but Western blot negative, IV, were antibody-EIA positive with an 
indeterminate Western blot, V, were Western blot positive but with no p31 band and VI, 
were Western blot positive with a p31 band (Ruwayhida Thebus and Melissa-Rose 
Abrahams, unpublished data, University of Cape Town).  From here on, all the sequences 












transmissions that occurred between October 2004 and March 2006.   
 
The study was approved by the ethics review boards of the Nelson R. Mandela 
School of Medicine at the University of KwaZulu-Natal and University of Cape Town 
(REC 025/2004).  Informed consent was obtained from all the participants.  Participants 
were terminated from the acute infection study on initiation of antiretroviral therapy. 
 
 
2.2.1.2 Durban sex worker cohort 
 
HIV negative sex  workers were recruited with informed consent from truck stops 
along the main route connecting two major South African cities, in different provinces, 
namely Durban (in KwaZulu Natal) and Johannesburg (in Gauteng).  Plasma samples 
(Table 2.1) were drawn from 12 participants that were originally recruited and monitored 
monthly as part of a UNAIDS-funded phase III vaginal microbicide (COL-1492) trial 
(van Damme et al., 2002).  Sequences generated from this cohort are identified by the 
prefix Du and reflect transmissions that occurred in 1998. The study was approved by the 
ethics review boards of the Nelson R. Mandela School of Medicine at the University of 
KwaZulu-Natal and the University of Cape Town (REC 137/95). 
 
 
2.2.2 Diagnostic test and criteria 
 
2.2.2.1 CAPRISA 002 
 
HIV infection was detected monthly by screening using two rapid antibody tests 
Determine (Abbott Laboratories, Tokyo, Japan) and Capillus (Trinity Biotech, 
Jamestown, NY, USA).  Unclotted blood was collected in EDTA from antibody positive 
individuals and the plasma stored at -70oC.  All the antibody negative samples were also 
screened by pooled PCR testing for HIV-1 RNA using the Ampliscreen v1.5 assay 












Table 2.1 Study participants’ sample and clinical data and 9 kb amplicon heterogeneity at time of 
sampling. 
 






bLaboratory stage cNumber of bands on 
HTA gel 




360 V 1 




989 V 1 




974 V ND 




389 VI 1 




584 dV 2 
CAP65 42 d 90800 
 
243 VI 2 
CAP69 14 d 15300 ND 
 
I/II 1 




636 V 2 




419 V 2 




963 VI 1 




353 VI 1 




365 VI 1 




461 V 1 
CAP217 67 d 75600 375 
 
VI 1 
CAP221 14 d 24300 ND 
 
I/II 1 
CAP228 53 d 2360 851 
 
dVI 1 




558 ND 1 




845 V 2 




557 VI 1 




420 V 1 




693 VI 1 




689 VI 1 







Du114 5 mo 14100 ND 
 
ND ND 
Du123 2 yrs 6018 ND 
 
ND ND 
Du172 10 mo 1042 ND 
 
ND ND 
Du258 5 yrs 17774 601 
 
ND ND 
Du301 10.5 mo 11797 ND 
 
ND ND 
Du368 12 mo 2875 ND 
 
ND ND 
Du442 4.5 yrs 1762 727 
 
ND ND 
Du457 12.5 mo 7327 ND 
 
ND ND 
Du467 2 yrs 85262 ND 
 
ND ND 
CAP = CAPRISA 002 acute infection study participants, Du = Durban sex worker cohort study participants, ND = not done, d = days, mo = months,  
yrs = years, aInfection date was estimated as the midpoint between the last negative and first positive antibody test or as 14 days if the sample was PCR 














confirmed using a quantitative RNA test (Roche Amplicor v1.5, Rotkreuz, Switzerland) 
and the BEP 2000 HIV enzyme immunoassay (Dade Behring, Marburg, Germany).  HIV-
1 viral loads were monitored using the COBAS AMPLICOR HIV-1 monitor v1.5 test 
(Roche Diagnostics, Rotkreuz, Switzerland).  The viral loads and CD4 counts (Table 2.1) 
were done by the CAPRISA Acute Infection study team in Durban, University of 
KwaZulu-Natal (data kindly provided by Dr. Koleka Mlisana).  HIV-1 specific antibody 
reactivity profiles in the early samples were determined using the GS Western blot assay 
following the manufacturer’s protocol (Bio-Rad Laboratories, Redmond, WA, USA). 
Participants were referred to the CAPRISA antiretroviral treatment programme (van 
Loggerenberg et al., 2008) when their CD4 counts dropped below 350 cells/mm3 at two 
consecutive timepoints and started treatment according to national guidelines when their 
CD4 counts were ≤ 200 cells/mm3. 
 
  
2.2.2.2 Du cohort 
 
HIV-1 serostatus, CD4 counts and viral loads (Table 2.1) were determined as 
described previously (Grobler et al., 2004).  The recombinant HIV-1/HIV-2 ELIZAQ 
assay (Abbott Laboratories, Chicago, USA) was used for initial HIV diagnosis and 
positive tests were confirmed using the Vironostika HIV Uniform II micro-ELISA 4 
system (Omnimed, United Kingdom; Grobler et al., 2004).  Viral loads were determined 
by bDNA (version 3.0, Bayer, Emeryville, CA, USA).  Diagnostic tests were performed 
at the National Institute for Communicable Diseases (Dr. Adrian Puren, NICD, 
Sandringham, Johannesburg, RSA) and CAPRISA, University of KwaZulu-Natal, RSA 
(data kindly provided by Dr. Koleka Mlisana). 
  
 
2.2.3 RNA extraction and cDNA synthesis 
 
Viral RNA was extracted manually from 140 to 500 µl plasma using the 












Appendix C).  RNA was eluted into 50 µl AVE buffer.  The RNA was immediately used 
as template for complementary DNA (cDNA) synthesis using the Invitrogen 
SuperScript™ III Reverse Transcriptase (SSIII) System (Invitrogen, GmbH, Karlsruhe, 
Germany).  Reaction master mixes (1 and 2, Table 2.2) were prepared as shown in Tables 
2.2.1 and 2.2.2.  Master mix 1 was incubated at 65°C for 5 minutes, cooled to 45°C and 
master mix 2 pre-warmed to 45°C was added.  The reaction was incubated at 45°C for 1.5 
hours before spiking with an additional µl of SSIII enzyme and continued incubation for 
another 1.5 hours. 
Tables 2.2 cDNA synthesis reagent mixes for longer (~9 kb) transcripts 
Table 2.2.1: Master mix 1 
RNA 50 µl 
dNTPs (20 mM)  2 µl 
Oligo-dT (50 mM)  2 µl 
Total volume  54 µl per reaction 
Table 2.2.2: Master mix 2 
5X buffer 20 µl 
100 mM DTT  5 µl 
H2O 15 µl 
RNase Inhibitor  2 µl 
Superscript III RT  4 µl 
Total volume  46 µl per reaction 
Following reverse transcription the enzyme was inactivated at 70°C for 15 
minutes.  The RNA template was removed from the newly synthesized cDNA by 
incubation at 37°C for 20 minutes after addition of 2U E. coli RNase H.  The cDNA was 
used as template for first round PCR amplification. 
2.2.4 First and second round PCR amplification of ~9kb HIV-1 genome fragment 
Near full-length HIV-1 genomes were amplified as a single fragment using a 
modified limiting dilution reverse transcription mediated nested PCR (Rousseau et al., 












replicates were tested at the determined cDNA dilution.  Briefly, the Expand long 
template PCR system (Roche Diagnostics, Rotkreuz, Switzerland) used in the first and 
second round PCRs is composed of a unique mixture of thermostable Taq DNA 
polymerase and a proofreading polymerase.  The primers used in the first and second 
round PCR are shown in Appendix A and Table 2.3. Two reaction mixtures (Table 2.3.1 
and 2.3.2) were prepared, separated in reaction tubes with a thin wax layer which melt at 
70°C thus allowing the reagents to mix and hot-starting the PCR reaction. 
 
 
Tables 2.3 Near full-length HIV-1 genome (~9 kb) PCR reaction mixtures for 1st and 2nd round 
amplifications 
 
Table 2.3.1: 1ST round PCR master mixes per reaction 
 
Lower mix  Upper mix  
H2O 18.2 µl H2O x µl 
20mM dNTPs 0.9 µl 10X long template buffer 1 5 µl 
50pmoles/µl 1.U5C 0.3 µl Expand long template enzyme 0.75 µl 
50pmoles/µl 1.U5Cb 0.3 µl cDNA y µl 
50pmoles/µl 1.3.3pIC 0.3 µl   
Total volume 20  µl  Total volume 30 µl 
 
 
Table 2.3.2: 2nd round PCR master mixes per reaction 
 
Lower mix  Upper mix  
H2O 18.5 µl H2O 23.25 µl 
20mM dNTPs 0.9 µl 10X buffer 1 5 µl 
50pmoles/ul 2.U5C 0.3 µl Expand enzyme 0.75 µl 
50pmoles/ul 2.3.3pIC 0.3 µl 1st round product 1 µl 
Total volume 20  µl  Total volume 30 µl 
 
 
All samples were first screened in triplicate (or up to 5 replicates) using 1 µl of 
cDNA in the first round PCR.  Two to 5 µl of second round PCR product was 
electrophoresed through a 1% agarose/ 1x TAE gel containing the DNA intercalating dye 
ethidium bromide (0.5 µg/ml, Appendix B).  A 1kb DNA ladder (or a known 9kb 












size) are visualized under ultraviolet light (UV illumination). 
 
 
2.2.5 Cloning of ~9kb fragments 
 
Amplified full-length genomes were gel purified and cloned into the TOPO® XL 
PCR rapid ligation vector (Invitrogen, GmbH, Karlsruhe, Germany) following the 
manufacturer’s instructions with minor modifications.  Prior to cloning, the purified 9 kb 
PCR products were incubated at 70-72°C for 10 minutes in the presence of 
deoxynucleosides (dATP or dNTPs) and Taq enzyme to add 3'-end A-tails.  The full 
transformation reaction was plated on a single LBagar plate containing kanamycin for 
selection (Appendix B).  Transformation plates and liquid bacterial cultures were 
incubated at 30-32°C. Plasmid DNA was extracted from overnight bacterial cultures of 
putative clones using the QIAprep miniprep kit (QIAGEN, Valencia, CA, USA).  
Restriction enzyme Mlu I and Xho I double or Not I single digestions were used to 
identify positive clones carrying the desired insert size.  Bacterial colonies containing the 
selected plasmids were cultured for midi-scale plasmid DNA isolation. The cloned HIV-1 
genomes were sequenced in both directions using primer-walking. 
 
We also controlled for potential sample mix-up or contamination during RNA 
preparation, PCR or cloning by inclusion of appropriate controls and physical separation 
of different steps as well as using phylogenetic analysis with tree drawing to identify any 
clustering of unrelated samples by including all sequences available in the laboratory as 
well a the appropriate reference sequences (http://www.hiv.lanl.gov/content/ 
sequence/TUTORIALS/CONTAM/). In the event of suspected sample mix-up or 

















using the ABI PRISM Dye Terminator Cycle sequencing kit V3.1 (Applied Biosystems, 
Foster City, CA, USA).  The reactions were slightly modified by using half the amount of 
prescribed sequencing enzyme mix in the presence of additional 5x Sequencing buffer.  
Whole genome sequencing primers (Appendix A) consisted of a combination described 
by Sanders-Buell et al. (1995) (some were re-optimised for subtype C), Rousseau et al. 
(2006) and in-house designed primers. 
 
 
2.2.7 Complete genome assembly and quality of DNA sequence data 
 
The CAPRISA sequence assembly pipeline tool (www.tools.caprisa.org) that 
employs the Phred, Phrap and Cross_Match software packages (Ewing & Green, 1998; 
Ewing et al., 1998) was used to assemble full-length genome sequences.  The assembled 
sequences and chromatograms were viewed and edited using Consed (Gordon et al., 
1998).  The BushMan (Beta Version br1, developed by Ruby van Rooyen and Tulio de 
Oliveira, South African Bioinformatics Institute, University of the Western Cape, RSA, 
www.tools.caprisa.org) sequence/chromatogram assembly tool, a modification of the 
CAPRISA sequence assembly tool, was used to produce graphical output of the quality 
scores for single chromatograms and the assembled contig. 
 
The Phred algorithm assigns the quality value for chromatograms where the 
average quality score for a chromatogram is the sum of the quality scores at each position 
divided by the sequence length.  Each chromatogram was evaluated and sequence 
fragments categorized as either edge, bad or good read (Figure 2.1).  Edge indicate 
average quality scores less than 35 at the start and end of a chromatogram, bad reads is a 
quality score of less than 35 in the middle of a chromatogram and good reads have a 
quality score of more than 35. 
 
A quality evaluation of each chromatogram was done during assembly and a 
report generated with an average quality score of 35-40% being good or acceptable.  The 












obtained at each alignment position divided by the number of sequences that overlap at 
that position.  The assembled contig depth coverage was also obtained and is the average 
number of overlapping reads at any alignment position.  Sequence assemblies in 
Bushman were done with the help of Ruby van Rooyen (South African National 
Bioinformatics Institute [SANBI], University of the Western Cape, RSA). 
2.2.8 Heteroduplex Tracking Assay (HTA) 
First round whole genome PCR products corresponding to second round products 
selected for whole genome cloning were used as templates to amplify the V1V2 env gene 
fragment to asses the diversity of the viral population.  A V1V2 env gene (HIV-1 subtype 
C, Du151) probe  radioactively labeled  with 35S  dATP  through  nick-translation  with 
Klenow enzyme was used to identify complementary heteroduplex bands.  Heteroduplex 
formation reactions were performed as follows: each reaction mixture consisted of 1 µl 
10x HTA annealing buffer (Appendix B), 7 µl V1V2 PCR product and 2 µl labeled probe 
in a 10 µl final volume.  Reaction mixtures were denatured at 95°C for 2 minutes and 
allowed to re-anneal for 5 minutes at room temperature for heteroduplex formation before 
addition of 2 µl loading dye and separation on a 5% non-denaturing polyacrylamide gel 
(Appendix B) (Kitrinos et al., 2002, http://ubik.microbiol.washington.edu/HMA /). 
Assays were preformed and data were kindly provided by H. Bredell, UCT. 
2.2.9 Phylogenetic analysis 
Reference whole genome HIV-1 subtype C and B sequences were downloaded 
from the HIV sequence database (http://hiv-web.lanl.gov).  Multiple sequence alignment 
was done with Clustal X (Thompson et al., 1994) and manual sequence editing and 
translation was done using BioEdit (Hall, 1999).  Near full-length HIV-1 genome 
sequences (n = 419) were used for Neighbor-Joining phylogenetic tree construction in 























Figure 2.1 Graphical displays of the quality classifications for chromatograms (reads). Each dot represents 
one nucleotide position in a read. For overlapping reads the final quality score classification (solid line at 
bottom) for each nucleotide position in the contig is determined by the average score at that position. (a) 
good sequence data with ~25%  of assembled reads classified as edge (average quality scores less than 35 
at the ends of reads) or (b) bad data with >75% of the reads being classified as bad (average quality scores 














with gamma distribution (α = 1) and 500 bootstrap replicates as a measure of confidence 
(Kumar et al., 2004; Tamura et al., 2007).  The HXB2 subtype B strain was used as root.  
Pairwise DNA distances were also determined in MEGA4. The program, RDP3.34 (RDP, 
Martin & Rybicki, 2000) was also used to detect recombination in the full-length genome 
sequences. The automated settings for RDP, GENECONV and SISCAN previously 
described for the RDP2 program (Martin et al., 2005) were used with default settings. 
The Bonferroni corrected p-value cutoff was 0.05. 
 
Full-length genome sequences were split into the individual genes for gene-
specific comparisons between primary infection subtype C viruses and the 
SAAVI/HVTN, Merck and mosaic protein immunogens.  Pairwise amino acid distances 
were determined using the PROTDIST program based on the Dayhoff PAM 001 matrix, 
Kimura’s distance and the Catagories distance models (Felsenstein, 1993) as described in 
BioEdit (Hall, 1999). 
 
 
2.2.10 Vaccine constructs 
 
The SAAVI DNA and MVA vaccine constructs express gag (Du422), reverse 
transcriptase (RT, Du422), tat (a consensus of Du151 and Du422), nef (Du151) and env 
(Du151) genes as described by Burgers et al. (2006; 2008).  The HIV-1 subtype C strains 
(Du422 and Du151) on which the vaccine constructs are based were selected because of 
their high degree of similarity to the South African consensus subtype C at the time.  
Merck’s Ad5 trivalent gag/pol/nef vaccine construct carry gene fragments from three 
subtype B strains [gag from CAM-1, RT and integrase (IN) from IIIB, and nef from 
JRFL, Priddy et al., 2008].  All the genes included in vaccines were optimized for 
expression in humans. 
 
Epitope coverage by test vaccines and newly derived consensus subtype C 
sequences was assessed using the epicover tool 












2008).  The epicover tool calculates the proportion of 9-mer peptide epitopes matched in 
the “vaccine” when compared to the background alignment (all naturally occurring 
subtype C proteins).  The positional epitope coverage assessment tool (Posicover; 
http://www.hiv.lanl.gov/content/sequence/MOSAIC/posicover.html; Fischer et al., 2007; 
Thurmond et al., 2008) show position-by-position how well the “vaccine” 9-mer peptide 
epitopes map to the background of naturally occurring subtype C proteins.  The average 
entropy was used to estimate the variability of amino acid residues at each alignment 
position using BioEdit (Hall, 1999). 
 
 
2.2.11 Statistical analyses 
 
The Kruskal-Wallis non-parametric test was used to identify differences between 
median amino acid distances for all vaccine immunogens versus primary infection virus 
datasets, with Dunn’s correction for multiple comparisons. A p-value <0.05 was taken as 
significant. These statistical tests were performed using GraphPad Prism® 5.0 (GraphPad 





2.3.1 Participant data 
 
The participants from the CAPRISA cohort with primary infection (CAP, n = 23) 
were infected for an estimated median of 36 days (range 14 to 67 days), with date of 
infection estimated as the midpoint between the last seronegative and first seropositive 
sample, or 14 days if diagnostic tests were antibody negative but RNA-positive.  Most 
participants had high vireamia typical of primary infection with a median of 90 800 viral 
RNA copies/ml (range 610 to 621 000 copies/ml).  The median CD4 counts of these 
individuals were 557 cells/mm3 (range 243 to 989 cells/mm3).  The Durban sex worker 












months post infection), and 4 with chronic infection, having been infected for between 2 
to 5 years.  The median viral load in the Durban cohort was 7 327 copies/ml (range 1 042 
to 85 262 copies/ml).  CD4 counts were available for only two participants (Table 2.l). 
2.3.2 HIV-1 near full-length genome amplification, cloning and quality of sequence 
data generated 
Our strategy for amplification of near full-length HIV-1 genomes was as follows. 
Firstly, samples were amplified in triplicate using 1 µl of cDNA template.  If all or most 
of the replicate samples showed a sharp ~1.7 kb band (Fig 2.2a; lanes 5, 6, 7), a mixture 
of 9 and 1.7 kb bands (Figure 2.2b, lanes 8, 9, 10) or a 9 kb band size for all replicates 
(Figure 2.2), limiting dilution of cDNA samples was performed.  If all replicate samples 
were negative (Figure 2.2a, lanes 20, 21, 23), the amount of template was increased and 
the replicates of 2, 3 and 5 µl cDNA was amplified. 
A total of 46 plasmid clones containing near the full-length genomes were 
generated from 23 individuals from the CAPRISA cohort with primary infection (n = 38); 
and from eight Du cohort participants with varying times post infection (n = 8).  For a 
single Du participant (Du457), only gag-pol and env gene fragments were generated.  The 
heterogeneity of full-length amplicons generated from CAPRISA primary infection 
samples was assessed by heteroduplex tracking assay (performed by H. Bredell, UCT).   
Genetic homogeneity in V1V2 of the templates, indicative of amplification from a 
single genome, was confirmed for 16 of the 23 full-length genome amplicons.  Two 
variants were identified from the remaining seven samples (Table 2.1).  Thus, in 
summary the full-length genomes were generated from a homogenous viral population in 
the majority of participants, with a heterogeneous inoculum in seven. 
Assessment of the quality of assembled whole genome sequences was performed 












79.8 and 89.6 was obtained for all full-length genome sequences evaluated with an 
average depth coverage from 3.5 to 7.1 (Appendix D1).  Thus the sequence data 
generated for this study was of high quality with good overlapping sequence reads on 
both strands. 
In the following sections sequences generated from the eight Du cohort 
participants infected in 1998 were added to the global pool of subtype C viruses obtained 
from the HIV Sequence database, whereas the CAPRISA sequences represent the 
primary infection viruses. 
Figure 2.2 Ethidium bromide stained and UV illuminated 1% agarose gels: 
(a) 2nd round whole genome PCR products showing in lane 1: 1 kb DNA ladder where top band (double
band) = 8-10 kb, lanes 2-4: CAP8 , lanes 5-7: CAP30 , lanes 8-10: CAP45 , lanes 11-13: CAP61 , lanes 14-
16: CAP63 , lanes 17-19: CAP84 , lanes 20-22: CAP88 and lanes 23-25: CAP210. (b) Gel-purified whole 
genome PCR products showing in lane 1: 1 kb DNA ladder, lanes 2 ; 4 ; 6 ; 8: Du258, lanes 3 ; 5 ; 7 ; 9 : 
Du123 and lane 10 : no sample 
(a)
1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
9 kb
(b)













2.3.3 Phylogenetic analysis 
All sequences were classified as HIV-1 subtype C throughout the genome with no 
evidence of inter-subtype recombination.  The phylogenetic relationship between subtype 
C sequences generated from this study was compared to other full-length subtype C 
sequences from South Africa and sequences representing the global subtype C epidemic 
(Figure 2.3).  South African viruses (all unlabelled tips and open red boxes) are spread 
throughout the starburst-like phylogeny.  The primary infection strains from this study 
(filled red boxes) did not cluster together, indicating that we were not sampling from a 
single transmission network.  One sequence from the CAPRISA cohort, CAP210 (gray 
line), was an outlier of the South African sequences and grouped with the Brazilian (pink 
lines) subcluster with 81% bootstrap support.  This sequence was also closer in the 
median pairwise DNA distance to the Brazilian sequences than to the South Africa 
primary infection strains (7.6% compared to 9.6% respectively). 
HIV only became apparent in the heterosexual population in South Africa in the 
late 1980s/early 1990s, and the high diversity star-like phylogeny of South African 
sequences represents the multiple introductions and subsequent spread of the virus in 
South Africa. This is in contrast to countries such as India (turquoise) and Brazil (pink), 
where there is evidence of founder effects, with sequences from these regions each 
forming a distinct monophyletic cluster.  This pattern suggests a single introduction of 
subtype C into these countries. As a consequence, the subtype C epidemic in South 
Africa has higher overall diversity compared to the subtype C epidemics of India and 
Brazil, with median pairwise distances of 7.8% for South Africa sequences compared to 
6.1 % for both India and Brazil (Figure 2.4).  However the median pairwise DNA 
distances for the South African sequences (7.8%) was less than the median pairwise 
distances between virus sampled from Botswana (8.5%), Tanzania (8.7%), and Zambia 
(9.2%) as well as the CAPRISA primary infection viruses (ZA-PI, 9.5%) from this study. 
This lower median pairwise DNA distance within the South African (ZA) viruses may be 
the result of recent epidemiologically linked transmissions within the data, indicated by 












infection viruses from this study represent the diversity generally seen in subtype C virus 
epidemics without significant evidence of founder effects. 
 
 
2.3.4 Amino acid diversity of vaccine strains compared to subtype C primary 
infection strains 
 
The high degree of genetic diversity found in HIV-1 is one of the major 
challenges to developing an effective vaccine.  Our laboratory has been involved in the 
design and preclinical  testing of the  SAAVI/HVTN  subtype C vaccine, and we are also 
investigating breakthrough infections in participants from the suspended HVTN503 
(Phambili) phase IIb clinical trial.  Here we compared the antigenic diversity of primary 
infection sequences to immunogen sequences contained in (i) the SAAVI DNA/MVA 
vaccines, (ii) the Merck Ad5 vaccine, and (iii) mosaic antigen vaccines described by 
Fischer  et al.  (2007). The SAAVI immunogen was derived from recently infected 
individuals (Du422 and Du151) and selection was based on closest to a subtype C 
consensus sequence at the time (Williamson et al., 2003).  This vaccine expresses a 
polyprotein comprising Gag, RT, Tat and Nef, as well as Env (Burgers et al., 2006).  The 
Merck Ad5 vaccine expresses Gag, RT-IN and Nef from subtype B (Priddy et al., 2008).     
The mosaic immunogens were selected for comparison as they have been included in a 
number of vaccines in pre-clinical development.  These proposed vaccines will include 
expression of four recombinant proteins (mosaic proteins) each for HIV-1 subtype B 
(mosB), C (mos C) or M group Gag, RT, Nef core (most conserved) region and Gp150 
proteins (Fischer et al., 2007). 
 
We initially investigated the potential coverage of candidate vaccines by 
determining the median amino acid distances between the CAPRISA subtype C primary 
infection viruses and the vaccine antigens.  Gag, RT and Nef were compared for all 
vaccines, however as the Merck Ad5 vaccine did not contain env, this comparison was 
done only for the SAAVI and mosaic antigens. The SAAVI immunogen had the least 























































































































































































































Figure 2.3 Radial display of a Neighbor-Joining tree of near full-length HIV-1 subtype C viruses (n = 418). 
Primary infection subtype C sequences (filled red boxes) and the Durban sexworker cohort sequences from this 
study (open red boxes) with subtype C viruses from the Los Alamos HIV sequence database. Thick colored 
branches = supported subclusters with >75% bootstrap value: Red: South Africa, Blue: Botswana, Pink: Brazil, 
Turquoise: India, Black: Israel-Ethiopia, Yellow: Zambia-Tanzania. The green lines = viruses used in vaccine 
strategies and all unlabelled tips also represent viruses from South Africa. Scale bar = 2%. The subtype B strain 













Figure 2.4  Median DNA distances within each group of HIV-1 subtype C viruses from various geographic 
regions. BR: Brazil, BW: Botswana, IL: Israel, IN: India, TZ: Tanzania, ZA: South Africa, ZA-PI: Primary 
Infection viruses from South Africa and ZM: Zambia.  The 5-95% percentile indicated by Box and Wiskers 
plot. 
distances of 6.7%, 6.2%, 8.6% and 17.5% for Gag, RT, Nef and Env respectively (Figure 
2.5).  The next best matched immunogen was mosC with median amino acid distance for 
Gag, RT, Nef and Env of 9.7%, 7.2%, 11.2% and 17.8%. 
Although there was a significant difference in median amino acid distance for 
Gag and Nef immunogens included in the SAAVI compared to the mosC immunogens, 
this difference was not significant for RT and Env (Figure 2.5).  As expected, the 
immunogens which were not matched to subtype C had the greatest amino acid distance 
from the primary infection viruses with mosM immunogen being a better match than the 
subtype B immunogens.  The subtype C based immunogen had significantly lower amino  
































Figure 2.5 Amino acid distances between subtype C primary infection viruses and vaccine antigens from 
(a) Gag, (b) reverse transcriptase [RT], (c) Nef core and (d) Gp150 constructs. The box indicates median 
and 25th-75th percentiles, and the whiskers indicate minimum and maximum amino acid distances. 
Comparisons were made using the Kruskal-Wallis test with Dunn’s correction for multiple comparisons.  
An asterisk (*) indicates p<0.05; *** indicates p<0.001. 
 
 
acid distances for all genes compared to the non-subtype matched immunogens.  The 
amino acid distances for example, of Merck Ad5 B immunogen tested in the Phase IIb 
clinical trial in South Africa was 13.9% (for Gag and Nef), and 7.8% (for RT) different 
from currently circulating viruses.   
 
 
2.3.5 Comparison of CTL epitope coverage by vaccine strains 
 
Amino acid similarity is a crude estimate of potential vaccine coverage within a 
















































(c) Nef core 






























































9-mers, the typical length of a CD8 T cell epitope.  Here we estimate, and compare, the
proportion of 9-mer CD8 T cell epitope coverage provided by immunogen sequences 
included in the SAAVI DNA/MVA, Merck Ad5 and the mosaic candidate vaccines to 
both primary infection strains generated in this study, as well as subtype C  viruses from 
the database.  The analysis was restricted to antigens that are common in the candidate 
vaccines of interest, namely Gag, RT, Nef core region (all immunogens) and Gp150 
proteins (SAAVI and mosaic immunogens).  Utilizing tools provided on the HIV 
Sequence database (http://www.hiv.lanl.gov/content/sequence/HIV/HIVTools.html), we 
estimated the percentage of 9-mers that were perfectly matched between the immunogens 
and the viral sequences analysed.  This should be considered a minimum value, as not all 
9-mers will contain T cell epitopes, and single changes within an epitope will not always
affect T cell recognition (Valentine et al., 2008). 
The analysis included epitope coverage of the vaccine immunogens compared to 
the currently circulating subtype C viruses in South Africa (primary infection sequences, 
n = 23, except for Gag where n = 22), as well as to subtype C sequences from the 
database (subtype C database viruses, n = 407 for Gag, n = 407 for RT, n = 403 for Nef 
and n = 406 for Gp150).  The database sequences are comprised predominantly of 
sequences from individuals with chronic infection from Durban, South Africa (Kiepiela 
et al., 2004; Matthews et al., 2008).  This analysis did not include coverage against other 
subtypes (reviewed by Korber et al., 2009). Overall, similar degrees of 9-mer epitope 
coverage were obtained against primary infection subtype C viruses (CA) and the global 
subtype C virus pool (C, HIV database sequences) for all immunogens, with the 
exception of  Nef (Figure 2.6). 
For Gag immunogens, the best predicted coverage of perfectly matched 9-mers 
was obtained with the mosC mosaic immunogen (79% for C + CA, referred to as ‘all Cs’ 
in the text following), with the mosM (M group mosaic) performing nearly as well, at 
76% coverage (Figure 2.6a).  Although the SAAVI  subtype  C  Gag immunogen  was 
most similar in amino acid distance to the primary infection subtype C viruses, the 












immunogen.  A similar degree of coverage against all Cs was estimated for the SAAVI 
Gag immunogen and the mosaic B Gag immunogen (59% and 58%, respectively).  
Epitope coverage by the Merck Gag immunogen was only 34% against all Cs. Thus it can 
be predicted that a mosM vaccine will perform better against rare non-C subtypes that are 
circulating in South Africa than a mosC immunogen. 
 
To be expected, the conserved nature of HIV-1 RT resulted in less impact of on 
epitope coverage, with similar proportions of 9-mer epitope coverage obtained with the 
SAAVI (61%) and Merck (57%) immunogens (Figure 2.6b). However, the mosaic M 
group and subtype C derived RT immunogens still provided markedly better coverage 
(~90%) than the SAAVI subtype C RT immunogen. There was no difference in epitope 
coverage for the primary infection sequences compared to the database sequences. 
  
The Nef core region was specifically selected for inclusion as a mosaic 
immunogen as this was the most conserved region of the Nef protein (Fischer et al., 
2007; Korber et al., 2009).  Here we found that the Nef core region of the SAAVI 
vaccine was predicted to provide only 48% coverage for perfectly matched 9-mers, 
whereas the Merck vaccine only had 31% of 9-mers perfectly conserved between the 
vaccine and the global subtype C pool.  Again, the mosaic immunogens provided a 
marked improvement in predicted epitope coverage, with an increase to 60% by mosB, 
78% by mosM and 85% by mosC. Although there was no significant difference between 
the median amino acid distances for SAAVI and mosC immunogens against primary 
infection viruses, the mosC immunogen provide 85% coverage compared to 48% 
coverage by the SAAVI Nef core immunogen.  Here we also observed a difference in 
epitope coverage obtained against the global subtype C pool (C) and currently circulating 
viruses (CA) with the SAAVI (48% and 46% respectively), Merck (31% and 26% 
respectively) and mosB (60% and 57% respectively) Nef immunogens. 
 
For the variable Gp150 envelope glycoprotein, the predicted epitope coverage for 
the SAAVI immunogen was poor (31%) when compared to the mosaic Gp150 




























Figure 2.6 Predicted total epitope (9-mer) coverage of  the global pool (C = HIV sequence database) and 
primary infection (CA) HIV-1 subtype C viruses by (a) Gag, (b) RT and (c) Nef core and (d) Gp150 
immunogens from SAAVI, Merck and mosaic vaccine immunogens. The proportions of perfectly matched 
9-mers (0 mismatches) are shown in red, 1 mismatch in orange and 2 mismatches in yellow. 
 
 
variable HIV-1 proteins (Nef and Gp150) are potentially poorer immunogens compared 
with Gag and RT for the induction of cross-reactive cell mediated immune responses by 
vaccines, as immunogens derived from these variable proteins presents predicted CTL 
epitopes that are more frequently mismatched to the circulating viruses. This is especially 
pronounced for Gp150, where a lower predicted epitope coverage was also obtained for 
the mosaic immunogens, with a maximum coverage of 58% which is almost 20% lower 
than for Gag, Nef and RT. 
 
To identify the regions associated with poor coverage, we assessed epitope 




















































































































































































































































































































































































































(Thurmond et al., 2008). We found that for both the Gp150 and Nef core immunogens, 
regions of poor coverage map to high entropy (>0.2) regions of the HIV-1 subtype C 
proteins (Figure 2.7). A comparison between the epitope coverage across Nef and Gp150 
show that the mosaic immunogens, particularly mosC, have increased coverage in these 
variable regions of Nef (Figure 2.7) and Gp150 (data not shown). 
 
In summary, we observed that while subtype-matched vaccines (SAAVI 
DNA/MVA subtype C vaccine) have greater sequence and epitope coverage than subtype 
mismatched vaccines (Merck subtype B Ad5 vaccine), the increase in potential T cell 
coverage using the newer mosaic immunogen design strategy shows a marked increase  
in epitope  coverage.  However, it is clear that even with  mosaic  immunogens subtype- 
specific antigens for variable proteins (as shown here for subtype C) will be best suited in 
populations where a single subtype dominates the epidemic, followed by the M group 
specific mosaic immunogens. 
 
We did not find any differences in estimated epitope coverage for global subtype 
C viruses vs. the primary infection viruses, except in the Nef core region.  The primary 
infection viruses displayed overall increased entropy in the Nef core region compared to 
the global pool of subtype C viruses.  The possible reason for differences in primary and 





Genetic drift is a feature of the HIV-1 epidemic, and since vaccines need to target 
recently transmitted viruses, we were interested in characterizing full-length HIV 
genomes from individuals with primary HIV-1 infection.  We sequenced a total of 32 
full-length subtype C genomes, of which 23 were from primary infection, representing 
the largest available number of full-length genomes from primary infection.  All viruses 
belonged to HIV-1 subtype C, with no evidence of inter-subtype recombination.  While 












Figure 2.7 Comparison of the positional entropy for subtype C viruses with positional 9-mer epitope 
coverage against the highly variable Nef core from subtype C viruses by the SAAVI and mosaic mosC 
immunogens. The proportions of perfectly matched 9-mers are shown in red, 1 mismatch in orange and 2 















subtype C supported clusters were identified, suggesting some recent historical linkage 
between viruses. This may be the reason that the overall genetic distance between the 
South Africa sequences, whilst greater than founder epidemics such as those occurring in 
India and Brazil, was lower than the median DNA distance for sequences from Zambia, 
for example. 
 
However, the subtype C viruses from primary infection from this study showed no 
evidence of founder effects, indicating that we were not sampling from transmission 
networks, and they reflected the general diversity of the global subtype C epidemic.  
Interestingly, one sequence was genetically distinct from the other sequences from South 
Africa, grouping with the Brazilian subcluster. 
 
Candidate HIV vaccines that are being tested in South Africa contain 
immunogens based on natural sequences with close homology to the subtype consensus 
sequence.  The SAAVI subtype C immunogen, which is currently in Phase I clinical trial, 
was selected based on closest to the consensus C sequence.  Our analysis shows that this 
candidate vaccine was predicted to provide better epitope coverage against subtype C 
viruses than the subtype B Merck immunogen that was recently tested in a Phase IIb trial 
in this country. The SAAVI subtype C immunogen provide predicted epitope coverage of 
61%, 48% and 53% for RT, Nef and Gag, respectively compared to 57%, 31% and 30% 
respectively for RT, Nef and Gag immunogens from the Merck Ad5 subtype B based 
vaccine.  We would therefore predict that the SAAVI subtype C vaccine would generate a 
greater number of matched T cell responses against subtype C viruses in South African 
vaccinees who would receive the strain-specific SAAVI vaccines compared to the Merck 
subtype B vaccine, which may translate to greater control of viral replication or 
protection. 
 
This demonstrates clearly the advantages of a clade-matched vaccine in 
populations where a specific subtype predominantly circulates.  However, the overall, 
epitope coverage of the SAAVI vaccine based on natural strains was relatively low, 












mismatches, studies within subtype C-infected populations have shown extensive 
reactivity to peptides based on the SAAVI vaccine sequences (Masemola et al., 2004).  
They showed that most of the 46 participants from southern Africa recognized Nef (87%) 
followed by Gag (83%), Pol (75%), Env (63%), Vif (28%), Vpr (22%), Tat (17%), Rev 
(15%) and Vpu (2%). 
 
A new approach to vaccine design using the mosaic immunogen strategy of 
Fischer et al. (2007) markedly increases epitope coverage compared to vaccines based on 
natural proteins.  For example, a subtype C Gag vaccine against subtype C viruses 
(contained in the HIV sequence database) had a predicted coverage of 80% for perfectly 
matched 9-mers. Here we also show that even against the primary infection subtype C 
viruses, these mosaic immunogens (mosC) provide an 80% - 90% matched 9-mer epitope 
coverage for Gag, RT and the more conserved Nef core region.  Epitope coverage for the 
more variable Gp150 protein was 60%. 
 
Mosaic immunogens potentially provide superior immunological coverage against 
the high genetic diversity of HIV-1.  In recent studies on non-human primates Barouch et 
al. (2010) showed that mosaic immunogens with a valency of two can provide 3 times 
higher numbers/magnitude of T cell responses, especially cytotoxic T cell responses than 
consensus or natural immunogens.   Similarly, Santra et al. (2010) who used mosaic 
immunogens with a valency of four also showed superior T cell responses to those 
induced by consensus or natural immunogens.   These mosaic designs were based on 9-
mer optimal epitopes because it is most common length of MHC class I peptides. The 
mosaic peptides were generated through computer learning techniques to include virtual 
recombinants with high frequencies of optimal 9-mer coverage and to exclude rare 9-
mers and those with unnatural amino acid sequence.  An increase in the number of 
peptides (valency) in vaccine cocktails increased total epitope coverage (Fischer et al., 
2007). However no real increase in benefit was observed in cocktails with a valency of 6 
compared to 4, as the increased valency was predominantly associated with an increase in 
the number of very rare epitopes and there is concern that these rare epitope responses 













One of the concerns with the failure of the Merck vaccine in regions where 
subtype B is the major circulating subtype is that the vaccine immunogens did not induce 
T cell responses with sufficient breadth to recognize the infecting variant and prevent or 
control infection (McElrath et al., 2008); in fact, most vaccinees mounted only one or two 
epitope responses (Korber et al., 2009).  The goal for vaccine development is to combine 
vaccination strategies that induce a large number of T cell responses (immunogenicity 
breadth) with immunogens that incorporate the diversity of HIV-1 (coverage breadth), 
maximising the chances that vaccine-induced T cell responses will match the infecting 
variants.  Santra et al. (2008) showed that a consensus based M group immunogen 
induced broad cross-clade cell mediated immune responses in a rhesus macaque model.  
In a mouse model, a greater breadth of T cell responses was observed with a mosaic 
envelope-based DNA vaccine (Kong et al., 2009).  Thus mosaic immunogen design 
strategies in preclinical development are anticipated to induce responses of greater 
breadth, and also provide greater coverage against subtype or M group-specific antigens. 
 
Addressing the high degree of genetic diversity of HIV-1 to develop an effective 
vaccine is one of the key questions facing HIV vaccinologists today.  Here we show that 
the immunogens based on viral sequences are more likely to elicit cross reactive CTL 
responses if matched to the subtype circulating in the population.  However we also 
illustrate that despite the subtype C SAAVI immunogens showing the closest amino acid 
similarity to primary infection subtype C viruses, the mosaic immunogens are predicted 
to provide much greater coverage than vaccines that have been in clinical trial.  Fischer et 
al. (2007) showed that a single mosaic immunogen gives similar coverage compared to 
consensus-derived immunogens or the best natural strains (shown to be Du422 for 
subtype C; reviewed by Korber et al., 2009). Thus, the increased coverage with mosaic 
immunogens is in part linked to the valency (1 versus 4 mosaic proteins per immunogen), 
which increases the diversity to target additional high frequency or common T cell 
epitopes. We observed that for Gag, two mosaic proteins give the same degree of epitope 
coverage as the closest-to-consensus SAAVI immunogen (Appendix D2). Epitope 












frequency 9-mer epitopes (Rolland et al., 2007; Nickle et al., 2007; Nickle et al., 2008). 
A similar strategy could be employed to increase the epitope coverage by immunogens in 




















It is well established that HIV populations experience extreme bottlenecks during 
sexual transmission (Derdeyn et al., 2004; Wolfs et al., 1992) with approximately 80% to 
90% of infections being a consequence of a single transmitted variant (Abrahams et al., 
2009; Haaland et al., 2009; Keele et al., 2008). The strongest evidence that “transmission 
sieves” have been a major factor in HIV evolution is that, relative to viruses sampled 
during chronic infections, recently transmitted HIV-1 subtype C genetic variants are in 
general more sensitive to neutralization and tend to have both shorter V1V2 and V1V4 
loops and fewer glycosylation sites (Derdeyn et al., 2004; Li et al., 2006; Rong et al., 
2007). Differences in sites under selection have also been identified between the envelope 
glycoproteins (gp41) of viruses from the primary and chronic infection phases suggesting 
the existence of different selective pressures during these different infection phases 
(Bandawe et al., 2008). 
 
However, outside of studies on env, there is limited information on features which 
distinguish recently transmitted viruses from those found in chronic infections.   Viruses 
from chronic infections have usually undergone strong cytotoxic T lymphocyte (CTL) 
driven selection pressures and are therefore expected to have accumulated immune 
escape mutations.  These CTL escape mutations, while highly adaptive within the context 
of immune environments where hosts have the appropriate HLA-alleles (Brumme et al., 
2007; Brumme, et al., 2008; Kelleher et al., 2001; Rousseau et al., 2008), can also 
seriously diminish viral replicative fitness (Allen et al., 2005; Brockman et al., 2007; Liu 












there is some evidence from mother to child transmission pair studies that fitter virus 
variants are selectively transmitted (Kong et al., 2008), other studies have shown that 
genetic variants that carry attenuating CTL escape mutations are also transmitted 
(Chopera et al., 2008;Goepfert et al., 2008). 
 
Following transmission, viruses generally accumulate both immune evasion 
mutations and reversion mutations that recoup replicative fitness losses experienced due 
to deleterious escape mutations accrued in previous hosts (Brumme et al., 2008; Leslie et 
al., 2004; Liu et al., 2007; Matthews et al., 2008; Rousseau et al., 2008). The rate at 
which such reversion mutations occur is most likely dependant on the magnitude of their 
effects on replicative fitness (Brumme et al., 2008; Matthews et al., 2008).  The clinical 
importance of viruses carrying attenuating CTL escape mutations is that the recipients of 
such viruses will, in some cases at least, have lower set-point viral loads, higher CD4 
counts and, possibly, better survival prospects (Chopera et al., 2008;Goepfert et al., 
2008). 
    
    A successful HIV vaccine will need to effectively combat viruses during the 
earliest stages of infection. Identifying the specific genetic features that might predispose 
particular HIV variants to being more transmissible than others, and understanding the 
evolutionary processes at play during the early evolution of successfully transmitted 
variants, are therefore both important for defining potential targets for vaccine induced 
immunity.  As events during acute HIV-1 infections are thought to have a 
disproportionately large influence on both long-term disease outcomes (de Wolf et al., 
1997; Lavreys et al., 2006)  and global HIV evolution in general (Rambaut et al., 2004), 
understanding the transmission bottleneck and the subsequent evolution of successfully 
transmitted variants are probably key to identifying and understanding the viral and host 
determinants of HIV pathogenesis. 
  
To identify genetic features that are characteristic of recently transmitted viruses, 
we developed a phylogeny and recombination aware method to compare amino acid 












acid sites that differentiated between full-length HIV-1 subtype C genomes sampled 
during primary and chronic infections.  We then examined longitudinally sampled 
sequences to infer the processes that might underlie the amino acid frequency differences 
observed in viruses from the different infection phases. 
 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Primary infection study subjects 
 
Here we only included 20 of the 23 participants from the CAPRISA acute 
infection cohort described in chapter 2 (see 2.2.1) who were classified as Fiebig stage V 
and VI and whose full genome sequences covers the gag through to the nef gene. 
 
 
3.2.2 Assembly of a chronic infection dataset 
 
We assembled a reference HIV-1 subtype C chronic infection dataset consisting 
of 63 publicly available subtype C full-length sequences (Kiepiela et al., 
2004);http://hiv.lanl.gov/components/sequence/HIV/search/search.html) and we also 
generated an additional 3 full-length sequences from participants of in the Durban sex-
worker cohort (Van Damme et al., 2002).  Similar to the sequences from primary 
infection, the chronic infection sequences were obtained from heterosexually infected 
women with the same ethnic background (Xhosa/ Zulu) and from the same geographic 
location (KwaZulu-Natal, South Africa). 
 
Sequences from participants with AIDS as defined by CD4+ counts less than 200 
cells per mm3 were excluded.  In addition, sequences from participants with viral loads 
>200 000 copies/ml were also excluded to minimize inadvertent inclusion of primary 













3.2.3 Whole genome amplification and DNA sequencing 
Full-length genome sequences were generated as described in chapter 2 (2.2.3, 
2.2.4, 2.2.5 and 2.2.6) and only full-length genome sequences that covers gag to nef was 
included. Whole genome amplicon template diversity for each full-length genome 
sequence is indicated in Table 2.1 (Chapter 2). 
3.2.4 Phylogenetic analysis 
The primary and chronic infection full-length genome datasets were aligned using 
ClustalW  as implemented in BioEdit  with manual editing in BioEdit. Full-length 
genome sequences were split into individual gene fragments for gene-specific analyses. 
Maximum likelihood phylogenetic trees were inferred in PHYML  as implemented in 
RDP3.26,using the General Time Reversible nucleotide substitution model with gamma 
correction for site-to-site rate variation (α = 2) selected by FindModel 
(http://www.hiv.lanl.gov). 
3.2.5 Phylogeny-aware comparison of amino acid mutational spectra 
As recombination can seriously confound phylogenetic analyses, we sought to 
account for potential recombination by performing separate analyses for different 
alignment partitions as defined by identified recombination breakpoints (Scheffler et al., 
2006).  Recombination breakpoints were identified in different HIV gene alignments 
using the RDP (Martin & Rybicki, 2000), GENECONV (Padidam et al., 1999), 
BOOTSCAN (Martin et al., 2005a), MAXCHI , CHIMAERA (Martin & Rybicki, 2000; 
Martin et al., 2005b) and SISCAN (Gibbs et al., 2000)  methods implemented in RDP3. 
Default settings were used throughout and only potential recombination events detected 
by two or more of the above methods (with associate Bonferroni corrected P-values 












The gag, pol, env and nef genes were partitioned at breakpoint positions.  Vif, vpr, vpu, 
and tat genes were not detectably recombinant.  Recombination could also not be 
detected in these genes using the GARD (Genetic Algorithm for Recombination 
Detection) method implemented on the Datamonkey webserver (Pond et al., 2006; 
http://www.datamonkey.org).  Overlapping reading frames, variable regions in env as 
well as insertions or deletions were removed before genes and partition fragments were 
translated to amino acids.  Neighbor-joining trees for protein alignments (without 
bootstrapping) were inferred with MEGA 4 (Tamura et al., 2007) using the Poisson 
correction distance model which assumes equal substitution rates and equal amino acid 
frequencies.  Rev was not analysed as it is completely embedded in overlapping reading 
frames and was therefore unsuitable for analysis. 
 
For each alignment partition defined by identified recombination breakpoints we 
inferred the sequences at the ancestral nodes of the corresponding tree (Edwards & 
Shields, 2004;Edwards & Shields, 2005) and, for each site, designated the amino acid at 
the root of the tree as the ancestral amino acid for that site.. Each terminal branch with a 
mutation towards the ancestral amino acid was assigned a score of +1; terminal branches 
with a mutation from the ancestral amino acid to any other amino acid were assigned a 
score of -1 and terminal branches for which no amino acid replacement was inferred were 
assigned a score of 0. We then compared the numbers of -1, 0 and +1 scores in terminal 
branches (Figure 3.1) leading to sequences sampled during primary infection to the 
corresponding numbers from chronic infection sequences using a two-tailed Wilcoxon 
rank-sum test with a p-value cut-off of 0.025.  We then carried out a permutation test in 
order to investigate the impact of multiple hypotheses testing on our results. We 
randomly shuffled the sample labels (primary/ chronic infection) 1,000 times and for each 
randomization we repeated the test and evaluated the number of sites with a p-value 
below the significance threshold. 
 
We then investigated each site in detail to identify possible biological processes 
responsible for these differences. The methodology described was developed by N. Wood 















Figure 3.1 Diagram of a phylogenetic tree showing the relationship between evolution at the tip of the tree 
branches for primary infection and chronic infection sequences and the most recent common ancestor 
(MRCA) for each amino acid alignment position is used to demonstrate the methodology of phylogeny-
aware comparisons of amino acid mutational spectra in 2 datasets. Changes towards and away from the 
ancestral amino acid are indicated by +1 and -1 respectively and no change between the MRCA and the tip 
of the tree equals 0 (drawn by Gama Bandawe and Cathal Seoighe, UCT). 
 
 
3.2.6 Site-by-site Shannon entropy estimation  
 
The average entropy was used to estimate the variability at amino acid sites at 
each alignment position of the primary and chronic datasets at signature positions (Yusim 
et al., 2002; Korber et al., 1994; http://www.hiv.lanl.gov/tmp/ENTROPY/).  HIV-1 
subtype C sequences available on the HIV sequence database were used to determine the 
database frequency of amino acids at alignment positions for gp41 (n = 508); Gp120 (n = 












respectively), Vif (n = 409), Vpr (n = 401), and Pol (n = 412) 
(http://hiv.lanl.gov/components/ sequence/HIV/). 
 
Liu et al (2007) determined that in most instances the wildtype CTL epitope 
mutations are found at database frequencies of >50% whereas mutant forms are mostly 
found at frequencies that are less than half the frequency of the wildtype mutation in the 
CTL epitope. They also suggested that low frequency mutant mutations are associated 
with a fitness cost. 
 
 
3.2.7 Variable loop length and N-linked glycosylation sites (PNGs) 
 
The length (number of amino acids) of env variable loops and the total number of 
PNGs were determined with the N-Glycosite tool on the HIV sequence database 
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html,  (Zhang et al., 
2004).   
 
 
3.2.8 Screening for possible CTL epitopes 
 
Motif Scan (a program that uses known HLA-1 restricted CTL epitope binding 
motifs to predict HLA-peptide binding sites; 
http://www.hiv.lanl.gov/content/immunology/motif_scan/), the CTL epitope database 
(http://www.hiv.lanl.gov/content/immunology/ctl_search), the Los Alamos HIV 
Molecular Immunology Compendium 2006/2007  and the NetMHCpan tool 
(http://www.cbs.dtu.dk/services/NetMHCpan/) which use HLA and peptide sequence 
information to predict the affinity of peptide-HLA interactions (Nielsen et al., 2007)  
were used to identify putative CTL epitopes predicted to be restricted by each study 
participant’s particular HLA alleles. HLA-I A, B and C typing was carried out at high 
resolution by sequencing using the Atria AlleleSeqr (Abbott Diagnostics) and Assign-












the proportion of immunoreactive peptides with respect to the complete HIV-1 subtype C 
proteome, by mapping reported immunoreactive peptides in subtype C infections  onto 
the viral proteins. 
3.2.9 Statistical analyses 
The non-parametric Wilcoxon rank-sum test was used to identify differences 
between the primary and chronic infection datasets with respect to both the numbers of 
N-linked glycosylation sites (PNGs) and the lengths of the variable loops in env.
Differences in entropy scores between primary and chronic strains at each identified 
position were evaluated using the two-tailed Wilcoxon rank-sum test. These statistical 
tests were carried out using GraphPad Prism® 5.0 (GraphPad Software Inc., CA, USA). 
The 2X2 Chi-square test (http://faculty.vassar.edu/lowry/tab2x2.html) was used to 
determine whether or not sites with significant allele frequency spectrum differences 
between viral isolates from primary and chronic  infections, clustered within 
immunoreactive regions of the HIV-1 proteome (Fisher’s exact one-tailed T test was used 
to measure significance). 
3.3 RESULTS 
3.3.1 Classification of infection stages 
Twenty women experiencing primary HIV-1 infections who were recruited as part 
of the CAPRISA 002 acute infection study post seroconversion as described in chapter 2 
was included (van Loggerenberg et al., 2008).  These women were estimated to have 
been infected for a median of 39 days (range 22 to 62 days) at enrolment and were in 
Fiebig stage V and VI.  Most participants had high viraemia with a median viral load of 












excluded 3 participants who were seronegative or did not have a full-length genome 
sequence that covers gag to nef (CAP69, CAP217 and CAP221). 
 
 
3.3.2 Characterization of full-length HIV-1 genomes 
 
Full-length genomes were amplified and genetic homogeneity in V1V2 of the 
template, indicative of amplification from a single genome, was confirmed for 13 out of 
20 amplicons from 20 participants and heterogeneity was identified in each of the 
remaining seven samples (Table 2.1).  All 20 of the full length genome sequences clearly 
belonged to HIV-1 subtype C and none were detectably inter-subtype recombinants 
(Chapter 2, 2.3.3; Figure 2.3). 
 
To identify polymorphisms associated with recently transmitted viruses, we 
compiled from public databases a dataset of subtype C chronic sequences which were 
closely matched to our acute infection dataset for geographical origin, host population 
and mode of transmission.  As we were interested in identifying genetic features that 
differed between viruses sampled during primary and chronic infections, it was necessary 
to ensure that there were no obvious sampling biases. The mean genetic distances 
between the env genes of viruses within each dataset was similar:  11.5% (range 8.2% - 
14.8%) in the primary infection dataset compared to 10.9% (range 6% - 15.1%) in the 
chronic infection dataset. In addition, there was no obvious evidence of close 
epidemiological linkage as the sequences were generally dispersed throughout a subtype 
C phylogenetic tree containing viruses sampled world-wide (Chapter 2, Figure 2.3). 
 
A comparison of the 86 sequences used in this study showed limited structure in 
the phylogenetic tree (Figure 3.2) with only seven lineages displaying bootstrap support 
above 75%. Of these seven lineages, six consisted of only two sequences each.  Most 
lineages contained a mixture of acute and chronic sequences.  Thus, despite a common 
geographic origin, there was no obvious evidence of close genetic and phylogenetic 















Figure 3.2 Maximum Likelihood tree of env gene sequences from primary (n= 20) and chronic (n= 66) 
infection HIV-1 subtype C strains. The HXB2 subtype B strain was used as root and 100 bootstrap 
replicates were done. Primary infection strains are indicated in blue squares and chronic strains as 
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   3.3.3 Envelope glycoprotein variable loop length and N-linked glycosylation 
 
Previous studies have shown statistically significant differences in both the 
lengths of variable loops and the numbers of N-linked glycosylation (PNGs) sites found 
in the envelope glycoproteins of viruses sampled during primary and chronic infections 
(Derdeyn et al., 2004; Li et al., 2006). Consistent with these studies we found 
significantly fewer PNGs in the V1V2 loop regions of the viral Env sequences sampled 
during primary infections (p = 0.025) (Figure 3.3). We did not, however, find any 
significant differences between the two datasets with respect to either the number of 
PNGs across the entire V1V4 region (median of 20 for both primary and chronic) or in 
the lengths of the V1V2 (median of 67 and 68 amino acids in the primary and chronic 
datasets, respectively) and V1V4 regions (median of 280.5 and 280 amino acids in the 
primary and chronic datasets respectively). 






























Figure 3.3 Number of potential N-linked glycosylation sites (PNGs) in the V1-V2 variable domains of 
gp120 from HIV-1 subtype C strains from primary and chronic infection (p <0.05). 
 












3.3.4 Site-specific differences in amino acid frequencies between the primary and 
chronic infection datasets  
We used a phylogenetic approach to test for more subtle differences between the 
primary and chronic infection datasets.   Our method accounts for detectable signals of 
recombination and controls for founder effects in the underlying evolution of these 
sequences (Bhattacharya et al., 2007; Scheffler et al., 2006). The method (developed by 
Natasha Wood and Cathal Seoighe, NBN node, UCT) infers the amino acid states of 
ancestral viruses, and evaluates the difference in the mutational patterns between two 
groups of sequences, at each site along a protein sequence alignment (See Materials and 
Methods for details). Intra-subtype recombination breakpoints were identified in gag, pol, 
env and nef genes. However, no recombination breakpoints were found in vif, vpr, vpu 
and tat using the GARD method (Pond et al., 2006; http://www.datamonkey.org). 
The primary and chronic datasets differed at 39 amino acid sites (Table 3.1), using 
the phylogenetically corrected test and a p-value threshold of 0.025 (without correction 
for multiple comparisons). We used a permutation test to investigate the impact of 
multiple hypotheses testing on our results. We permuted the sample labels (i.e. primary 
versus chronic infection) randomly 1,000 times and counted the number of sites in each 
permuted dataset that differed significantly (p < 0.025) between the permuted primary 
and chronic groups). 
While in the observed (unpermuted) data there were 39 sites with a p-value below 
0.025, among the 1,000 permuted samples, the mean number of sites with a p-value 
below 0.025 was 9.3 and there were no permuted datasets with as many as 39 significant 
sites. This provides evidence that the significant sites are enriched for true positives and 
allows us to estimate a false discovery rate of approximately 24% (9.3/39) for the sites 
with a p-value less than 0.025. Fourteen of the 39 sites were within Env, nine in Pol, six 
in Gag, four in Nef, three in Vif, two in Vpr and one in Vpu (Figure 3.4).  We then 
investigated each site in detail to identify possible biological processes responsible for 












Table 3.1 Amino acid positions were the frequency of gain and loss of specific amino acids at terminal branches 
differ significantly between HIV-1 subtype C strains from primary and chronic infection. 
 
Protein aAmino acid 
position  
(HXB2) 
P-value bSubtype C CTL reactive peptide sequence 
(site in boldface and underlined) 
bKnown HLA restriction 
Gag p17 
 
69 0.0037373 EGCKQIMKQLQPALQTGT, QLQPALQTGTEELRSLY B*0801, B*4006, A2, A*0101, B57 
Gag p17 72 0.0103261 QLQPALQTGTEELRSLY 
 
B*0801, B*4006, A2, A*0101, B57 





138 0.0097975 GKVSQNY/PIVQNLQGQMV B13, A68, A*6802, A*2402 
Gag p24 228 0.0163842 PVAPGQMREPRG 
 
B35, B13 
Gag p2 371 0.0192564 EAMSQANSVNIM 
 
A2, A*0201, A2 supertype, B*4002, B*4501 
Pol protease 113 0.0103261 GGIGGFIKVRQYDQIL 
 
A2, B13, Cw6 
Pol protease 
 
128  0.0015348 QIPIEICGKKAIGTVLV, GKKAIGTVLVGPTPVNII B*1503, B57, B58, B63 
Pol protease 131 0.0103261 GKKAIGTVLVGPTPVNII 
 
B*1503, B57, B58. B63, A*0201 
Pol RT 276 0.0165847 DAYFSVPLDEGFRKYTAF 
 
B*5702, B*5703, B35, B*3501, A11 
Pol RT 447 0.0140015 AKALTDIVPLTEEA 
 
B*0702, B*1501, B*3501, B*5101, B*5301, B35, B51, B7 
Pol integrase 726 0.0193219 KAQEEHEKYHSNWR 
 
B*4403 
Pol integrase 756 0.0103261 EIVASCDKCQLKGE 
 
B*8101 
Pol integrase 813 0.0103261 PAETGQETAYYILKLAGR 
 
A*6802, A*2601, B7, B56 
Pol integrase 850 0.0131367 VKAACWWAGIQQEFGIPYNPQS 
 
A2 supertype, B*1503 
Vif 46 0.0103261 RHHYESRHPKVSSE 
 
B*0702, B*4201, B7 
Vif 
 
78 0.0158979 D/WHLGHGVSI/, LQTGERDWHLGHGVSIEW B*1510, B*5703, B35 





68 0.0015348 AIIRILQQL/L A*0201, A2, A2 supertype 





33 0.0097975 YIEYRKLVRQR, EYRKILRQR A*3303 
Env gp120 106 0.0103261 KNDMVDQMHEDIISLW 
 
A*0201, B*3801, A2,  
Env gp120 
 
162 0.0015348 CSFNITTELRDKKQKVYA, NCSFNISTSI Cw8, Antibody pressure 
Env gp120 
 
171 0.0007625 CSFNITTELRDKKQKVYA  
Env gp120 
 
184 0.0099403 YALFYRLDIVPLNENNSSEY  





352 0.0200731 QQVRKKLEEHFPNKTIIF A*0201, A11 
Env gp120 
 
476 0.0197145 TFRPGGGDMRRNWRSELY, MRRNWRSELYKYKVVEI A*2601 
Env gp120 
 
477 0.0003449 TFRPGGGDMRRNWRSELY, MRRNWRSELYKYKVVEI A*2601 
Env gp120 485 0.0103261 NWRSELYKYKVVEI 
 
 





583 0.0015348 GIKQLQTRVLAIERYLK, RVLAIERYLKDQQLLGIW B*5802, B14 
Env gp41 
 
668 0.0173911 EKDLIALDKW(Q/N)NLWNWFDIT  
Env gp41 687 0.0165847 WYIKIFIMIVGGLIGLR 
 
A*2402, A2, A*0201 
Env gp41 708 0.0103261 AVLSVVNRVRQGYSPLS 
 
A*2501, A*3002, A30 





65 0.0000520 WLRAQEEEEEVGFPVRPQV, EVGFPVRPQVPLRPMTFK B*4501, B45, B7, A*0201, A1, B8, B35 
Nef 
 
88 0.0171700 KAAFDLSFF, GAFDLSFFL B57/ B*5801, A*0205, B60, B62, A2, Cw8, Cw*0802 




Sites identified with a p-value <0.025 are reported. bReactive peptides of which some contains published CTL epitopes were obtained from the Los Alamos HIV database 















Figure 3.4  Amino acid positions that displayed a significant difference between primary and chronic 
infection subtype C sequences are showed graphically across the HIV-1 proteome (p<0.025). 
 
 
3.3.5 Sites differentiating the primary and chronic infection datasets have higher 
entropy in the primary infection dataset 
 
To better explore the nature of the changes in amino acid mutational spectra 
between the primary and chronic infection datasets, we examined the relative entropies of 
the 39 identified sites (Figure 3.5a).  On average, the site-specific entropy was higher in 
the primary infection dataset (median = 0.518) than it was in the chronic infection dataset 
(median = 0.263, p < 0.0001, two-tailed Wilcoxon rank-sum test) (Figure 3.5b).  Based 
on analysis of HIV-1 protein sequences sampled from public databases,  Bansal et al. 
(2005)  defined  high entropy sites as  those  with an  entropy score greater than 0.25 and 
low entropy sites as those with an entropy score less than 0.15.  Whereas in the primary 
infection dataset all 25/39 sites had high entropy, in the chronic infection dataset only 
twelve had high entropy. Seventeen sites with entropies from 0.325 to 0.588 in the 
primary infection dataset were either fully conserved or highly conserved, in the chronic 
infection dataset (Figure 3.5c). 
 
 
3.3.6 Sites with differential amino acid frequency spectra are significantly clustered 
within known CTL epitopes 
 
It has been suggested that there is typically higher sequence entropy at amino acid 

































































































































































































































































































Figure 3.5 A comparison of the 39 positions identified with significant changes (p<0.025), in amino acid 
spectra between primary and chronic infection showing (a) amino acid variety and relative frequency (b) 
difference in median entropy (p<0.05) and (c) site-specific entropy at each position. 












early infections mostly target peptides with high degrees of entropy (Bansal et al., 2005). 
To investigate whether the sites identified by our analysis were associated with CTL 
responses we checked the sites against the genomic positions of peptides that were 
immuno-reactive in Elispot assays (Gray et al., 2009; Kiepiela et al., 2007; 
http://www.hiv.lanl.gov/content/immunology/hlatem/study4/; Matthews et al., 2008). 
We found that 33 of the 39 sites were located within immunoreactive peptides (Table 
3.1). Immunoreactivity has been mapped to approximately 48% of the HIV-1 subtype C 
proteome. We found that the 39 sites clustered more frequently within these 
immunoreactive regions than is expected by chance (p= 0.006).  This implied that 
polymorphisms at the sites differentiating the primary and chronic infection datasets are 
most likely associated with CTL immune pressures. 
3.3.7 Longitudinal monitoring of evolution at amino acid sites which differed 
between primary and chronic phases of infection 
To more directly determine the nature of discordant amino acid mutation spectra 
in our primary and chronic infection datasets, we obtained longitudinal samples from 18 
of the 20 study participants at between three and six months after our initial samples were 
taken.  We were specifically interested in determining whether increased entropy at the 
sites  identified  in  our  analysis  was  due  to  (i) viruses  sampled  in  primary infections 
carrying transient immune evasion mutations that they had carried over from former hosts 
(reversion), (ii) viruses accumulating novel immune evasion mutations in response to 
changes in the immune environment following transmission (escape), or (iii) a 
combination of both (i) and (ii). 
 Here we defined probable CTL escape mutations as amino acid substitutions 
within epitopes restricted by patient HLA alleles (or in immediately adjacent amino 
acids) where changes were from amino acids found in >50%  in the population (i.e. 
consensus or wild-type states) to amino acids found in <50% of the population (i.e. 












probable reversion mutations as being amino acid substitutions within known CTL 
epitopes that were not targeted by a patients HLA alleles in which low frequency amino 
acids were replaced with high frequency ones such as those corresponding with the 
subtype consensus sequence (Allen et al., 2005; Liu et al., 2006; Li et al., 2007). 
 
Amino acid changes were seen in 13 participants at 20 sites, of which four sites 
were associated with both escape and reversion (Tables 3.2 and 3.3, HLA data are 
reported in chapter 4, table 4.1). Evolution from low to high frequency amino acids 
(putative reversion) occurred at 14 sites (Table 3.3), and evolution to low frequency 
amino acids (putative CTL escape) were seen at seven sites (Table 3.2).  At three sites we 
saw escape followed by reversion to the original wild-type amino acid within six months 
(transient escape) post infection (Table 3.2). In total, eight putative escape events were 
identified at seven sites (Vif 78, Env 162, Env 352, and Nef 65) in six individuals with 
one individual (CAP256) showing escape at three sites (Gag 371, Pol 113, and Vif 78).   
Seven sites associated with escape evolved from high frequency (median frequency of 
0.775) to low frequency (median frequency of 0.168) amino acids. At position 65 in Nef 
a change from the consensus E (frequency of 0.865) to a D is associated with CTL escape 
in HLA-B*45/ B*4501 positive individuals (Rousseau et al., 2008). However in CAP63 
position 65 in Nef evolved from a low frequency amino acid (G = 0.046) to another low 
frequency amino acid (D = 0.07). Although it is slightly more frequent, this new amino 
acid polymorphism was classified as an escape mutation. It is also possible that the 
original G polymorphism was itself also an early escape mutation as the first sample 
recorded for this patient was only obtained approximately 34 days post infection.  
Mutation to D at this site may have simply provided more selectively beneficial escape 
than was provided by the intermediate G state. In three participants the Vif and Nef sites 
were located in peptides restricted by the host HLA (B*1503 and HLA-B*45 
respectively) providing further evidence that these sites were associated with evasion of 
CTL responses.   The one putative escape in Env 162 reverted to consensus at 29 weeks 
with concomitant escape at an adjacent site.  This oscillation of amino acids within nine–
mer CTL epitopes is commonly observed in the early stages of escape prior to the 















Table 3.2 Putative escape mutations within CTL epitopes  
 
 
Site PID Weeks post 
infection 
Putative epitopes aligned to matching 
test peptides 
Amino acid frequency change HLA restricted 







  .........TN.L... 
  .........TN.L... 




Affinity = 6.24 
B*1503 







  ...............T. 
  ...............T. 





Affinity = 457.37 
B1503 







  .K................ 
  .K................ 













  ......E......A.... 
  ......E......A.... 
  ......A........... 
 











  .................. 
  .................. 













  ....QQ.G........G. 
  ....QQ.G........G. 
  ....QQ.GE...K...G. 
 












  ...K........... 
  ...ED.......... 
  ...ED.......... 
 
0.865 → 0.07 











  Q..EG.......... 
  Q..EG.......... 
  Q..ED..L....... 
 
0.046 → 0.07 
G → D 
 
B *4501 
Transient escape at sites within 6 months post infection 







  ................. 
  .....N........... 
  ................. 
 
96.33> 0.73> 96.33 
S>N>S 
 
Affinity = 137.72, 
A*2902 







   .........L.....K.. 
   .....AS..L.....K.. 
   .....A..AL.....K.. 
 











  ......G.F...... 
  ......G.F..G... 



















mutation (Borrow et al., 1997; Delport et al., 2008; Iversen  et  al.,  2006). However as this 
site was located in an N-linked glycosylation motif, it is also possible that antibody 
pressures played some role in its selective value. 
In total 17 potential reversion mutations were identified at 14 sites, within viruses 
sampled from nine of the study participants.  Longitudinally sampled viruses from CAP256 
showed putative reversion at 7/14 sites with CAP174 and CAP206 each having putative 
reversion mutations at two sites. Reversion mutations involved substitutions of low 
frequency amino acids (median population-wide frequencies = 0.058 at the site in question) 
with higher frequency amino acids (median population-wide frequencies = 0.930). These 
potential reversion mutations were distributed throughout the genome with six occurring in 
Env, three in Pol, two in Gag, and one each in Vif, Vpr and Nef (Table 3.3).  There was no 
predicted HLA association for 14 out of the 17 reversion mutations providing further 
evidence that these sites were associated with reversion of CTL escape mutations that had 
occurred in former hosts which had different HLA alleles than the virus’ current hosts.    
The one exception was a probable reversion mutation located at Nef 65 within the 
CTL epitope restricted by one participant’s HLA-B*4501 allele.  Importantly, escape 
mutations were also seen at adjacent positions (63, 64) within this putative CTL epitope. 
The potential reversion at amino acid position 162 in Env is probably associated with 
regain-of-function as this site is almost invariably a threonine (T) residue (HIV-1 subtype C 
population-wide frequency = 0.979) and resides within a potential N-linked glycosylation 
site motif in the V2 loop. 
In summary, a total of 28 evolutionary events were observed in 13 participants at 
20 sites of which three events were associated with transient escape (10.7%), eight with 
putative escape (28.6%) and 17 with putative reversion (60.7%). Thus the longitudinal 
evolutionary changes observed at these sites were mainly associated with reversion to 
high frequency amino acids during primary infection with a minority of changes 












Table 3.3  Putative reversion mutations 
 
Site PID Weeks 
post 
infection 
Putative epitopes aligned to 















  K.....F...........   
  K.....F........... 
  ...............V.F 
 
0.157 → 0.823 
K → Q 
5.24 No 







  .....I......... 
  .....I......... 
  ...N........... 
 
0.0024 → 0.981 
I → I → M 
409 No  






  .......A.......... 
  .................. 
 










  ..A.....V......... 
  ..A............... 
 
0.0534 → 0.944 
V → I 
 
17.7 No 







  .........V........ 
  .................. 
  .................. 
 
0.0139 → 0.981 









  .........T........ 
  .........I........ 
   
0.0046 → 0.981 
T → I 
 
213.3 No 







  ..S...E.LT..S..... 
  ..S...E.LT........ 
  ..S............... 
 
0.0073 → 0.993 
T →T → A 
 
136 A*2902 







  ..........V....... 
  .................. 
  .................. 
 
0 → 1.00 
V → I → I 
 
 *No 







  ..........K...S.. 
  ..........K...S.. 
  ..............S.. 
 
0.0019 → 0.932 
K → K → E 
 
490.5 No 







  ......A........Q.. 
  ...X...........Q.. 
  ...............Q.. 
 
0.004 → 0.979 
A → T 
 
245 No 







  E...QR.SEE.RK..... 
  E...QR.SEE..K..... 
  E...QR.SE......... 
 
0.168 → 0.727 
K → E 
 
4.33 No 







  ...N.............. 
  .................. 
  .T................ 
 
0.070 → 0.927 









  D.RN.............. 
  D.RN.............. 
  ..R..............V 
 
0.070 → 0.927 
N → D 
 
13.2 No 







  ...........MA..... 
  ...........MA..... 
  .................. 
 
0.063 → 0.852 
M → M → I 
 
13.5 No 







  .S.NS..N....ST.... 
  .S.NS..N....ST.... 
  .S.N...N..D.ST.... 
 
0.173 → 0.781 












  ..GED.....K.... 
  ..GD......K.... 
  ..GD........... 
 
0.070 → 0.865 















  ...GD.......... 
  ...GD.......... 
  ..AE.........E. 
 
0.070 → 0.865 
D → E 
12.4 No 
  













3.3.8 GenBank accession numbers 
 
Near full-length sequences from the primary infection stage were submitted to 





HIV transmission is associated with a severe virus population bottleneck and there 
is some evidence that viral envelopes with specific genotypic and phenotypic properties 
are selected during transmission (Derdeyn et al., 2004; Rong et al., 2007; Wolfs et al., 
1992).  However, open questions remain as to whether this holds true both for genome 
regions other than the envelope, and for all HIV-1M subtypes. To further explore this 
concept, we generated full-length genomes from 20 recently HIV-1 subtype C infected 
individuals and compared these sequences to those sampled during chronic infections.  
Similar to Li et al. (2006) we also found fewer glycosylation sites but not shorter variable 
loop lengths within the envelopes of viruses sampled during primary infections.  
However, in an analysis corrected for founder effects and recombination, we found that 
site-specific amino acid mutational differences across the full-length proteome are almost 
exclusively associated with signals of virus adaptation to the new host rather than with 
signatures obviously associated with preferential transmission. 
  
Our study describes full-length HIV-1 subtype C genomes sampled from 
individuals during the primary phase of infection. We identified thirty-nine sites within 
the proteomes of these viruses that differentiated them from viruses sampled during 
chronic infections.  Through longitudinal analysis of amino acid frequency changes that 
occurred during the first six months of infection, together with data on host HLA alleles, 
we provide evidence that approximately 28.6% of site-specific differences in amino acid 
frequency spectra between primary and chronic infection proteomes are potential immune 
escape mutations.  The remaining 60.7% of frequency differences between the two 












amino acid states following transmission.  This data provides further understanding of 
processes determining the genomic and immunogenic properties of viruses during early 
infections which is important if we are to understand HIV pathogenesis sufficiently well 
to design protective vaccines against the virus. 
Almost all of the sites displaying substantially different amino acid frequency 
spectra between viruses sampled during primary and chronic infections were located 
within peptides that have known immuno-reactivity.  Most of these sites were in Env 
followed by Pol and Gag containing more sites than any of the remaining proteins. We 
further investigated the nature of the immune selection operating on these sites through 
analysis of sequence sampled longitudinally from the study participants.  Based on 
changes in amino acid frequencies relative to the global HIV database, we found that the 
amino acid frequency variations in 14/39 of the identified sites were consistent with high 
rates of reversion mutations being associated with either transmission or primary 
infection.  The frequency spectra differences at 7/39 sites were consistent with early 
escape from CTL responses during primary infection. The timing of escape may well be 
crucial, as none of the individuals had IFNg responses to subtype C-based peptide pools 
containing the presumptive immunoreactive epitopes screened using the ELISPOT assay 
(Gray et al., data not shown). It is also possible, however, that these assays may have 
missed responses due to mismatches between the peptide sequences used and the 
infecting virus. 
Our observation that reversion mutations are potentially more common than CTL 
escape mutations during the early stages of HIV infections is  broadly in agreement with 
that of Li et al. (2007) but is at odds with those of Goonetilleke et al. (2009) and Kearney 
et al. (2009).  What differentiates ours and the Li et al study from those of Goonetilleke 
et al. and Kearney et al., is that the latter studies examined sequences sampled pre-
seroconversion (Fiebig I/II and III). We and Li et al. sampled sequences post-
seroconversion, in Fiebig V, VI and beyond. Although CTL escape mutations were only 
believed to be detectable 30 or more days after peak vireamia (Borrow et al., 1997; Liu et 












escape mutations as early 14 days post infection. Thus we may potentially have 
underestimated the numbers of CTL escape mutations in viruses which were only 
sampled a median of 39 days post infection. This possibly indicates that despite a more 
rapid initial accumulation of novel CTL escape mutations during the first weeks of an 
infection, over the following months the rates at which successful CTL escape mutations 
emerge trails off to the point where their frequency is surpassed by that of reversion 
mutations. 
 
 Nevertheless our classification of reversion and escape mutations was supported 
by the fact that some of the sites predicted to be associated with escape (in Vif and Nef) 
were located in peptides reported to be restricted by the HLA-alleles of the relevant study 
participants, whereas 14/17   evolutionary events at fourteen sites we classified as being 
potentially associated with high frequency reversion mutations which were not restricted 
by the HLA-alleles of the relevant study participants. It must be pointed out, however, 
that certain HLA-epitope associations may have been missed as it has previously been 
shown that CTL responses are poorly predicted in subtype C sequences due, in part, to 
lack of detailed characterisation of HLA alleles in African populations (Ngandu et al., 
2007).  This result, based on full-length genomes, supports previous studies based on 
Gag, Pol and Nef (Brumme et al., 2008; Li et al., 2007) which suggest that most of the 
high entropy sites displaying amino acid frequency differences between viruses sampled 
in primary and chronic HIV infections represent defunct escape mutations accumulated in 
former hosts that had different HLA alleles from the virus’ current hosts. 
   
During early infection many CTL evasion mutations accumulated within previous 
hosts revert to their consensus states because these “wild-type” polymorphisms provide a 
greater degree of replicative fitness (Brumme et al., 2008; Martinez-Picado et al., 2006). 
At the same time that defunct CTL evasion mutations are reverting, viruses are forced to 
escape the immune pressures exerted by the immune environment of their new hosts. 
CTL escape during early infections has been associated with oscillation of amino acids 
within CTL targeted epitopes prior to their convergence on more stable states (Borrow et 












the negative replicative fitness effects of some CTL evasion mutations, or due to some 
mutations only providing partial escape from CTL responses due to, for example, their 
influencing epitope processing rather than recognition (Borrow et al., 1997).  By the 
chronic phase of infections many of these changes may have reached a degree of 
equilibrium.  It is possible, therefore, that in our study we have detected different stages 
of this oscillation process in the different infection stages.   The increased entropy within 
targeted CTL epitopes in early infections may be due to amino acid switching or 
shuffling within targeted epitopes as the viruses try to balance the survival benefits of 
CTL escape with the replicative fitness costs incurred by many CTL evasion mutations 
(Delport et al., 2008; Goonetilleke et al., 2009;Iversen et al., 2006). 
 
We provide evidence that the innate potential of particular genetic variants to 
mutationally respond to the selective constraints imposed by new hosts underlie virtually 
all detectable differences in amino acid frequency spectra between viruses sampled 
during primary and chronic infections.   These data provide valuable insights into unique 
virological and immunological events during primary infection.  We provide evidence 
which suggests that during the early stages of HIV infections adaptation to the immune 
environment of new hosts is perhaps secondary to the mutational recovery of replicative 
fitness losses incurred during CTL escape in former hosts.  Our discovery that early 
infections are primarily characterised by reversion mutations adds to an accumulating 
body of evidence suggesting the transience of many immune evasion mutations during 
global population-wide HIV evolution.  It is becoming increasingly apparent that CTL 
escape mutations often have complex evolutionary costs and benefits such that many are 
likely to have subtle and difficult to predict influences on long-term HIV pathology, 
epidemiology and evolution.  Given that the mutational accessibility and fitness benefits 
of reversion mutations that occur during early infections should strongly impact the 
broader effects of CTL evasion mutations, our study emphasizes the importance of 














Although our data suggest that the majority of the amino acid frequency spectrum 
differences we have observed between viruses sampled during acute and chronic 
infections are rationally attributable to evolutionary processes at play post-transmission, it 
would nevertheless be of great interest to determine whether all such signals are 
generated de novo at the onset of infections.  Evidence of even a small proportion of these 
signals having being generated prior to transmission would provide valuable support for 













EARLY VIRAL EVOLUTION IN PRIMARY HIV-1 SUBTYPE C 
INFECTION 
4.1 INTRODUCTION 
Elucidation of events in acute infection will make an important contribution to 
understanding pathogenesis, as well as informing vaccine design. Following 
transmission, changes in viral sequence will provide insights into selective forces during 
this early stage of infection.  There are several host factors, such as HLA and host 
restriction genes (Lehner et al., 2008; Fellay et al., 2007), that are important in mediating 
HIV disease progression.  These factors can directly impact by controlling virus 
replication; alternatively they may also act indirectly by inducing mutations that affect 
the replicative fitness of the virus.   As events in acute infection are thought to be critical 
in defining long term disease outcome, it is of great interest to understand pressures 
driving early viral evolution and the consequences of these changes in the context of 
disease progression.  There is limited information on the early evolution of the full-length 
HIV-1 genomes (Liu et al., 2006; Li et al., 2007; Salazar-Gonzalez et al., 2009), and 
there have been no studies on how these changes impact on subsequent disease 
progression.  It is therefore of interest to define sequence changes occurring in acute 
infection, to identify selective pressures responsible for these changes, and to determine 
the impact on disease progression. 
Cell-mediated immune pressure during primary HIV-1 infection drives the earliest 
viral evolutionary changes (Allen et al., 2005; Goonetilleke et al., 2009). CD8 cytotoxic 
T cells (CTLs) recognize HIV-1 antigens in association with human leukocyte antigen 
molecules (HLA). The cytotoxic T cell (CTL) mediated immune response abrogates viral 












(CTL escape) these protective immune responses resulting in subsequent loss of immune 
control (Leslie et al., 2004).  Escape can occur by mutations in the HLA anchor residues 
which abrogate binding and presentation of the peptide, mutations or shuffling of amino 
acids involved in T cell receptor binding, as well as through mutations in epitope flanking 
regions that affect proteosomal cleavage (Kelleher et al., 2001; Iversen et al., 2006; 
Troyer et al., 2009).  CTL escape mutations have been identified across the HIV 
proteome with the envelope glycoprotein as a major target of CTLs (Liu et al., 2006; Li 
et al., 2007; Goonetilleke et al., 2009). 
 
In a cross-sectional study of chronic subtype C infection, seven amino acid 
residues across the viral proteome (4 in Gag and 1 each in Pol, Vif and Rev) were 
associated with viral escape mutations that resulted in lower plasma viral loads (Rousseau 
et al., 2008).  The mechanism behind this is thought to be due to the fact that some CTL 
escape mutations (e.g. the T242N mutation in the TW10 epitope) result in impairment of 
the replicative fitness of the virus and have been associated with viral control and better 
prognosis (Leslie et al., 2004; Martinez-Picado et al., 2006; Chopera et al., 2008; aMiura 
et al., 2009). 
 
Most of the escape mutations that impair viral fitness arise in the presence 
protective HLA alleles which are associated with better protection against symptomatic 
HIV disease (B*13, B*27, B*51, B*57, B*5801 and B*8101) (Saah et al., 1998; 
Ioannidis et al., 1999; Costello et al., 1999; Fellay et al., 2007; Goulder & Watkins, 2008, 
aMiura et al., 2009). Individuals carrying these protective HLA types generally have 
immune responses against peptides located in essential functional domains of the viral 
proteins which are under pressure to maintain wild-type features (Allen et al., 2005; 
Wang et al., 2009).  A recent study found reduced fitness associated with Gag escape 
mutations whereas Env escape mutations did not carry a fitness cost (Troyer et al., 2009).  
Further evidence of the fitness cost of these escape mutations is illustrated by the fact that 
on transmission to HLA-mismatched recipients these CTL escape mutations often revert 













These ‘attenuating’ escape mutations can have benefit even in individuals who do 
not have these protective HLA alleles.  Studies in the CAPRISA cohort, as well as 
transmission pairs from Zambia, have shown that transmission of HLA-B*57/B*5801-
induced escape mutations to HLA-mismatched recipients was associated with a survival 
benefit although the duration of this benefit is not known (Chopera et al., 2008; Goepfert 
et al., 2009). Recipients of these transmitted Gag escape mutations have lower viral loads 
and higher CD4 counts during primary infection. It was shown recently that HLA-
B*57/B*5801 positive individuals who select the Gag escape mutants with reduced 
replicative ability eventually lose viral control after acquiring compensatory mutations 
which overcome the defects of the original escape variants (Crawford et al., 2009). 
 
 
APOBEC3G/F is cellular proteins that form part of the innate response which 
restricts HIV-1 infection by viral genome inactiviation through G-to-A hypermutation 
(Harris et al., 2003; Zhang et al., 2003). There is some conflicting information on the 
impact of hypermutation on disease progression.  While one study found that higher 
APOBEC mRNA levels were associated with lower viral loads and higher CD4 counts 
(Jin et al., 2005), this was not confirmed in a second study (Cho et al., 2006).   In more 
recent studies on levels of APOBEC associated mutations Ulenga et al. (2008) did not 
find any association between APOBEC-associated G-to-A mutations and viral load. 
However when assessing significantly hypermutated proviruses Land et al. (2008) found 
that the level of proviral hypermutation correlates with CD4 counts in infected Kenyan 
women. In addition to inactivating the virus, APOBEC may also be an important 
mechanism that the virus uses to avoid immune responses as a recent analysis linked 
APOBEC-induced mutations to rapidly evolving amino acid positions in CTL epitopes in 
HIV-1 envelope glycoproteins (Wood et al., 2009).   
 
In this chapter we investigated the effect of early viral divergence, reversion 
mutations, and APOBEC-induced mutations across the HIV-1 proteome on markers of 













4.2 MATERIALS AND METHODS 
 
4.2.1 Full-length HIV-1 genomes 
 
Samples were collected from eighteen individuals monitored over time for CD4 
counts and viral load as described in 2.3.2 (Table 2.1) and in Table 4.1.  Near full-length 
genome sequences were generated using two methods: for 20 individuals, sequences were 
generated from full-length cloned genomes at two (n = 7) to three (n = 13) time points 
from 2 weeks to 33 weeks post infection as described in chapter 2 (2.3.3 to 2.3.6); and for 
two participants (CAP45 and CAP63) sequences were also generated from single genome 
amplicons at three time points (enrolment, 3 months and 6 months post infection.  The 
method for the generation of near full-length HIV-1 genomes as described in chapter 2 
(2.3.3 and 2.3.4) was modified to obtain single genome amplification (SGA) derived ~9 
kb amplicons (Salazar-Gonzalez et al., 2009, Appendix C6).  SGAs were generated using 
the approach described below for gp160 SGAs (4.2.4).  For CAP45 and CAP63 a total 
number of 17 (2, 5, 12, 16 and 65 weeks post infection) and 24 (2, 5, 11, 29 and 37 weeks 
post infection) near full-length SGA derived HIV-1 genomes were generated 
respectively.  Additional sequences were included in the analysis including full-length 
single genome amplification (SGA) derived env gene sequences from week 52 for 
CAP45 (n = 7) provided by Gama Bandawe (University of Cape Town); and CAP84 gag 
gene sequences (n = 1) at 3 months post infection was kindly provided by Denis Chopera 
from our laboratory. 
 
 
4.2.2 Single genome amplicons (SGA) derived gp160 sequences 
 
HIV-1 RNA was reverse transcribed to cDNA using Superscript III Reverse 
Transcriptase (RT) System (Invitrogen, CA) with oligo-dT as described in chapter 2 
(2.2.3).  Full-length gp160 envelope sequences were derived by single template based 
amplification and direct sequencing as described by Salazar-Gonzalez et al., (2008) 












Table 4.1 Study participants’ HLA, and viral loads and CD4 counts at sample time points. 






Viral load (c/ml) 
@ 12 mo PI 
CD4 count 
(cells/mm3) @ 12 mo 
PI 
HLA 









39300 332 A*2301/*2301, 
B*0801/*1510 









204000 573 A*0201/ *3402, 
B*440301/ *4501 









556 1030 A*2301/ A*2902, 
B*1510/*4501 









418 412 A*6602/ *6802, 
B*1401/ *4201 









* 214000 * 235 A*0201/A*2301 
B*4501/B*4501 









4350 479 A*2902/ *7401, 
B*1503/ *4407 









< 400 682 A*3002/ *3002, 
B*0801/ *4501 






38700 499 A*2902/ *6601, 
B*4501/ *5802 






33600 303 A*0301/ *7401/ 
B*4901/ *5802 









315000 337 A*3204/ *741N, 
B*0702/ *440301 









376000 344 A*6802/*6802, 
B*1510/ *1510 






22500 680 A*0101/ *0101, 
B*5801/ *5801 









156000 793 A*0101/ *2902, 
B*4201/*5801 









14500 303 A*2301/ *3004, 
B*440301/ *5802 






64600 313 A*0205/ *2902, 
B*1401/ *1503 






18200 397 A*0301/ *8001, 
B*0801/ *1807 









178000 291 A*2902/ *6601, 
B*1503/ *5802 









10000 470 A*2301/*2902, 
B*4202/*4403 
CAP = CAPRISA 002 acute infection study participants, ND = not done, d = days, mo = months, yrs = years. 
Infection date was estimated as the midpoint between the last negative and first positive antibody test or as 14 days if the sample was PCR positive, 
antibody negative sample.  












30% positive amplicons from a set of replicate reactions and all sequences are screened 
for the absence of any heteroduplex peaks on the chromatograms. For CAP256, a total of 
35 single genome amplicons derived gp160 envelope sequences at 1.5, 3, 6 and 24 
months post infection. In addition, SGA derived gp160 sequences were generated from 2 
weeks (n = 19) and 29 weeks (n = 26) post infection for CAP63 and 52 weeks post 
infection for CAP45 (n = 7). 
 
This limiting dilution approach was initially described by Simmonds et al., (1990) 
and after several modifications (Edmonson and Mullins, 1992; Palmer et al., 2005) it was 
finally modified by Salazar-Gonzalez et al. (2008). 
 
 
4.2.3 Phylogenetic analysis 
 
Near full-length genome sequences were aligned using ClustalW (Thompson et 
al., 1994) as implemented in BioEdit (Hall, 1999) with correction of indel placements 
being carried out by manual editing in BioEdit. The HXB2 subtype B strain was included 
as reference (root). Full-length genome sequences were split into individual gene 
fragments for translation to viral proteins and gene-specific analyses using Gene Cutter 
(http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html). 
 
A maximum likelihood (PHYML) phylogenetic tree depicting full genome 
evolution of HIV-1 subtype C was carried out using the F81 substitution model 
(Felsenstein, 1981) with gamma distribution (α = 4) and ignoring recombination by using 
PHYML (Guindon and Gascuel, 2003) with automated best fit model selection and tree 
drawing in RDP3.34 (Martin et al., 2005a). The RDP3 beta 34 
(http://darwin.uvigo.es/rdp/rdp.html) software programs, Recombination Analysis 
Program (RAP) on the HIV sequence Database (http://www.hiv.lanl.gov) and the Genetic 
Algorithm for Recombination Detection (GARD) in Datamonkey (http:// www. 














4.2.4 APOBEC signatures and hypermutation analysis 
The Highlighter tool (http://www.hiv.lanl.gov/content/sequence/HighLighter/) 
was used to determine the total number of mutations in the full genome sequence with the 
APOBEC-associated and G>A mutations indicated. All sequences with APOBEC-
associated signatures were further examined to identify any significantly hypermutated 




4.2.5 HLA data 
 
HLA typing was performed on all 20 participants as described (Masemola et al., 
2004). Briefly, DNA was extracted and high resolution HLA typing for HLA-A, -B, and 
–C was performed by sequencing exons 2, 3 and 4 using the Atria AlleleSeqr kits (Abbott 
Diagnostics) and Assign-SBT 3.5 (Conexio Genomics). Ambiguities were resolved with 
sequence-specific primers. Participants HLA data were kindly provided by Dr Clive Gray 




4.2.6 Identification of amino acid positions under positive selection 
 
The Genetic Algorithm Recombination Detection (GARD) program in 
DATAMONKEY (Pond et al., 2006; http://www.datamonkey.org) was used to determine 
recombination breakpoints by searching for sequence fragment-specific phylogenetic 
trees and use fragment breakpoints to eventually assess goodness of fit for each segment 
by an information based-criterion. After breakpoint partitioning appropriate evolutionary 
models were used for each data set to identify sites under positive selection. The Internal 
Fixed Effects maximum Likelihood (IFEL) tool in Datamonkey 












negative selective pressures in longitudinally sampled gene fragments (partitions).  This 
method are able to distinguish between mutations that occur at the terminal ends or at the 
internal nodes of branches of the phylogenetic tree and can determine if selective 
pressures are different between two populations (Pond et al., 2006). Thus IFEL allows 
you to identify sites under selection that are associated with overall evolutionary change 
in longitudinally sampled data.   
4.2.7 CTL epitope prediction and CTL escape 
Putative CTL was defined as changes that occur within or flanking known or 
predicted HLA restricted epitopes.  Known epitopes were defined using the list provided 
by the Los Alamos HIV Molecular Immunology Compendium 2006/2007.   We also 
included significant HLA associations identified using a large database of subtype C 
sequences (Mathews et al., 2008; Rousseau et al., 2008).  In addition MotifScan 
(http://www.hiv.lanl.gov/content/immunology/motif_scan/) and NetMHCpan 
(http://www.cbs.dtu.dk/services/NetMHCpan/) programs were used to identify putative 
CTL epitopes restricted by the participant’s HLA-1 background.  MotifScan uses known 
HLA-1 restricted CTL epitope binding motifs to predict HLA-peptide binding sites. 
NetMHCpan was used to supplement this analysis as N’gandu et al. (2007) reported that 
CTL responses against HIV-1 subtype C are poorly predicted by these known epitope-
HLA binding motifs. NetMHCpan is a high-throughput computational bioinformatics 
tool which uses HLA and peptide sequence information to predict the affinity of peptide-
HLA interactions (Nielsen et al., 2007).  Validation of the NetMHCpan tool showed that 
more than 86% of peptides predicted to bind to the HLA molecule with a binding affinity 
<500 nM could experimentally be confirmed as HLA-binders (Nielsen et al., 2007). 
In this study we selected for each participant predicted peptides with a binding 
affinity of <500 nM.  Changes in binding affinity in longitudinal sequences were also 
noted to identify escape (an increase in binding affinity over time) or reversion (a 












CTL epitopes identified through HLA-peptide association algorithms were also used 
(Matthews et al., 2008). The number of peptides with putative CTL escape was 
enumerated for each viral protein and across the proteome. 
 
 
4.2.8 Statistical analyses 
 
Correlation of number of CTL epitopes, CTL escape mutations, reversion 
mutations and APOBEC induced mutations with CD4 counts and viral loads at 12 months 
post infection was done using Spearman nonparametric correlation with a two-tailed p-
value (p <0.05) as measure of significance. A two-tailed p-value (p <0.05) was used as 
measure of significance. These statistical tests were carried out using GraphPad Prism® 
5.0 (GraphPad Software Inc., CA, USA). 
 
 
4.2.9 GenBank accession numbers 
 
Envelope sequences derived by single genome amplification sequencing from the 
acute infection stage were submitted to GenBank under accession numbers FJ443149 to 
FJ443158 and FJ443292 to FJ443297 for CAP45 and accession numbers FJ443215 to 





4.3.1 HIV-1 complete genome analysis 
 
A total of 52 near full-length subtype C HIV-1 genome sequences were generated 
from 20 individuals (Figure 4.1).   Twenty-two near full-length HIV-1 subtype C genome 
sequences were generated from samples collected between 2 and 9 weeks post infection 



























































Figure 4.1 Maximum likelihood tree of 50 near full-length HIV-1 subtype C genomes from 20 individuals 
with primary infection sampled at 1 to 3 time points within 6 months post infection. The tree was rooted on  




































































































Figure 4.2 The % DNA distance between the earliest and 6 months post infection (PI) near full-length 
subtype C sequences for 13 participants. *CAP45 had viral loads below detection limit and we used the 3 
months PI sequence as no 6 months PI whole genome amplicons were obtained. 
from   samples  obtained   longitudinally   from  about  3  and  6  months   post   infection 
respectively. Eighteen participants had complete genome sequences generated at more 
than one time points, and 11 of the 18 had HIV-1 complete genomes generated at 3 time 
points. 
Phylogenetic analysis showed that sequences from sequential time points from 18 
participants clustered with a percentage DNA distance of ≤1% indicating infection with a 
single strain (Figure 4.1 and Figure 4.2). However sequences from two participants 
(CAP84 and CAP256) had higher than expected diversity between longitudinal 
sampleswith a percentage DNA differences of 2.2 % and 8.5% respectively (Figure 4.2). 
Analysis of the gag gene showed that for CAP84, the sequences clustered together 
however the 3 and 6 month sequences were divergent from the 22 day post infection 
sequence (Figure 4.3).  This individual was subsequently identified as infected with two 
epidemiologically unlinked HIV strains at three weeks post infection (co-infection with 
two strains) thus explaining the high diversity between these sequences (Zenda 
Woodman, University of Cape Town) and were excluded from further analysis.  For 
CAP256, the 42 days and 3 months post infection time points clustered together, while 
the sequences generated from the 6 month time point clustered separately suggestive of 
superinfection.  Interestingly, CAP256 had a more than one log increase (1.7 logs) in 
































































Figure 4.3 Maximum likelihood tree of full-length HIV-1 subtype C gag genes illustrating the relationship 
between sequences sampled at enrolment [2 to 8 weeks post infection (PI)], ~ 3 months, and 6 months PI.  
The subtype B strain, HXB2 was used as root and 100 bootstrap replicates were performed. Horizontal 
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Figure 4.4 (a) Log viral load and CD4 T cell counts over time for CAP256. Arrow indicates the suspected 
time point of superinfection.  (b) Maximum likelihood tree showing the relationship between partial env 
sequences (end C2 to beginning C3 region of gp120) sampled at the different time point indicated by 
colored dots.  Red open circles:  6 weeks pi; red closed circles: 3 months (13 weeks); blue dots: 6 months 

































































































































































































associated with superinfection. 
 
4.3.1.1 Recombination in CAP256 envelope glycoprotein. 
 
To further characterize viral evolution in CAP256, a total of 35 complete env 
sequences were derived from single genome amplicons generated from samples collected 
at 6 weeks, 3 months, 6 months and 24 months post infection.  Similar to full-length 
genome results, HIV-1 sequences at 6 weeks to 3 months post infection clustered together 
with a mean gp160 DNA distance of 0.3%; and virus variants present at 6 months and 2 
years post infection were phylogenetically distinct from early variants with a mean DNA 
distance of 9.1% (Figure 4.4b).  A comparison of the  sequences to the  sequence  from 6 
weeks post infection using the highlighter plot (Figure 4.5a) shows the differences in 
sequence corresponding to emergence of a new variant (second infection) at 6 months 
post infection.  This variant contained regions of similarity to viruses sampled at 6 weeks 
and 3 months post infection. This superinfecting virus became dominant across most of 
the genome at 6 months post infection, however by 24 months appears to have acquired 
the C2 region of gp120 and the V5 to beginning of gp41 (Figure 4.5b) from the first 
infecting virus. Two recombinants (B10, E10) were identified at 6 months post infection 
and 6 recombinants (A1, A3, A6, C2, D12 and F1) at 2 years post infection (Figures 4.5a 
and 4.5b).   Thus CAP256 was excluded from further analysis 
 
 
4.3.2 Number of escaping CTL epitopes is not associated with CD4 counts or viral 
load at set point 
 
Very little is known about the impact of CTL escape across the full-length 
genome and disease progression (Liu et al., 2006; Li et al., 2007).  Many studies 
investigating CTL escape have either focused on specific genes (Borrow et al., 1997; 
Allen et al., 2005; Brumme et al., 2007; 2008; Crawford et al., 2007; Karlsson et al., 



















Figure 4.5 (a) Highlighter plot showing similarity in gp160 from CAP256 for longitudinal data (3, 6 and 24 
months post infection) compared to the first sample collected at 6 weeks post infection. Each colored tick 
represents a nucleotide mismatch (A = green, T = red, G = orange, C = light blue, IUPAC = dark blue, gaps 
= grey) when compared to the 6 weeks (master) sequence.  (b) Plot showing recombination between the 
“transmitted” (3 months post infection, red ticks) and a superinfecting variant (6 months post infection, 
blue ticks) detected at 6 months post infection. The C2 region is indicated by a pink box and the V5-gp41 



































































samples collected during chronic infection.  Here we identified putative escape mutations 
as amino acid changes in known or predicted epitopes associated with the participants 
HLA allele that evolved from high frequency to low frequency amino acids, and persisted 
between 3 and 6 months post infection.  We also took into consideration HLA associated 
polymorphisms identified by Matthews et al. (2008).  To account for escape associated 
with proteosomal cleavage sites we also investigated mutations within 8 amino acids of a 
known CTL epitope.  Two individuals co-infected with two epidemiologically unlinked 
viruses as it is difficult to predict escape due to large shifts in viral sequences (CAP84 
and CAP256).  This analysis was performed only on the 11 individuals who were 
followed for 6 months, and for whom we have sequences from at least 3 time points. CTL 
escape mutations reported in this chapter are predicted and further work is required to 
confirm their role in cytotoxic T cell-mediated responses. This analysis excluded 
mutations or insertions and deletions in env that resulted in loss, gain or shift of N-linked 
glycosylation site motifs (NX[T/S]X, where X ≠ P) as these were classified as putative 
antibody escape.    
  
Escape was most frequently detected in Env and Nef (n = 10), followed by Pol 
and Vif (both n = 8) and Gag (n = 7), with lower number of individuals with viruses that 
escape in Vpr, Vpu, Rev and Tat (n = 5, 3, 2 and 1 respectively) (Figure 4.6).  Epitope 
regions associated with CTL escape in these individuals (Appendix D3) are summarized 



























Table 4.2 Putative escaping CTL epitopes in Gag and Pol.  
 







































B*0801 Predicted (232.43 nM) 
 MTNPPIPV/GG 
 




















A*6802 Predicted (272.92 nM) 
 ELAENREIL/KEPVH 
 






















































A*2902 Predicted (181.27 nM) 
 MAVFIHNFK/RK 
 
A*2902 Predicted (276.27 nM) 
 TKELQ/KQITKIQNF 
 
A*2301 Predicted (282.83 nM) 
 
*Published = HIV Sequence Compendium, http://www.hiv.lanl.gov/content/immunology/; HLA-association = Matthews et al., 2008; Predicted = 














Table 4.3 Putative escaping CTL epitopes in Vif, Vpr, Vpu, Tat, Rev and Nef.  
 







Predicted (442.54 nM) 
 KPKKRKPPL 
 













































    
Vpu MEQLRLLDV/N 
 
B*0801 Predicted (270.27 nM) 
 IIAVILAIV 
 
A*6802 Predicted (62.61 nM) 
 AIIVWTITYLEY 
 
A*3002 Predicted (346.57 nM) 




    
Rev EALL/LAVRTIKLL 
 









Predicted (484.82 nM) 





























A*3002 Predicted (228.05 nM) 
 MAREKHPEF 
 







 QEILDLWVY B*4403 HLA association 
 
*Published = HIV Sequence Compendium, http://www.hiv.lanl.gov/content/immunology/; HLA-association = Matthews et al., 2008; Predicted = 













Table 4.4 Putative escaping CTL epitopes in Env. 
Protein Epitope region HLA Comments 
Env WWIWSSLGF/WML A*2301 Predicted (28.64 nM) 





Predicted (463.57 nM) 
Predicted (137.19 nM) 
EIMIRSENL B*0801 Predicted (184.12 nM) 





Predicted (250.03 nM) 
Predicted (62.65 nM) 







Predicted (86.87 nM) 
Predicted (142.21 nM) 
Predicted (402.5 nM) 
VYEREVH/ NVWATHACV A*0201 Published 
ALFYRPDIV/LLSQND A*0201 Predicted (89.3 nM) 
T/IIVHLNESV A*0201 Predicted (460 nM) 
SGGD/LEITTHS/FNCR A*0201 Published 













WKNDMVDQM B*4403 Predicted (123.08 nM) 
TEN/FNMWKNDMV A*6802 Published 
NM/KDNWRSELY A*3002 Predicted (126.89 nM) 
YTNTIYRLL A*6802 Predicted (45.9 nM) 
HFPNKTITF A*2301 Predicted (45.18 nM) 
NYTQTIYQL A*2301 Predicted (57.46 nM) 






Predicted (190.19/ 202.06 nM) 
KPCVKLTPLC/VTLN B*0702 Published 
VTFDPIPIHY/CAPA A*2902 Published 
THI/FNCRGEFFY A*2902 Published 
FSITNWLWY A*0101/ B*5801 Predicted (34.96/ 61.5 nM) 
GMLRNYQQW A*2301 Predicted (394.97 nM) 
YEKEVHNVW B*4403 Predicted (472.64 nM) 
NYTNSIYKL/LEE A*2301 Predicted (100.12 nM) 
D/KWQNLWNWF A*2301 Predicted (20.07 nM) 
*Published = HIV Sequence Compendium, http://www.hiv.lanl.gov/content/immunology/; HLA-association = Matthews et al., 2008; Predicted =
























































Figure 4.7 The normalized frequency of CTL escape mutations in HIV-1 proteins at 3 and 6 months post 
infection, as well as overall.  
highest amount of escape per amino acid was found in Nef followed by Vif > Vpr > Env 
> Vpu > Gag/ Rev > Pol > Tat.  The earliest escape was seen in Nef, Env, Gag, Pol, Vpu
and Vpr with  the  highest  density of  escape  in Nef,  the  protein  which  is  also  elicits 
the most immunodominant CTL response in acute infection (Gray et al., 2009).  None of 
the participants developed CTL escape within the first 3 months in Vif, Tat and Rev. 
In chronic subtype C infection, the number of HLA-B associated mutations in 
predicted CTL epitopes has been shown to be associated with lower viral loads and 
higher CD4 counts (Matthews et al., 2008; Rolland et al., 2008).  However we find no 
association between CD4 or VLs and the total number of predicted CTL epitopes with 
escape associated with either HLA-A or B (Figure 4.8).   We also found no association 
between CD4 and VLs and the total number of escaping CTL epitopes in Gag, Pol and 
Env. 
4.3.3 Increase in reversion mutations are associated with lower CD4 counts at set 
point 
While the virus tries to escape host immune responses through CTL escape 
















Figure 4.8 Total number of CTL escape epitopes compared to the (a) viral load (VL) and (b) CD4 counts at 
12 months post infection. 
 
 
deleterious mutations. Reversions appear during early primary infection (Li et al., 2007) 
and are thought to be associated with restoration of the fitness cost of transmitted escape 
mutations.  Here we investigated the effect of reversions within six months of infection 
on the viral set point at 12 months post infection, with reversion defined as change of 
amino acid to consensus amino acid or to an amino acid present at a high frequency in the 
database. 
 
The total number of reversions across the HIV-1 proteome was inversely 
correlated with the CD4 counts at 12 months post infection (p = 0.0084, R2 = 0.5558) 
where increase in the number of reversions was associated with lower CD4 counts 
(Figure 4.9a).  However only a trend was seen between number of reversions and viral 
loads at 12 months post infection (p = 0.0892, R2 = 0.2873). Reversions in the structural 
proteins (Gag, Pol and Env) were also inversely correlated with CD4 counts (p = 0.032, 
R2 = 0.416) and were associated with increased viral loads at 12 months post infection 
however this was not significant (p = 0.092, R2 = 0.283) (Figure 4.9b). Similar trends 
were seen when Gag and Env were assessed alone (Figure 4.9c and d). 
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Figure 4.9 Correlation between the number of reversions across (a) the proteome, (b) structural proteins 
[Gag, Pol, and Env], (c) Gag and (d) Env with viral loads and CD4 counts at 12 months post infection.  
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4.3.4 Increased HIV-1 divergence is associated with lower CD4 counts at set point 
Exploring the impact of viral divergence on viral set point at 12 months post 
infection we found that an increase in the genetic distance over time (divergence) was 
significantly associated with lower CD4 counts (p = 0.0239, R2 = 0.4500) (Figure 4.10a). 
However, no association was found between viral divergence and viral load at set point (p 
= 0.5731, R2 = 0.0366). Early HIV-1 divergence was also significantly associated with 
the total number of CTL escape epitopes (p = 0.0373, R2 = 0.3982) and the total number 
of reversion mutations (p = 0.0162, R2 = 0.4918) suggesting that both escape and 
reversion were significant contributors to early viral evolution (Figure 4.10b). 
(a) 
(b) 
Figure 4.10 Early viral divergence compared to (a) CD4 count and VL, and (b) to the number of escaping 
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4.3.5 APOBEC signature mutations are associated with decreased CD4 counts 
Studies have shown no association between the level of APOBEC3G associated 
mutations  in  viral  RNA  and  viral  load  (Ulenga et al., 2008),  however  the  degree  of 
proviral hypermutation was significantly associated with CD4 counts in HIV-1 infected 
individuals (Land et al., 2008).  Here we investigated the effect of APOBEC induced 
mutations in viral RNA on viral set point and CD4 count at 12 months post infection. 
Interestingly, we found that an increased number of APOBEC signature mutations 
was significantly associated with lower CD4 counts (p = 0.0011, R2 = 0.7144) and there 
was a trend towards increased viral loads (p = 0.0899, R2 = 0.2863) (Figure 4.11a).  In 
this study, none of the viral sequences were significantly hypermutated.  The APOBEC 
associated mutations were found to contribute to viral diversity as increased numbers of 
APOBEC signature mutations was associated with an increase in viral divergence (Figure 
4.11b) although this association was not significant (p = 0.1240, R2 = 0.2423).  In 
addition, the number of reversions was significantly associated with the number of 
APOBEC signature mutations (p = 0.0206, R2 = 0.4660) (Figure 4.11c) suggesting that 
APOBEC may be a mechanism the virus uses to restore fitness which may account for 
the association between APOBEC signatures and lower CD4 counts.  Although studies 
have suggested that the virus also uses APOBEC to generate CTL escape mutations 
(Wood et al., 2009), we found no association between APOBEC signature mutations and 
CTL escape (p = 0.7196, R2 = 0.015). 
4.3.6 Longitudinal evolutionary changes in a slow (CAP45) and rapid progressor 
(CAP63) 
Previous data reported on an analysis of single sequences generated through 
limiting diluting, cloning and sequencing.  New approaches use the single genome 
amplification approach to eliminate errors introduced through in vitro recombination or 




























Figure 4.11 Correlation of APOBEC signature mutations with (a) viral load and CD4 count at 12 months 
post infection, (b) early divergence and (c) CTL escape epitopes and reversions. 
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directly sequenced from single genome or limiting dilution amplicons from two 
individuals, CAP45 and CAP63. Both individuals were recruited during acute infection 
with CAP45 were classified as Fiebig stage I/II (RNA positive, antibody negative) 
(Fiebig et al., 2003), whereas CAP63 was in Fiebig stage III [RNA positive, antibody-
enzyme immuno assay (EIA) positive but Western blot negative]. Full-length genomes 
were generated for CAP45 at 2 (n = 3), 5 (n = 6), 12 (n = 3), 16 (n = 1) and 65 (n = 3) 
weeks post infection; and for CAP63 at 2 (n = 10), 11 (n = 7), 29 (n = 2) and 37 (n = 3) 
weeks post infection.  SGA-derived  full-length gp160 sequences from 2 weeks and 52 
weeks post infection were available for CAP45 (n = 16 and n = 7 respectively), as well as 
for CAP63 at 2 (n = 19) and 29 (n = 26) weeks post infection.  The generation of multiple  
 (~10) sequences from two individuals in acute infection (antibody negative or 
indeterminate) enabled us to derive the transmitted consensus sequence which allowed us 
to more accurately investigate the effect of HIV-1 specific cytotoxic T cell mediated 
immunity on viral evolution over time.   
CAP45 was defined as a slow progressor as she consistently controlled viral load 
to below 2000 copies per ml.  CAP63 was defined as a rapid progressor and she was 
terminated from the study and initiated on anti-retroviral therapy at nine months post 
infection as her CD4 count reached below 200 cells/mm3 (Table 4.1).  CAP45 carries the 
following HLA alleles: A*2301or A*2304, A*2902 or A*2903 and B*1510/ B*4501; 
and CAP63 carries the HLA-A*0201/A*2301 and HLA-B*4501/B*4501 alleles. The 
envelope SGA sequences from 2 weeks post infection for these two individuals had been 
used to determine the viral heterogeneity at transmission and in both, a single variant was 
responsible for establishing infection (Abrahams et al., 2008). 
Comparison of HIV-1 full-length genome sequences derived after cloning with 
directly sequenced SGA-derived genomes shows the presence of mutations in the clonal-
derived sequences that are not present in any of the SGA derived sequences, as well as 
ambiguous bases shown in dark blue for directly sequenced amplicons in Figure 4.12. 
Salazar-Gonzalez et al. (2008) reported that bulk PCR and cloning of gp160 results in a 


































Figure 4.12 Comparison of directly sequenced HIV-1 full-length genomes and clone-derived sequences 
(indicated by black arrows) from CAP63 to the 2 weeks post infection consensus sequence. 
 
 
errors (ambiguous bases) and recombination during bulk PCR was identified as the cause 
and found that the effect of Taq-induced errors was more pronounced in cloned bulk PCR 
sequences.  Similarly we find increase numbers of guanosine (G) (shown as orange ticks) 
in the clonal-derived full-length sequences which may represent artifacts of Taq-induced 
G/A mixed bases. Of the 17 putative escape mutations that we identified in CAP63, we 
find only 14 were supported by the SGA analysis.  However, in addition to the single 
CTL escape identified in the analysis of CAP45 clones being supported in SGA analysis, 
a further seven were identified. Using the expanded SGA derived dataset we identified 
CTL escape in CAP45 at one epitope in Nef within 12 weeks post infection, at one 














infection as well as in three epitopes in Gp120 at 52 – 65 weeks post infection (Figure 
4.13a, Appendix D4).  For CAP63 escape was seen in a  total of only 14 CTL epitopes 
(Figure 4.13b, Appendix D5) namely: one each in Gag, Vpr, and Rev, two epitopes in 
Nef, three epitopes in Pol, in six epitopes for Env and no escape was identified in Vif.   
 
Oscillation of amino acid residues within epitopes has been seen in both SIV 
(Friedrich et al., 2004) and HIV (Borrow et al., 1997; Goonetilleke et al., 2009) infection.  
Similarly shuffling escape was seen in CAP63 in putative CTL escape epitopes in Pol (n 
=1), Vpr (n =1), Rev (n = 1), and Env (n = 4) (Figure 4.14a). Here, shuffling escape also 
involved different amino acid positions (“clustered mutations”) within the same putative 
CTL epitope or in adjoining regions (Figure 4.14b). Thus 7/14 (50%) putative CTL 
epitopes from CAP63 was experiencing shuffling escape. Only 1/8 CTL epitopes (Rev) 
from CAP45 showed shuffling between wild-type and escape residues. 
 
We then identified which codons in the viral proteins were under positive 
selection pressure using a recombination aware Internal Fixed Effects maximum 
Likelihood (IFEL) method with p-value <0.2 regarded as significant.  Three amino acid 
positions under positive selection were associated with APOBEC activity as shown here 
in Gp120 for CAP45 and four positions for CAP63 (Figure 4.15).  The slow progressor, 
CAP45, had ten sites under positive selection, one site in Pol and nine in Gp120 (Figure 
4.16a). Six of the nine sites in Gp120 were located in three known CTL epitopes 
associated with the participants HLA, and three were in two sites associated with 
glycosylation shifts and therefore thought to be associated with antibody pressure. The 
only positively selected site in Pol was also located in a predicted CTL epitope restricted 
by HLA-A*2902/ -B*4501 (LEGKIILVAVHVASGY). 
 
In contrast, the rapid progressor, CAP63 had twenty-one sites under positive 
selection.  These were located in Gag (n = 2), Pol (n = 5 with 4/5 in RT), Vif (n = 1), Vpr 
(n = 1) and Env (n = 11 in Gp120, n = 1 in Gp41) (Figure 4.15b).  Positively selected 
sites located in putative CTL epitopes were identified in one epitope in Gag 
















Figure 4.13 (a) Nucleotide polymorphisms in the full-length genome of CAP45 highlighting the putative 
escape mutations [boxed]. (b) Nucleotide polymorphisms in the full-length genome of CAP63 highlighting 
the putative escape mutations [boxed]. 
 






















Figure 4.14 Shuffling escape of amino acid residues at (a) a single alignment position in Pol and Vpr from 
11 weeks post infection, (b) at multiple sites within the putative CTL epitope shown here for Env and Rev 
from CAP63.
Env 
CONSENSUS_C  GEIKNCSFNITTELRDKKQKVYALFYR 
63.2wks.T9  .........A................. 
63.2wks.T11  .........A................. 
63.2wks.T20  .........A................. 
63.2wks.T30  .........A................. 
63.2wks.T31  .........A................. 
63.2wks.T31B  .........A.............#... 
63.2wks.T32  .........A................. 
s63.2wks.T42  .........A................. 
63.2wks.T45  .........A................. 
63.2wks.T1  .........A................. 
63.11wks.T34  .........A..V.............. 
63.11wks.T5  .........AS................ 
63.11wks.T6W  .........AS................ 
63.11wks.T27s  .........A..A.............. 
63.11wks.T19  .........A................. 
63.11wks.T13W  .........A.......E......... 
63.11wks.T14W  .........AS................ 
63.29wks.T50  .........S................. 
63.29wks.T46B  .........S................. 
s63.29wks.A2  .........S................. 
s63.29wks.A3  .........A....W............ 
s63.29wks.A4  .........AS................ 
s63.29wks.A5  .........A..I....Q......... 
s63.29wks.A6  .........A...I............. 
s63.29wks.A7  .........A................. 
s63.29wks.A8  .........T...I............. 
s63.29wks.A9  .........A...I............. 
s63.29wks.A10  .........A..A.............. 
s63.29wks.A11  .........S................. 
s63.29wks.A12  .........A...I............. 
s63.29wks.A13  .........A...I............. 
s63.29wks.A14  .........T...I............. 
s63.29wks.A15  .........A....W............ 
s63.29wks.A16  .........A....W............ 
s63.29wks.B1  .........A....W............ 
s63.29wks.B2  .........A....W............ 
s63.29wks.B3  .........A..V....E......... 
s63.29wks.B4  E........A..A.............. 
s63.29wks.B5  .........S................. 
s63.29wks.B9  .........A...I............. 
s63.29wks.C3  .........T...I............. 
s63.29wks.C4  .........S................. 
s63.29wks.TA1  .........A................. 
s63.29wks.TA3  .........A...I............. 
s63.29wks.TA4  .........A....W............ 
63.37wks.T15B  .........A..I....Q......... 
s63.37wks.T18B  .........A...I............. 
63.37wks.T19  ....X....S................. 
Rev 
CONSENSUS_C  NRRRRWRARQRQIHSISERILS 
63.2wks.T9  ..........Q...K....... 
63.2wks.T11  ..........Q...K....... 
63.2wks.T20  ..........Q...K....... 
63.2wks.T30  ..........Q...K....... 
63.2wks.T31  ..........Q...K....... 
63.2wks.T31B  ..........Q...K....... 
63.2wks.T32  ..........Q...K....... 
s63.2wks.T42  ..........Q...K....... 
63.2wks.T45  ..........Q...K....... 
63.2wks.T1  ..........Q...K....... 
s63.2wks.4223  ..K.......Q...K....... 
63.11wks.T34  ..........Q...K....... 
63.11wks.T5  ..........Q..QK....... 
63.11wks.T6W  ..........Q...K....... 
63.11wks.T27s  ..........Q...K....... 
63.11wks.T19  ..........Q..QK....... 
63.11wks.T13W  ..........Q..QK....... 
63.11wks.T14W  ...K......Q...K....... 
63.29wks.T50  ..........Q...K....... 
63.29wks.T46B  ..........Q...K....... 
s63.29wks.A2  ..........Q...K....... 
s63.29wks.A3  ..........Q..NK....... 
s63.29wks.A4  ..........Q...K....... 
s63.29wks.A5  .......E..Q...K....... 
s63.29wks.A6  ..........Q...K....... 
s63.29wks.A7  ..........Q...K....... 
s63.29wks.A8  .......T..Q...K....... 
s63.29wks.A9  ..........Q..NK....... 
s63.29wks.A10  ..........Q..NK....... 
s63.29wks.A11  .......G..Q...K....... 
s63.29wks.A12  .......T..Q..NK....... 
s63.29wks.A13  ..........Q..NK....... 
s63.29wks.A14  ..........Q..YQ....... 
s63.29wks.A15  ..........Q..NK....... 
s63.29wks.A16  .......E..Q...K....... 
s63.29wks.B1  ..........Q...K....... 
s63.29wks.B2  ..........Q..NK....... 
s63.29wks.B3  ..........Q..NK....... 
s63.29wks.B4  ..........Q...K....... 
s63.29wks.B5  ..........Q...K....... 
s63.29wks.B9  ..........Q..NK....... 
s63.29wks.C3  ..........Q..NK....... 
s63.29wks.C4  ..........Q..NK....... 
s63.29wks.TA1  .......E..Q...K....... 
s63.29wks.TA3  .......G..Q...K....... 
s63.29wks.TA4  ..........Q..NK....... 
63.37wks.T15B  .......E..Q...K....... 
s63.37wks.T18B  ..........Q..NK....... 
63.37wks.T19  .......T..Q..NK....... 
Pol 
CONSENSUS_C  KIKALTAICEEMEKEGKI 
63.2wks.T9  ......E........... 
63.2wks.T11  ......E........... 
63.2wks.T20  ......E........... 
63.2wks.T30  ......E........... 
63.2wks.T31  ......E........... 
63.2wks.T31B  ......E........... 
63.2wks.T32  ......E........X.. 
s63.2wks.T42  ......E........... 
63.2wks.T45  ......E........... 
63.2wks.T1  ......E........... 
63.11wks.T34  ......E..K........ 
63.11wks.T5  ......K........... 
63.11wks.T6W  ......E..K........ 
63.11wks.T19  ......E..K........ 
63.11wks.T13W  ......E..K........ 
63.11wks.T14W  ......E..K........ 
63.29wks.T50  ......E..D........ 
63.29wks.T46B  .................. 
63.37wks.T15B  ......E..G........ 
63.37wks.T19  ......E..G........ 
Vpr 
CONSENSUS_C  TWTGVEAIIRILQQLLF 
63.2wks.T9  .......L......... 
63.2wks.T11  .......L......... 
63.2wks.T20  .......L......... 
63.2wks.T30  .......L......... 
63.2wks.T31  .......L......... 
63.2wks.T31B  .......L......... 
63.2wks.T32  .......L......... 
s63.2wks.T42  .......L......... 
63.2wks.T45  .......L......... 
63.2wks.T1  .......L......... 
63.11wks.T34  .......L..M...... 
63.11wks.T5  .......L..S...... 
63.11wks.T6W  .......L.K....... 
63.11wks.T19  .......L..T...... 
63.11wks.T13W  .......L..S...... 
63.11wks.T14W  .......L..S...... 
63.29wks.T50  .......L..T...... 
63.29wks.T46B  .......L..M...... 
63.37wks.T15B  .......L..T...... 
s63.37wks.T18B  .......L..T...... 














Figure 4.15 Positive selection as determined with IFEL (p <0.2) in Gp120 with significant sites indicated by red stars: (a) CAP45 and (b) CAP63. Green boxes = 
putative CTL epitopes, Grey boxes = putative Ab escape epitopes, Gold star = APOBEC induced mutations, R = reversion to consensus, V1 to V5 indicate 
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DAYFSVPLDEDFRKYTAFTI, DVKQLTEAVHKIAIES) and in three epitopes in Env. 
One positively selected site in Env was located in an epitope predicted to be under both 
CTL and neutralizing antibody pressure and four positively selected sites were found in a 
single putative neutralizing antibody epitope. 
Thus we observed escape in a total of eight CTL epitopes up to 65 weeks post 
infection in the slow progressor (CAP45) and 14 CTL epitopes by 37 weeks post 
infection in the rapid progressor (CAP63). CAP45, the slow progressor, experienced CTL 
escape at two epitopes at 16 weeks post infection, whereas the rapid progressor showed 
escape at seven epitopes by 11 weeks post infection (Figure 4.16). The rapid progressor 
(CAP63) showed increased escape early (at 11 weeks post infection) when compared to 
the later time points (Figure 4.16).  
Figure 4.16 Frequency of escape during primary infection in a slow (CAP45) and rapid (CAP63) 
progressor over time. 
4.4 DISCUSSION 
Understanding the adaptive immune responses during early infection is important 
for the identification of determinants correlated with viral control during early infection. 
Here we show a high frequency of putative CTL escape mutations in longitudinally 
CAP63




























































































sampled full-length viral genomes from eleven individuals recruited during primary 
infection.  While the total number or location of putative escape was not associated with 
disease progression; viral diversification, reversion and APOBEC signature mutations 
was significantly associated with lower CD4 counts.   In an in depth analysis of two 
individuals with discrepant disease profiles (rapid versus slow progression), we showed 
that the rapid progressor had an increased number of sites under positive selective 
pressure with a high percentage (~50%) of escape occurring through amino acid shuffling 
or complex escape patterns.  This compared to the slow progressor whose virus showed 
very limited CTL escape. 
Early CD8 T cell mediated immune responses were shown to contribute to early 
viral control after peak vireamia with rapid selection of escape mutations (Goonetilleke et 
al., 2009).  Within the CAPRISA cohort, Nef is the major protein targeted by the immune 
response during primary infection followed by Pol, Gag, Env, Vif, Vpr, Rev, Vpu and Tat 
(Gray et al., 2009). In the same cohort, we find a similar hierarchy of putative CTL 
driven escape; with escape most frequently observed in Nef and Env, followed by Pol, 
Vif, Gag and Vpr.  It is possible that in immune studies, the high diversity in Env results 
in an underestimation of responses to this region due to mismatch between reagents and 
infecting virus.   In the CAPRISA cohort, immune responses were identified using a 
pooled peptide approach and further work is needed to confirm the specific peptides and 
identify optimal epitopes. 
Escape from cell mediated immune responses is associated with loss of immune 
control and subsequent disease progression, except in individuals carrying protective 
HLA alleles where escape has been associated with slow disease progression (Leslie et 
al., 2004; Miura et al., 2008). In this study no association was found between the number 
of CTL epitopes and subsequent disease progression based on viral load and/or CD4 
counts at 12 months post infection.  It is likely that we did not see an effect due the 
conflicting impact of escape where escape may be beneficial, detrimental or neutral to the 
host.  Strong selective pressure by protective HLA alleles has been identified in this 












mutations resulted in lower viral loads and higher CD4 counts in these individuals 
(Chopera et al., 2008).  It is likely that we will need larger numbers to differentiate 
between “good’” escape that results in fitness cost to the virus, and “bad” escape which 
results in loss of immune control of the virus and increased disease progression. This in 
depth analysis of viral evolution in early infection (within 6 months post infection) 
showed limited putative escape in a slow progressor (2/9 viral proteins) compared to the 
rapid progressor (5/9 viral proteins). We also found that shuffling or oscillation of amino 
acid residues was characteristic of escape in putative CTL epitopes in viruses from the 
rapid progressor.   
In contrast to a previous study (Rousseau et al., 2008; Matthews et al., 2008) of 
chronic HIV-1 subtype C infection where the number of reversions in Gag and Pol had 
been associated with lower viral loads, we observed that an increased number of 
reversions to consensus C sequence during early infection are significantly associated 
with lower CD4 counts and show a trend of association with higher viral loads. This was 
driven by one point of low reversion and high CD4 count for participant CAP45. This 
individual shows good control of virus replication in early infection, but do not carry any 
of the known protective HLA alleles and no defects in the HIV-1 genes were observed. 
Recent studies also showed that APOBEC-3G induced mutations are associated with 
early viral evolutionary changes in HIV-1 infection (Wood et al., 2009; Goonetilleke et 
al., 2009). Goonetilleke et al. (2009) also reported that APOBEC induced mutations was 
associated with reversions in early infection, but that reversions did not play a major role 
in early viral evolution.  Here, we firstly show a significant association between 
APOBEC induced mutations and reversions, as well with viral diversity during early 
infection. Secondly, both increased viral divergence and an increasing numbers of 
APOBEC induced mutations were significantly associated with lower CD4 counts at 12 
months with a trend of association with higher viral loads. APOBEC inactivates lentivirus 
genomes by inducing hypermutation whereas the viral Vif protein facilitates the 
degradation of APOBEC although this mechanism isn’t perfect and some effects of 
APOBEC activity can be seen in HIV-1 genomes. Our observations here suggest that the 












overall increase in viral diversity.  Some early reversion mutations are the result of 
APOBEC induced mutations and reversions are associated with restoration of viral 
fitness. Thus the direct correlation between the numbers of APOBEC induced and 
reversion mutations observed here in early infection suggests that more APOBEC 
mutations are associated with more reversions which will result in increased viral fitness 
and an accompanying decrease in CD4 target cells. How HIV-1 may potentially use 
selective APOBEC activity during early infection to its advantage as observed here need 
further investigation. 
Collectively our data indicate that there is rapid viral evolution in CTL epitopes in 
early infection which implies that cellular immune responses are exerting a strong 
pressure.  The hierarchy of escape is similar to the hierarchy of immune recognition. 
Screening eleven individuals over time showed no association between escape and 
disease progression however, in depth analysis showed that CTL escape is much more 
frequent in a rapid progressor compared to a slow progressor.  Lastly, we find that 
APOBEC is playing a significant role in reversions suggesting that the virus is using this 















Since 1990 there was a steady increase in the prevalence of HIV-1 infection in 
women attending antenatal clinics from 0.7% to 29% making South Africa one of the 
hardest hit countries in the world (National HIV and Syphilis Prevalence survey, South 
Africa, 2007; Dorrington & Bourne, 2008). The development of an effective vaccine is 
thus a high priority for the region.  Here we were interested in firstly, characterizing HIV 
diversity in full-length genomes as diversity remains one of the greatest challenges in 
vaccine development; and secondly in defining factors driving early viral evolution as 
events in early infection are thought to be predictive of long term disease outcome. This 
information would therefore be useful in informing correlates associated with control of 
viral replication. 
Characterisation of full-length genomes from an acute infection cohort in Durban 
found no evidence of a transmission network, however for the first time we observed a 
number of supported clusters of viruses from chronic infections within the South African 
epidemic, suggesting a recent common ancestor for each of them.  As expected the 
subtype matched vaccine, SAAVI subtype C consensus-based immunogen currently 
being evaluated in Phase I clinical trial, was predicted to provide better coverage against 
the primary infection than the subtype B Merck immunogen tested in the HVTN503/ 
Phambili  trial. However the new generation mosaic immunogens based on group M or 
subtype C (valency of 4) are predicted to give the best coverage.  However interestingly, 
the mosaic Gag immunogens with a valency of 2 gave similar coverage as the SAAVI 
consensus-based Gag (valency of 1) immunogen. Thus we propose that the inclusion of 
additional mosaic immunogens to the HIV-1 subtype C SAAVI vaccine may be sufficient 
to broaden epitope coverage of this candidate. However it is also possible that suboptimal 
vaccine candidates that do not induce sterilizing immunity may still be beneficial as they 












and thus reduce viral setpoint.  While this has been demonstrated in many non-human 
primate models, unfortunately this has not been shown in the HVTN502/503 vaccine 
trial. 
HIV transmission is associated with a severe virus population bottleneck and there 
is some evidence that certain genotypic and phenotypic properties of the viral envelope 
are selectively advantageous during transmission (Derdeyn et al., 2004; Rong et al., 
2007; Wolfs et al., 1992).  However, open questions remain as to whether this holds true 
both for genome regions other than the envelope, and for all HIV-1M subtypes. We 
identified thirty-nine sites within the proteomes of these viruses that differentiated them 
from viruses sampled during chronic infections.  Through longitudinal analysis of amino 
acid frequency changes that occurred during the first six months of infection, together 
with data on host HLA alleles, we provide evidence that approximately 28.6% of site-
specific differences in amino acid frequency spectra between primary and chronic 
infection proteomes are potential immune escape mutations.  The remaining 60.7% of 
frequency differences between the two groups are probably due to defunct immune 
evasion substitutions reverting to consensus amino acid states following transmission. 
This data provides further understanding of processes determining the genomic and 
immunogenic properties of viruses during early infections which is important if we are to 
understand HIV pathogenesis sufficiently well to design protective vaccines against the 
virus. 
Lastly, we investigated the role of the adaptive immune response on early viral 
evolution.  In eleven individuals monitored over time, we found that viral diversification, 
reversion and APOBEC induced mutations were associated with disease progression. 
While CTL escape in these individuals was not associated with disease progression, an in 
depth analysis of multiple full-length viral genomes from a rapid compared to a slow 
progressor showed that viruses from the rapid progressor had an increased number of 
sites under positive selection pressure and an increased number of escape mutations. 
Fifty percent of escape in this individual occurred through amino acid shuffling or 












In summary this study contributes to our understanding of optimal immunogen 
design for South Africa.  It shows that, within the first three months of infection, almost 
all changes in the viral genomes are associated with adaptation to the HLA of the new 
host, with a larger proportion of changes attributable to reversion as the virus presumably 
adapts to restore viral fitness.  Host genetic factors such as APOBEC- induced mutations 
and HLA associated mutations are key factors driving viral evolution in early infection. 
However, larger numbers are needed to unravel the relative importance of the different 













HIV-1 SUBTYPE C PCR AND COMPLETE GENOME 
SEQUENCING PRIMERS 
A1.  PCR primers for near full-length genome amplification 
A2. Gag gene sequencing primers optimised for subtype C from Sanders-Buell et al. 
(1995). 
Primer Location Sequence (5’-3’) 
G00 767→782 GAC TAG CGG AGG CTA GAA G (19mer) 
GF20 895→912 GTA TGG GCA AGC AGG GAG CTG (21mer) 
GF40 1078→1094 GAC ACC AAG GAA GCC TTA GA (20mer) 
GF60 1176→1192 CAG TCA AAA TTA TCC TAT AG (20mer) 
GF80 1477→1493 AGA GAA CCA AGG GGA AGT GA (20mer) 
G100 1820→1834 TAG AAG AAA TGA TGA CAG (18mer) 
G110 2081→2095 AGG CTA ATT TTT TAG GGA (18mer) 
GF01 2264←2278 AGG GGT CGC TGC CAA AGA (18mer) 
GF15 1960←1978 CCT TGC CAC AGT TGA AAC ATT T (22mer) 
G35 1817←1835 CAT GCT GTC ATC ATT TCT TCT A (22mer) 
GF45 1740←1758 TTG GAC CAA CAA GGT GTC TGT C (22mer) 
GF65 1295←1307 GCT GTA AAC ATG GGT A (16mer) 
GF85 1177←1193 TGC ACT ATA GGA TAA TTT TG (20mer) 
Primer Direction Location Sequence (5’-3’) 
1.U5C forward 5’ GGG TGA GTG CTC TAA GTA GTG TGT GCC CGT CTG T 
1.U5Cb forward 5’ GGG TGA GTG CTC TAA GTA GTG TGT GCC CAT CTG T 
1.3.3pIC reverse 3’ GGG ACT TAG AGC ACT CAA GGC AAG CTT TAT TG 
2.U5C forward 554-580, 
5’ 
GGC CGC GGA TCC AGT AGT GTG TGC CCG TCT GTT GTG 
TGG ACT 
2.3.3plC reverse 3’ GGC CGC GCG GCC GCT AGA GCA CTC AAG GCA AGC TTT 












A3. Env gene sequencing primers optimised for subtype C from Sanders-Buell et al. 
(1995). 
Primer Location Sequence (5’-3’) 
EF0 5856→5883 TAG AGC CCT GGA ACC ATC CAG GAAGTCAGC C 
EF00 6204→6228 GGG AAA GAG CAG AAG ACA GTG GCA ATG A (28 mer) 
EF20 6433→6456 GGG CTA CAC ATG CCT GTG TAC CCA CAG (27mer) 
E70 6562→6585 GGG ATC AAA GCC TAA AGC CAT GTG TAA (27mer) 
E90 6956→6976 CAC AGT ACA ATG TAC ACA TGG AAT (24mer) 
EF110 7005→7025 CTG TTA AAT GGT AGC CTA GCA GAA (24mer) 
EF140 7669→7687 GTG AAT TAT ATA AAT ATA AAG T (22mer) 
E170 7802→7816 AGC AGG AAG CAC TAT GGG (18mer) 
E200 8095→8118 GGG ATA ACA TGA CCT GGA TGC AGT GGG (27mer) 
E230 8276→8296 AAT ATT CAT AAT GAT AGT AGG AGG (24mer) 
EF260 8523→8544 TTC AGC TAC CAC CGA TTG AGA GAC T (25mer) 
E01 9064←9086 TCC AGT CCC CCC TTT TCT TTT AAA AA (26 mer) 
EF05 8587←8605 TAC TTA AGG GCT TCC CAC CCC C (22mer) 
EF15 8424←8442 CTT GCT CTC CAC CTT CTT CTT C (22mer) 
EF35 8343←8362 GGT GAG TAT CCC TGC CTA ACT CT (23mer) 
EF55 7914←7937 GCC CCA GAC CGT GAG TTG CAA CAT ATG (27mer) 
E75 7793←7816 GCG CCC ATA GTG CTT CCT GCT GCT CCC (27mer) 
EF95 7524←7538 AAT GGG AGG GGC ATA CAT (18mer) 
EF115 7351←7371 AGA AAA ATT CTC CTC TAC AAT TAA (24mer) 
EF135 7061←7084 AGA TGT ACT ATT ATT GTT TTG ACA TTG T (28mer) 
EF155 6505←6530 CTG ATC CAC CAT GTC ATT TTT CCA CAT GT (29mer) 












A4. Pol gene sequencing primers 
Primer Location Sequence (5’-3’) 
P1 2255→2271 CCC TCA AAT CAC TCT TTG GC (20mer) 
P2 2585→2595 ATT AAA GCC AGG AA (14) 
P3 2885→2899 GGG GGA TGC ATA TTT TTC (18) 
P4 3205→3220 ACA AGA AAC ATC AGA AAG A (19) 
P5 3489→3505 CCA GTA CAT GGA GTA TAT TA (20) 
P6 3765→3780 TAT TGG CAA GCC ACC TGG A (19) 
P7 4025→4039 AGA AGT AAA CAT AGT AAC AG 
P8 4325→4339 AGT AGC AAA AGA AAT AGT (18) 
P9 4655→4669 TCC CTA CAA TCC CCA AAG (18) 
P10 4954→4969 TAC TCT GGA AAG GTG AAG G (19) 
PR 5199←5214 TAA TGG (T/G)AT GTG TAC TTC T (19) 
A5. Select pol and accessory genes sequencing primers described by Rousseau et al. 
(2006) 
Primer Location Sequence (5’-3’) 
SQ9FC(3) 5074→5099 , pol-vif CAGGTAGACAGGATGAAGATCAGAAC 
SQ10FC 5833→5857, tat exon 1 start GGAGCCAGTAGATCCTAACCTAGAG 
SQ8R 5963←5988, tat exon 1 CTCCGCTTCTTCCTGCCATAGGAGAT 
SQ9’RC 5341←5366, vif ATATGAATTAGTTGGTCTGCCAGGCC 
SQ9RC(3) 5165←5188, vif TTGGATGTCTGCTTTCATAATGAT 
SQ16F 3’ LTR CCACACACAAGGCTACTTCC 
SQ8R 5988, tat exon 1 CTCCGCTTCTTCCTGCCATAGGAGAT 
SQ8RC 4660←4685, pol TTCTACTACTCCCTGACTTTGGGGAT 
SQ10RC 4555←4583, pol GCCATTGTCTGTATGTATTACTTTGACTG 
RT2 (reverse) 3301←3321, pol GTATGTCATTGACAGTCCAGC 
SQ11RC(3) 3687←3713, pol TTTAGGAGTCTTTCCCCATATTACTAT 
SQ11RC(4) 3960←3981, pol CAGTCTTCTGATTTGTTGTTTC 
SQ12R 3304←3322, pol TGTATGTCATTGACAGTCC 
HIP202 
(reverse) 
2328←2352, pol CTAATACTGTATCATCTGCTCCTGT 












A6. Additional full-length env gene sequencing primers 
Primer Location Sequence (5’-3’) 
ENV A 5957 - 5982 GGC TTA GGC ATC TCC TAT GGC AGG AAG AA 
ENV N 9544 - 9521 CTG CCA ATC AGG GAA GTA GCC TTG TGT 
VIF1 4903 - 4923 GGG TTT ATT ACA GGG ACA  GCA GAG 
Env-CF 6208 - 6224 AAG AGC AGA AGA CAG TGG CA 
Env-CR 6875 - 6859 ACA ATA ATG TAT AGG AAT TG 
Env-AF 6206 - 6223 GAA AGA GCA GAA GAC AGT GGC 
Env-AR 7799 - 7783 TGC TGC TCC CAA GAA CCC AA 
Env-DF 7211 - 7226 AGC ACA TTG TAA CAT TAG T 
Env-DR 7684 - 7665 ACT TTA TAT TTA TAT AAT TCA CT 
Env-MF 7641 - 7661 GGA GGA GAT ATG AGG GAC AAT TGG 
Env-BR 7334 - 7317 AAT TTC TAG GTC CCC TCC TGA 
Env-NF 8104 - 8117 TGA CCT GGA TGC AGT GG 














REAGENTS AND BUFFERS 
 
B1. 50X TAE buffer 
121g Tris base 
28.55 ml glacial acetic acid 
50 ml 0.5M EDTA pH 8.0 
Make up to 500 ml with deionised sterile H2O (Sambrook et al., 1989). 
 
B2. 0.5M EDTA (pH 8.0) 
Add 186.1g disodium ethylenediaminetetraacetate.2H2O to ~800 ml deionised 
sterile water. Dissolve by stirring vigorously on magnetic stirrer while adjusting 
the H to 8.0 with ~20g NaOH pellets. The disodium salt of EDTA will only 
dissolve if the pH of the solution is adjusted to ~8.0 (Sambrook et al., 1989) 
 
B3. 6X loading buffer II (for agarose gel electrophoresis) 
 0.25% bromophenol blue 
 0.25% xylene cyanol FF 
 15% ficoll (type 400) 
Make up in deionised sterile H2O and store at room temperature (Sambrook et al., 
1989). 
 
B4. 10X TBE buffer 
 108g Tris-HCl 
 55g Boric acid 
 20 ml 1.5M EDTA 
 Make up to 1 liter with deionised sterile H2O 
 
B5. 6X Polyacrylamide gel loading dye 
 0.25% Bromophenol blue 












 15% Ficoll in deionised sterile H2O 
 
B6. 30% Acrylamide stock solution (29:1) 
 29g Acrylamide 
 1g Bis-acrylamide 
Dissolve in 60 ml deionised sterile H2O at 37°C. Make up to 100 ml with water 
and filter sterilize through a Nalgene 0.45 µm filter 
 Keep in dark bottle at 4°C for a month. 
Caution! Acrylamide is a potential neurotoxin that is absorbed through the 
skin. (Sambrook et al., 1989) 
  
B7. 5% Non-denaturing Polyacrylamide gel 
 8.3 ml 30% Acrylamide stock (29:1) 
 5 ml 10X TBE 
 10g urea 
Add water to about 36.7 ml. Allow reagents to dissolve by stirring and when all 
powder is dissolved make up with water to a final volume of 50 ml. 
When ready to pour gel add 200 µl 25% APS and 33 µl TEMED to initiate gel 
polymerization. Pour gel immediately after addition of APS and TEMED. 
 
B8. 5% Denaturing Polyacrylamide gel 
 8.3 ml 30% Acrylamide stock (29:1) 
 5 ml 10X TBE 
 10g urea 
 
B9. 25% Ammonium persulfate (APS) 
 2.5g APS 
Make up to 10 ml with deionised sterile water. Store at 4°C. 
  
B10. HTA annealing buffer 













20 mM EDTA 
B11. LB broth 
10g NaCl 
5g Yeast extract 
10g Tryptone 
Dissolve and make up to 1 liter with deionised sterile water. Autoclave 
immediately. 
B12. LB agar selection plates containing Kanamycin 
Prepare LB medium as above, but add 15 g/L agar before autoclaving. 
Autoclave on a liquid cycle for 20 minutes at 15 psi. 
After autoclaving, cool to ~55°C. 
Add 50 µg/ml of kanamycin, and pour into 10 cm plates. 














METHODS AND MANUFACTURERS’ PROTOCOLS 
 
 
C1: Purification of Viral RNA (Spin Protocol, QIAGEN) 
 
This protocol is for purification of viral RNA from 140 µl plasma, serum, urine, cellculture 
media, or cell-free body fluids using a microcentrifuge. For automated 
purification of viral RNA using the QIAamp Viral RNA Mini Kit on the QIAcube, refer 
to the QIAcube User Manual and the relevant protocol sheet. 
Larger starting volumes, up to 560 µl (in multiples of 140 µl), can be processed by 
increasing the initial volumes proportionally and loading the QIAamp Mini column 
multiple times, as described below in the protocol. Some samples with very low viral 
titers should be concentrated before the purification procedure; see ”Protocol: Sample 
Concentration“ (page 30). 
Alternatively, larger sample volumes can be processed using one of the following kits, 
which provide simultaneous purification of viral DNA and RNA. 
■ QIAamp MinElute® Spin Kit* 200 µl 
■ QIAamp MinElute Vacuum Kit 500 µl 
■ QIAamp UltraSens® Virus Kit 1000 µl 
Important points before starting 
■ Read “Important Notes” (pages 15–22) before starting the protocol. 
■ All centrifugation steps are carried out at room temperature (15–25°C). 
Things to do before starting 
■ Equilibrate samples to room temperature (15–25°C). 
■ Equilibrate Buffer AVE to room temperature for elution in step 11. 
■ Check that Buffer AW1 and Buffer AW2 have been prepared according to the 
instructions on page 17. 
■ Add carrier RNA reconstituted in Buffer AVE to Buffer AVL according to instructions 
on page 15. 
Procedure 
1. Pipet 560 µl of prepared Buffer AVL containing carrier RNA into a 1.5 ml 
microcentrifuge tube. 
If the sample volume is larger than 140 µl, increase the amount of Buffer 
AVL–carrier RNA proportionally (e.g., a 280 µl sample will require 1120 µl 
Buffer AVL–carrier RNA) and use a larger tube. 
2. Add 140 µl plasma, serum, urine, cell-culture supernatant, or cell-free body fluid 
to the Buffer AVL–carrier RNA in the microcentrifuge tube. Mix by pulse-vortexing 
for 15 s. 
To ensure efficient lysis, it is essential that the sample is mixed thoroughly with 
Buffer AVL to yield a homogeneous solution. Frozen samples that have only been 
thawed once can also be used. 
3. Incubate at room temperature (15–25°C) for 10 min. 
Viral particle lysis is complete after lysis for 10 min at room temperature. Longer 
incubation times have no effect on the yield or quality of the purified RNA. 
Potentially infectious agents and RNases are inactivated in Buffer AVL. 
4. Briefly centrifuge the tube to remove drops from the inside of the lid. 
5. Add 560 µl of ethanol (96–100%) to the sample, and mix by pulse-vortexing for 
15 s. After mixing, briefly centrifuge the tube to remove drops from inside the lid. 
Only ethanol should be used since other alcohols may result in reduced RNA 
yield and purity. Do not use denatured alcohol, which contains other substances 
such as methanol or methylethylketone. If the sample volume is greater than 
140 µl, increase the amount of ethanol proportionally (e.g., a 280 µl sample will 
require 1120 µl of ethanol). In order to ensure efficient binding, it is essential that 
the sample is mixed thoroughly with the ethanol to yield a homogeneous solution. 
6. Carefully apply 630 µl of the solution from step 5 to the QIAamp Mini column 












at 6000 x g (8000 rpm) for 1 min. Place the QIAamp Mini column into a clean 
2 ml collection tube, and discard the tube containing the filtrate. 
Close each spin column in order to avoid cross-contamination during 
centrifugation. 
Centrifugation is performed at 6000 x g (8000 rpm) in order to limit 
microcentrifuge noise. Centrifugation at full speed will not affect the yield or 
purity of the viral RNA. If the solution has not completely passed through the 
membrane, centrifuge again at a higher speed until all of the solution has passed 
through. 
7. Carefully open the QIAamp Mini column, and repeat step 6. 
If the sample volume was greater than 140 µl, repeat this step until all of the 
lysate has been loaded onto the spin column. 
8. Carefully open the QIAamp Mini column, and add 500 µl of Buffer AW1. Close 
the cap, and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the QIAamp Mini 
column in a clean 2 ml collection tube (provided), and discard the tube containing 
the filtrate. 
It is not necessary to increase the volume of Buffer AW1 even if the original 
sample volume was larger than 140 µl. 
9. Carefully open the QIAamp Mini column, and add 500 µl of Buffer AW2. Close 
the cap and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min. Continue 
directly with step 11, or to eliminate any chance of possible Buffer AW2 
carryover, perform step 10, and then continue with step 11. 
Note: Residual Buffer AW2 in the eluate may cause problems in downstream 
applications. Some centrifuge rotors may vibrate upon deceleration, resulting in 
flow-through, containing Buffer AW2, contacting the QIAamp Mini column. 
Removing the QIAamp Mini column and collection tube from the rotor may also 
cause flow-through to come into contact with the QIAamp Mini column. In these 
cases, the optional step 10 should be performed. 
10. Recommended: Place the QIAamp Mini column in a new 2 ml collection tube (not 
provided), and discard the old collection tube with the filtrate. Centrifuge at full 
speed for 1 min. 
11. Place the QIAamp Mini column in a clean 1.5 ml microcentrifuge tube (not 
provided). Discard the old collection tube containing the filtrate. Carefully open 
the QIAamp Mini column and add 60 µl of Buffer AVE equilibrated to room 
temperature. Close the cap, and incubate at room temperature for 1 min. 
Centrifuge at 6000 x g (8000 rpm) for 1 min. 
A single elution with 60 µl of Buffer AVE is sufficient to elute at least 90% of 
the viral RNA from the QIAamp Mini column. Performing a double elution using 
2 x 40 µl of Buffer AVE will increase yield by up to 10%. Elution with volumes of 
less than 30 µl will lead to reduced yields and will not increase the final 
concentration of RNA in the eluate. 
Viral RNA is stable for up to one year when stored at –20°C or –70°C. 
 
Preparation of reagents 
Addition of carrier RNA to Buffer AVL* 
Add 310 µl Buffer AVE to the tube containing 310 µg lyophilized carrier RNA to obtain 
a solution of 1 µg/µl. Dissolve the carrier RNA thoroughly, divide it into conveniently 
sized aliquots, and store it at –20°C. Do not freeze–thaw the aliquots of carrier RNA 
more than 3 times. 
Check Buffer AVL for precipitate, and if necessary incubate at 80°C until the precipitate 
is dissolved. Calculate the volume of Buffer AVL–carrier RNA mix needed per batch 
of samples by selecting the number of samples to be simultaneously processed from 
Table 1. For larger numbers of samples, volumes can be calculated using the following 
sample calculation: 
n x 0.56 ml = y ml 
y ml x 10 µl/ml = z µl 
* Contains chaotropic salt. Take appropriate laboratory safety measures, and wear gloves when handling. 
Not compatible with disinfecting agents that contain bleach. See page 6 for safety information. 
where: 
n = number of samples to be processed simultaneously 
y = calculated volume of Buffer AVL 












Gently mix by inverting the tube 10 times. To avoid foaming, do not vortex. 
 
Note: The sample-preparation procedure is optimized for 5.6 µg of carrier RNA per 
sample. If less carrier RNA has been shown to be better for your amplification system, 
transfer only the required amount of dissolved carrier RNA to the tubes containing Buffer 
AVL. (Use of less than 5.6 µg carrier RNA per sample must be validated for each particular 
sample type and downstream assay.) 
Buffer AVL–carrier RNA should be prepared fresh, and is stable at 2–8°C for up to 
48 hours. This solution develops a precipitate when stored at 2–8°C that must be redissolved 
by warming at 80°C before use. Do not warm Buffer AVL–carrier RNA solution 
more than 6 times. Do not incubate at 80°C for more than 5 minutes. Frequent warming 
and extended incubation will cause degradation of carrier RNA, leading to reduced 
recovery of viral RNA and eventually false negative RT-PCR results. This is particularly 
the case with low-titer samples. 
Buffer AW1* 
Buffer AW1 is supplied as a concentrate. Before using for the first time, add the 
appropriate amount of ethanol (96–100%) as indicated on the bottle and in Table 2. 
Buffer AW1 is stable for 1 year when stored closed at room temperature, but only until 
the kit expiration date. 
* Contains chaotropic salt. Take appropriate laboratory safety measures, and wear gloves when handling. 
Not compatible with disinfecting agents that contain bleach. See page 6 for safety information. 
† Contains sodium azide as a preservative. 
Buffer AW2† 
Buffer AW2 is supplied as a concentrate. Before using for the first time, add the 
appropriate amount of ethanol (96–100%) to Buffer AW2 concentrate as indicated on 
the bottle and in Table 3. 
Buffer AW2 is stable for 1 year when stored closed at room temperature, but only until 
the kit expiration date. 
(extracted from QIAamp Viral RNA Mini Handbook 12/2007) 
 
 
C2: pCR-XL TOPO cloning of large (3 - 10 kb) DNA inserts (Invitrogen) 
 
Gel-Purifying PCR Products 
Before Starting 
Bring the Sodium Iodide solution, Binding Buffer, 4X Final Wash, and TE Buffer 
to room temperature. Mix well to re-dissolve salts before using. Store these 
solutions at room temperature after the first use. 
To prepare 1X Final Wash, take a sterile 15 ml bottle and transfer all of the 4X 
Final Wash solution to the bottle. Add 7.5 ml of 100% ethanol to the 4X Final 
Wash solution to prepare the 1X Final Wash solution. Store at room temperature. 
 
Nuclease Control 
It is very important to minimize the presence of nucleases to ensure the highest 
cloning efficiencies. Follow the guidelines listed below. While some guidelines 
may not appear as rigorous as others, they are sufficient for purifying long PCR 
fragments. 
• Wear gloves at all times 
• Use sterile plasticware and glassware 
• Autoclave TAE to use as the running buffer 
• Rinse agarose gel apparatus and comb with autoclaved water or TE buffer 
• Use a new razor to excise gel slice* 
• Use new plastic wrap (e.g. Saran® Wrap) if needed 
*The same razor may be used to excise different bands in the same gel if you are 
careful not to bring over pieces from an earlier excision. 
 
Preparing the Gel 
Follow the instructions below to prepare a 0.8% agarose gel. The recipe will make 
one agarose gel with a volume of 50 ml. 
1. Mix 0.4 g of general purpose agarose and 50 ml 1X TAE buffer in a clean glass 
flask. 












agarose and continue to heat in this fashion for 3 minutes to destroy 
nucleases. 
3. Remove from the microwave and allow to cool for 3 minutes. 
4. Add 20-40 µl of the 2 mg/ml Crystal Violet solution to the agarose and swirl 
to mix. The agarose should be light to medium purple in color. 
5. Rinse the gel box and comb with autoclaved water or TE buffer. 
Note: Use a comb that will hold all of the PCR amplification (48 µl) in one well, if 
possible. 
6. Pour the gel and set the comb in the gel. 
7. When the gel has solidified, cover the gel with 1X TAE buffer. You do not 
have to add crystal violet to the running buffer. Proceed to the next section to 
prepare your sample. 
 
Loading and Running the Gel 
1. Add 8 µl of 6X Crystal Violet Loading Buffer to 40 µl of the PCR amplification 
and load onto the gel. Prepare the control PCR product in the same manner. 
2. Run the gel at 80 volts until the crystal violet in the gel has run about a 
quarter of the way UP the gel (crystal violet appears to migrate towards the 
negative pole). You should also see the thin blue PCR product move down 
into the gel. If no PCR product is visible, insufficient DNA was loaded 
(<200 ng). 
3. Compare your PCR product to the 7 kb control PCR fragment. If your PCR 
product is sufficiently resolved so that you can easily excise the fragment, 
turn off the power supply. Proceed directly to Excising the PCR Product, 
below. 
 
Excising the PCR Product 
Remember to excise the control fragment as well as your band. 
1. Pour off the buffer (or transfer the gel to new Saran® Wrap). 
Note: Placing the gel on a fluorescent light box may help visualize the fragments. 
2. Using a new razor blade, carefully excise the desired band from the gel. 
Note: Razor blade may be rinsed with autoclaved water or TE prior to cutting the next 
band. 
3. Cut up the excised piece of agarose into small chunks and transfer to a sterile 
1.5 ml microcentrifuge tube. 
Note: Cutting up the agarose piece reduces the time and temperature required to melt 
the agarose. 
4. Estimate the volume of the agarose pieces (generally this is around 100 µl). 
Alternatively, you can weigh the gel slice and assume that 1 mg ~ 1 µl. 
5. Add 2.5 times its volume of 6.6 M sodium iodide (i.e. 250 µl) and mix by 
shaking vigorously by hand or vortexing. 
6. Incubate at 42 to 50°C until the agarose is completely melted (~2 minutes). 
Mix the solution periodically by shaking vigorously. 
7. Place the tube at room temperature and add 1.5 volumes of Binding Buffer 
(i.e. 525 µl) and mix well. Proceed directly to Isolating the PCR Product, next 
page. 
 
Isolating the PCR Product 
1. Assemble a S.N.A.P.™ purification column and collection vial and 
load all of the mixture from Step 7, previous page, onto the column (875 µl). 
2. Centrifuge at 2,000 to 3,000 x g in a microcentrifuge for 30 seconds at room 
temperature. 
3. Pour the liquid in the collection vial back onto the column and repeat Step 2. 
4. Repeat Step 3 one more time to bind all the DNA to the column (i.e. load 
solution onto the column for a total of 3 times). 
5. After the last centrifugation, discard the liquid in the collection tube. 
6. Add 400 µl of 1X Final Wash to the S.N.A.P.™ column and centrifuge as in 
Step 2. 
7. Repeat Step 6 and discard the liquid in the collection tube after the final 
centrifugation (800 µl). 
8. Centrifuge the column again at maximum speed (>10,000 x g) for at least 












9. Transfer the column to a new, sterile 1.5 ml microcentrifuge tube.
10. Add 40 µl of TE buffer directly to the column material and incubate for
1 minute at room temperature to let the buffer absorb into the column.
11. Centrifuge the column at maximum speed (>10,000 x g) for 1 minute to elute
the DNA into the microcentrifuge tube.
12. Place the tube on ice and discard the column.
13. Assay 10 µl by ethidium bromide agarose gel electrophoresis to estimate the
DNA concentration. Concentration should be between 2 and 40 ng/µl. In
most cases, there is no need to concentrate the DNA further.
Store the DNA at -20°C for up to one week or proceed directly to Setting Up the
TOPO® Cloning Reaction, next page. For the highest efficiencies, proceed
directly to TOPO® Cloning.
TOPO® Cloning Reaction 
1. Set up the following 5 µl TOPO® Cloning reaction in a sterile microcentrifuge
tube. Remember to set up a reaction for the control PCR product. You may
also wish to set up a "vector-only" reaction as a negative control (use TE
buffer instead of insert).
Gel-purified long PCR product from Step 12, page 8 4 µl
pCR®-XL-TOPO® vector 1 µl
Final Volume 5 µl
2. Mix gently and incubate for 5 minutes at room temperature (~25°C). For the
best possible results, do not leave for more than 5 minutes at room
temperature or the transformation efficiencies will decrease!
3. After the 5 minute incubation, add 1 µl of the 6X TOPO® Cloning Stop
Solution and mix for several seconds at room temperature.
Note: Addition of the Stop Solution increases the yield of transformants by an average
of 2-fold for chemically competent cells and 10-fold for electrocompetent cells.
4. Briefly centrifuge the tube and place on ice.
Note: The TOPO® Cloning reaction may be stored on ice or frozen at -20°C for up to
24 hours. You may see a decrease in the transformation efficiency, but the cloning
efficiency should remain high. We recommend that you proceed immediately to
Transforming Competent Cells
Transforming Competent Cells 
Introduction Once you have performed the TOPO® Cloning reaction, you will transform your 
pCR®-XL-TOPO® construct into competent E. coli provided with your kit. 
Materials Supplied by the User 
• LB plates containing 50 µg/ml kanamycin or Low Salt LB plates containing
25 µg/ml Zeocin™ (see page 18 for recipes)
Note: For the control reaction you will need an additional LB plate containing
50 µg/ml kanamycin and 50 µg/ml ampicillin
• 37°C shaking and non-shaking incubator
• 42°C water bath (for transformation of chemically competent cells)
Preparing for Transformation
For each transformation, you will need one vial of competent cells and two
selective plates.
• Thaw the vial of S.O.C. medium from Box 2 and bring to room temperature.
• Warm selective plates at 37°C for 30 minutes.
• Thaw on ice 1 vial of One Shot® competent cells for each transformation.
One Shot®  Chemical Transformation
Use this protocol only with One Shot® TOP10 chemically competent cells.
1. Add 2 µl of the TOPO® Cloning reaction into a vial of One Shot® cells and
mix gently. Do not mix by pipetting up and down.
2. Incubate on ice for 30 minutes.
3. Heat-shock the cells for 30 seconds at 42°C without shaking.
4. Immediately transfer the tubes to ice and incubate for 2 minutes.
5. Add 250 µl of room temperature S.O.C. medium.
6. Cap the tube tightly and shake the tube horizontally at 37°C for 1 hour. Place
on ice.
7. Spread 50-150 µl from each transformation on a prewarmed plate. For the












containing 50 µg/ml kanamycin and on an LB plate containing 50 µg/ml 
kanamycin and 50 µg/ml ampicillin. 
8. Incubate plates overnight at 37°C. 
9. An efficient TOPO® Cloning reaction will produce several hundred colonies. 
Note: Larger plasmids will produce fewer colonies. 
 
Analyzing Positive Clones 
1. Pick ~10 colonies and culture them overnight in LB medium containing 
50 µg/ml kanamycin. Alternatively, you may use Low Salt LB medium 
containing 25 µg/ml Zeocin™. 
Note: If you transformed One Shot® Mach1™-T1R competent E. coli, you may inoculate 
overnight-grown colonies and culture them for 4 hours in prewarmed LB medium 
containing 50 µg/ml kanamycin or Low Salt LB medium containing 25 µg/ml Zeocin™ 
before isolating plasmid. For optimal results, we recommend inoculating as much of a 
single colony as possible. 
2. Isolate plasmid DNA using your method of choice.  
3. Analyze the plasmids by restriction analysis to confirm the presence and 
correct orientation of the insert. Use a restriction enzyme or a combination of 
enzymes that cut once in the vector and once in the insert. 
Sequencing You may sequence your construct to confirm that your gene is cloned in the 
correct orientation.  
(extracted from Invitrogen Life Technologies Instruction manual Version M, 14 June 2004, 25-0199) 
 
 













C3: Plasmid DNA Purification Using the QIAprep Spin Miniprep Kit (QIAGEN) 
This protocol is designed for purification of up to 20 µg of high-copy plasmid DNA from 
1–5 ml overnight cultures of E. coli in LB (Luria-Bertani) medium. For purification of 
low-copy plasmids and cosmids, large plasmids (>10 kb), and DNA prepared using 
other methods, refer to the recommendations on page 44. 
Please read “Important Notes” on pages 15–21 before starting. 
Note: All protocol steps should be carried out at room temperature. 
Procedure 
1. Resuspend pelleted bacterial cells in 250 µl Buffer P1 and transfer to a microcentrifuge
tube.
Ensure that RNase A has been added to Buffer P1. No cell clumps should be visible
after resuspension of the pellet.
If LyseBlue reagent has been added to Buffer P1, vigorously shake the buffer bottle
to ensure LyseBlue particles are completely dissolved. The bacteria should be
resuspended completely by vortexing or pipetting up and down until no cell clumps
remain.
2. Add 250 µl Buffer P2 and mix thoroughly by inverting the tube 4–6 times.
Mix gently by inverting the tube. Do not vortex, as this will result in shearing of
genomic DNA. If necessary, continue inverting the tube until the solution becomes
viscous and slightly clear. Do not allow the lysis reaction to proceed for more than
5 min.
If LyseBlue has been added to Buffer P1 the cell suspension will turn blue after addition
of Buffer P2. Mixing should result in a homogeneously colored suspension. If
the suspension contains localized colorless regions or if brownish cell clumps are
still visible, continue mixing the solution until a homogeneously colored suspension
is achieved.
3. Add 350 µl Buffer N3 and mix immediately and thoroughly by inverting the tube
4–6 times.
To avoid localized precipitation, mix the solution thoroughly, immediately after
addition of Buffer N3. Large culture volumes (e.g. ≥5 ml) may require inverting up
to 10 times. The solution should become cloudy.
If LyseBlue reagent has been used, the suspension should be mixed until all trace
of blue has gone and the suspension is colorless. A homogeneous colorless suspension
indicates that the SDS has been effectively precipitated.
4. Centrifuge for 10 min at 13,000 rpm (~17,900 x g) in a table-top microcentrifuge.
A compact white pellet will form.
5. Apply the supernatants from step 4 to the QIAprep spin column by decanting or
pipetting.
6. Centrifuge for 30–60 s. Discard the flow-through.
7. Recommended: Wash the QIAprep spin column by adding 0.5 ml Buffer PB and
centrifuging for 30–60 s. Discard the flow-through.
This step is necessary to remove trace nuclease activity when using endA+ strains
such as the JM series, HB101 and its derivatives, or any wild-type strain, which
have high levels of nuclease activity or high carbohydrate content. Host strains
such as XL-1 Blue and DH5™ do not require this additional wash step.
8. Wash QIAprep spin column by adding 0.75 ml Buffer PE and centrifuging for
30–60 s.
9. Discard the flow-through, and centrifuge for an additional 1 min to remove residual
wash buffer.
Important: Residual wash buffer will not be completely removed unless the
flow-through is discarded before this additional centrifugation. Residual ethanol
from Buffer PE may inhibit subsequent enzymatic reactions.
10. Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute DNA,
add 50 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or water to the center of each QIAprep
spin column, let stand for 1 min, and centrifuge for 1 min.













C4: Plasmid DNA Purification Using QIAfilter Plasmid Midi and Maxi Kits (QIAGEN) 
This protocol is designed for preparation of up to 100 µg of high- or low-copy plasmid  
or cosmid DNA using the QIAfilter Plasmid Midi Kit, or up to 500 µg using the QIAfilter 
Plasmid Maxi Kit. In this protocol, QIAfilter Cartridges are used instead of conventional 
centrifugation to clear bacterial lysates. For purification of double-stranded M13 
replicative-form DNA, see the recommendations at www.qiagen.com/goto/ 
plasmidinfo . 
Low-copy plasmids which have been amplified in the presence of chloramphenicol 
should be treated as high-copy plasmids when choosing the appropriate culture volume. 
Maximum Recommended Culture Volumes* 
QIAfilter Midi QIAfilter Maxi 
High-copy plasmids 25 ml 100 ml 
Low-copy plasmids 50–100 ml 250 ml†
* For high-copy plasmids, expected yields are 75–100 µg for the QIAfilter Plasmid Midi Kit and 300–500 µg 
for the QIAfilter Plasmid Maxi Kit. For low-copy plasmids, expected yields are 20–100 µg for the QIAfilter 
Plasmid Midi Kit and 50–250 µg for the QIAfilter Plasmid Maxi Kit using these culture volumes. 
† The maximum recommended culture volume applies to the capacity of the QIAfilter Maxi Cartridge. If 
higher yields of low-copy plasmids are desired, the lysates from two QIAfilter Maxi Cartridges can be 
loaded onto one QIAGEN-tip 500. 
Important points before starting 
■ New users are advised to familiarize themselves with the detailed protocol
provided in this handbook. In addition, extensive background information is
provided on our plasmid resource page www.qiagen.com/goto/plasmidinfo .
■ If working with low-copy vectors, it may be beneficial to increase the lysis buffer
volumes in order to increase the efficiency of alkaline lysis, and thereby the DNA
yield. In case additional Buffers P1, P2, and P3 are needed, their compositions
are provided in Appendix B: Composition of Buffers, on page 37. Alternatively,
the buffers and additional QIAfilter Cartridges may be purchased separately (see
page 42).
■ Optional: Remove samples at the steps indicated with the symbol☞ in order to 
monitor the procedure on an analytical gel (see page 34).
■ In contrast to the standard protocol, the lysate is not incubated on ice after addition
of Buffer P3. 
■ Blue (marked with a ▲) denotes values for the QIAfilter Plasmid Midi Kit; red
(marked with a ●) denotes values for the QIAfilter Plasmid Maxi Kit. 
and Maxi Kits 
Things to do before starting 
■ Add the provided RNase A solution to Buffer P1 before use. Use one vial of RNase
A (centrifuge briefly before use) per bottle of Buffer P1, to give a final concentration 
of 100 µg/ml. 
■ Check Buffer P2 for SDS precipitation due to low storage temperatures. If
necessary, dissolve the SDS by warming to 37°C.
■ Pre-chill Buffer P3 at 4°C.
■ Optional: Add the provided LyseBlue reagent to Buffer P1 and mix before use. Use
one vial LyseBlue (centrifuge briefly before use) per bottle of Buffer P1 to achieve
a 1:1000 dilution. LyseBlue provides visual identification of optimum buffer mixing
thereby preventing the common handling errors that lead to inefficient cell lysis
and incomplete precipitation of SDS, genomic DNA, and cell debris. For more
details see “Using LyseBlue reagent” on page 15.
Procedure 
1. Pick a single colony from a freshly streaked selective plate and inoculate a starter
culture of 2–5 ml LB medium containing the appropriate selective antibiotic. Incubate
for approx. 8 h at 37°C with vigorous shaking (approx. 300 rpm).
Use a tube or flask with a volume of at least 4 times the volume of the culture.
2. Dilute the starter culture 1/500 to 1/1000 into selective LB medium. For high-copy
plasmids, inoculate ▲25 ml or ● 100 ml medium with ▲25–50 µl or ● 100–200 µl
of starter culture. For low-copy plasmids, inoculate ▲ 50–100 ml or ● 250 ml












12–16 h with vigorous shaking (approx. 300 rpm). 
Use a flask or vessel with a volume of at least 4 times the volume of the culture. The 
culture should reach a cell density of approximately 3–4 x 109 cells per milliliter, 
which typically corresponds to a pellet wet weight of approximately 3 g/liter medium 
(see page 12). 
3. Harvest the bacterial cells by centrifugation at 6000 x g for 15 min at 4°C.
ƒ If you wish to stop the protocol and continue later, freeze the cell pellets at –20°C.
4. Resuspend the bacterial pellet in ▲ 4 ml or ● 10 ml Buffer P1.
For efficient lysis it is important to use a vessel that is large enough to allow complete
mixing of the lysis buffers. Ensure that RNase A has been added to Buffer P1.
If LyseBlue reagent has been added to Buffer P1, vigorously shake the buffer bottle
before use to ensure LyseBlue particles are completely resuspended. The bacteria
should be resuspended completely by vortexing or pipetting up and down until no
cell clumps remain.
5. Add ▲4 ml or ● 10 ml Buffer P2, mix thoroughly by vigorously inverting the sealed
tube 4–6 times, and incubate at room temperature (15–25°C) for 5 min.
Do not vortex, as this will result in shearing of genomic DNA. The lysate should
appear viscous. Do not allow the lysis reaction to proceed for more than 5 min. After
use, the bottle containing Buffer P2 should be closed immediately to avoid
acidification from CO2 in the air.
If LyseBlue has been added to Buffer P1 the cell suspension will turn blue after
addition of Buffer P2. Mixing should result in a homogeneously colored suspension.
If the suspension contains localized colorless regions or if brownish cell clumps are
still visible, continue mixing the solution until a homogeneously colored suspension
is achieved.
During the incubation prepare the QIAfilter Cartridge: 
Screw the cap onto the outlet nozzle of the QIAfilter Midi or QIAfilter Maxi Cartridge. 
Place the QIAfilter Cartridge in a convenient tube. 
6. Add ▲ 4 ml or ● 10 ml chilled Buffer P3 to the lysate, and mix immediately and
thoroughly by vigorously inverting 4–6 times.
Proceed directly to step 7. Do not incubate the lysate on ice. 
Precipitation is enhanced by using chilled Buffer P3. After addition of Buffer P3, a 
fluffy white material forms and the lysate becomes less viscous. The precipitated 
material contains genomic DNA, proteins, cell debris, and KDS. The lysate should 
be mixed thoroughly to ensure even potassium dodecyl sulfate precipitation. If the 
mixture still appears viscous, more mixing is required to completely neutralize the 
solution. It is important to transfer the lysate into the QIAfilter Cartridge immediately 
in order to prevent later disruption of the precipitate layer. 
If LyseBlue reagent has been used, the suspension should be mixed until all trace of 
blue has gone and the suspension is colorless. A homogeneous colorless suspension 
indicates that the SDS has been effectively precipitated. 
7. Pour the lysate into the barrel of the QIAfilter Cartridge. Incubate at room
temperature (15–25°C) for 10 min. Do not insert the plunger!
Important: This 10 min incubation at room temperature is essential for optimal
performance of the QIAfilter Midi or QIAfilter Maxi Cartridge. Do not agitate the
QIAfilter Cartridge during this time. A precipitate containing proteins, genomic
DNA, and detergent will float and form a layer on top of the solution. This ensures
convenient filtration without clogging. If, after the 10 min incubation, the precipitate
has not floated to the top of the solution, carefully run a sterile pipet tip around the
walls of the cartridge to dislodge it.
8. Equilibrate a ▲ QIAGEN-tip 100 or ● QIAGEN-tip 500 by applying ▲ 4 ml or
● 10 ml Buffer QBT, and allow the column to empty by gravity flow.
Flow of buffer will begin automatically by reduction in surface tension due to the
presence of detergent in the equilibration buffer. Allow the QIAGEN-tip to drain
completely. QIAGEN-tips can be left unattended, since the flow of buffer will stop
when the meniscus reaches the upper frit in the column.
9. Remove the cap from the QIAfilter Cartridge outlet nozzle. Gently insert the plunger
into the ▲ QIAfilter Midi or ● QIAfilter Maxi Cartridge and filter the cell lysate into












Filter until all of the lysate has passed through the QIAfilter Cartridge, but do not 
apply extreme force. Approximately ▲10 ml and ● 25 ml of the lysate are generally 
recovered after filtration. ☞ Remove a ▲ 240 µl or ● 120 µl sample of the filtered lysate and save for an 
analytical gel (sample 1) in order to determine whether growth and lysis 
conditions were optimal. 
10. Allow the cleared lysate to enter the resin by gravity flow.☞ Remove a ▲ 240 µl or ● 120 µl sample from the flow-through and save for an
analytical gel (sample 2) in order to determine the efficiency of DNA binding to 
the QIAGEN Resin. 
11. Wash the QIAGEN-tip with ▲ 2 x 10 ml or ● 2 x 30 ml Buffer QC.
Allow Buffer QC to move through the QIAGEN-tip by gravity flow. The first wash is 
sufficient to remove all contaminants in the majority of plasmid DNA preparations. 
The second wash is especially necessary when large culture volumes or bacterial 
strains producing large amounts of carbohydrates are used. ☞ Remove a ▲ 400 µl or ● 240 µl sample from the combined wash fractions and 
save for an analytical gel (sample 3). 
12. Elute DNA with ▲ 5 ml or ● 15 ml Buffer QF.
Collect the eluate in a 15 ml or 50 ml tube (not supplied). Use of polycarbonate 
centrifuge tubes is not recommended as polycarbonate is not resistant to the alcohol 
used in subsequent steps. 
Note: For constructs larger than 45–50 kb, prewarming the elution buffer to 65°C 
may help to increase yield. ☞ Remove a ▲ 100 µl or ● 60 µl sample of the eluate and save for an analytical 
gel (sample 4). 
ƒ If you wish to stop the protocol and continue later, store the eluate at 4°C. 
Storage periods longer than overnight are not recommended. 
Plasmid Midi 
and Maxi Kits 
13. Precipitate DNA by adding ▲ 3.5 ml or ● 10.5 ml (0.7 volumes) room-temperature
isopropanol to the eluted DNA. Mix and centrifuge immediately at ≥15,000 x g for 
30 min at 4°C. Carefully decant the supernatant. 
All solutions should be at room temperature in order to minimize salt precipitation, 
although centrifugation is carried out at 4°C to prevent overheating of the sample. 
Alternatively, disposable conical bottom centrifuge tubes can be used for 
centrifugation at 5000 x g for 60 min at 4°C. Isopropanol pellets have a glassy 
appearance and may be more difficult to see than the fluffy, salt-containing pellets 
that result from ethanol precipitation. Marking the outside of the tube before 
centrifugation allows the pellet to be more easily located. Isopropanol pellets are also 
more loosely attached to the side of the tube, and care should be taken when 
removing the supernatant. 
14. Wash DNA pellet with ▲ 2 ml or ● 5 ml of room-temperature 70% ethanol, and
centrifuge at ≥15,000 x g for 10 min. Carefully decant the supernatant without
disturbing the pellet.
Alternatively, disposable conical-bottom centrifuge tubes can be used for
centrifugation at 5000 x g for 60 min at 4°C. The 70% ethanol removes precipitated
salt and replaces isopropanol with the more volatile ethanol, making the DNA easier
to redissolve.
15. Air-dry the pellet for 5–10 min, and redissolve the DNA in a suitable volume of buffer
(e.g., TE buffer, pH 8.0, or 10 mM Tris·Cl, pH 8.5).
Redissolve the DNA pellet by rinsing the walls to recover all the DNA, especially if
glass tubes have been used. Pipetting the DNA up and down to promote
resuspension may cause shearing and should be avoided. Overdrying the pellet will
make the DNA difficult to redissolve. DNA dissolves best under slightly alkaline
conditions; it does not easily dissolve in acidic buffers.
Determination of yield 
To determine the yield, DNA concentration should be determined by both UV 
spectrophotometry at 260 nm and quantitative analysis on an agarose gel. For reliable 













Agarose gel analysis 
We recommend removing and saving aliquots during the purification procedure 
(samples 1–4). If the plasmid DNA is of low yield or quality, the samples can be 
analyzed by agarose gel electrophoresis to determine at what stage of the purification 
procedure the problem occurred (see page 34). 












 C6: Single genome amplification (SGA) of HIV-1 subtype C complete genomes 
(based on SOP # CHAVI-MBSC-2 entitled “whole genome amplification of hiv-1 from a single RNA 
template”, University of Alabama at Birmingham, Alabama, USA) 
1. Purpose: 
To PCR amplify the whole HIV-1 genome, minus the Long Terminal Repeats (LTRs), 
from a single viral RNA template (single genome). 
2. Background and overview of procedures: 
-This protocol involves the dilution of viral cDNA to a point that, upon setting up 
multiple replicate PCR reactions with the cDNA as template, the product generated has a 












-In this case, according to Poisson’s distribution, no more than 30%, or 28 out of a 96-
well reaction plate with 2 negative controls, should be positive for amplification product 
to ensure that 6 of 7 amplified DNAs arise from a single-copy template. 
-For example, if viral load data is provided, a known amount of viral RNA is purified
from plasma using the QIAamp Viral RNA Mini Kit and it is transcribed at a theoretical 
concentration of 200 copies per µL using a gene-specific primer with Invitrogen’s 
Superscript III (a reverse transcriptase that has been genetically modified to reduce 
RNase H activity and to maintain cDNA synthesis activity at temperatures (ie. 50-55ºC) 
required to melt template secondary structure). 
-The viral cDNA is then serially diluted to obtain single copy in a two-step “nested”
PCR procedure. 
-Due to variations in sample integrity, stability (ex. freeze/thaw), and serum components,
etc., it may be necessary to repeat the PCR reactions at a lower or higher dilution to 
achieve the desired results. 
-The resulting positive amplification products are initially subjected to direct DNA
sequencing the entire amplicon, all of which must be free of any double peaks. 
3. Viral RNA extraction
NOTE 1: perform in RNA-only clean room. 
Use the QIAamp Viral RNA Mini Kit and protocol, (catalogue numbers 52904, 52906, or 
52908);  
4 cDNA synthesis 
4.1 Reagents and Solutions 
4.1.1 Superscript III Reverse Transcriptase, Cat. No. 18080-044, Invitrogen Corp. 
(components: SSIII RT (200 U/µL), 5X First-Strand Buffer, 0.1 M DTT) 
4.1.2 Sterile, RNase-free water 
4.1.3 10mM dNTP mix 
4.1.4 RNA template (Sec. 6) 
4.1.5 RNaseOUT, Cat. No. 10777-019, Invitrogen Corp. 













4.1.7 RNase H, Cat. No. 18021-014 
 
4.2 Procedure 
NOTE 1: Perform in RNA-only clean room. 
NOTE 2: Spin down condensate after heat incubation steps. 
NOTE 3: Use viral RNA extract equivalent to 5,000 copies. 
 
A. Pipette the following components into a 0.5 ml RNase-free tube: 
 
µL/tube  [ stock]   [final] 
8.50 H2O 
0.50 primer   20 µM   0.25 
2.00 dNTP mix  10 mM each  0.5 
15.00 RNA template 
26.00 per tube 
 
B. Place tube in 65ºC heat block for 5’, remove to ice for 1’. 
 
C. Add the following components: 
µL/tube  [ stock]   [final] 
8.00 5x Buffer   5x    1x 
2.00 DTT   0.1 M    0.005 M 
2.00 RNaseOUT  40 u/µL    2 u/µL 
1.00 SSIII RT   200 u/µL    5 u/µL 
13.00 per tube 
 
40.00 final volume 
 
D. Mix and incubate at 45ºC for 1.5 hr. 
E. Add 1 µL additional SSIII RT, and then increase to 45ºC for 1.5 hr. 












G. To each tube, add 1 µL RNase H, incubate at 37ºC for 20’. 
 
5. PCR amplification 
Note: PCR reaction mixes should be made up and aliquoted in an area free of PCR 
amplified or plasmid DNA. 
 
5.1 Establish appropriate titration 
5.1.1 cDNA Dilutions 
5.1.1.1 Perform serial dilutions of cDNA to obtain <30% positivity. 
5.1.1.2 Proceed to PCR amplification. If too few/too many positive reactions, 
repeat PCR with lower/higher dilution. 
 
5.2 First round amplification reaction 
5.2.1 Prepare PCR reaction mix for 1-16 reactions (ex. 15 test + 1 negative control). 
µL/rxn   x 16     [stock]    [final] 
40.00    640 dH2O 
5.00    80 10X buffer 1 
     with Mg++  
1.75    28 dNTPs    10mM each   0.35 µM 
0.75    12 Expand Long  
    Template Enzyme Mix 
0.75    12 1.U5C    20µM    0.3 µM 
0.75   12 1.U5Cb   20µM   0.3 µM 
0.75    12 1.5.5pIC    20µM    0.3 µM 
49.00    784 
 
5.5.2 If using master mix, add 49.00 µL + 1 µL H2O to the negative well. Add 1.0 µL of 
2-fold serially diluted cDNA per well in triplicate wells; for example. 1:2, 1:4, 1:8. 1:16, 
and 1:32. 
5.2.3 Once the correct cDNA dilution has been determined, add 15 µL of diluted cDNA 












5.2.3 Place in thermal cycler. 
5.2.4 Run with following parameters: 
ºC Time 
94 2 min 
10 cycles 94 15 sec 
60 30 sec 
68 8 min 
25 cycles 94 15 sec 
68 30 sec 
68 8 min, add 20 sec each cycle 
68 7 min 
 4 hold 
5.2.5 From all positive wells, save remaining first round in 0.5ml tube at -80ºC for future 
full-length genome cloning. 
6.1 Second round (Nested) PCR reaction 
6.1.1 Prepare PCR reaction mix for 1-16 reactions (ex. 15 test + 1 negative control). 
µL/rxn   x 16     [stock]   [final] 
40.00 640 dH2O 
5.00 80  10X buffer 1 (Mg++ ) 
1.75 28  dNTPs  10mM each 0.35 µM 
0.75 12  Expand Long 
     Template Enzyme Mix 
0.75 12  2.U5C  20 µM 0.3 µM 
0.75 12  2.5.5pIC   20µM 0.3 µM 
49.00 784 
6.1.2 Pipette 49.0 µL to each well of a 96-well plate. Add 1.0 µL from each of the First 
Round PCR reaction samples to the corresponding well of the nested PCR plate. Mix by 
pipetting up and down. 












6.1.4 Run with following parameters: 
ºC   Time 
94   2 min 
10 cycles  94   15 sec 
55   30 sec 
68   8 min 
25 cycles  94   15 sec 
55   30 sec 
68   8 min, add 20 sec each cycle 
68   7 min 
4   hold 
 
7 Proceed to reaction analysis. 
7.1 Agarose Gel Electrophoresis, 2 µL sample. Select all positive wells. 
7.2 Sequence DNA directly (0.5 – 1µL per sequencing reaction) after ExoSAP 
pretreatment. 
7.3 Store remaining 2nd round product for future use. 
 
 
C7: Single genome amplification of the HIV-1 env gene (gp160) 
(adapted from CHAVI-MBSC-0.03, University of Alabama at Birmingham, Alabama, USA) 
1.  Purpose: 
To amplify the HIV-1 envelope gene from a single viral RNA template (single genome). 
2.  Background and overview of procedures: 
-This protocol involves the dilution of viral cDNA to a point that, upon setting up 
multiple replicate PCR reactions with the cDNA as template, the product generated has a 
high probability of having been amplified from a single genome copy. 
-In this case, according to Poisson’s distribution, no more than 30%, or 28 out of a 96-
well reaction plate with 2 negative controls, should be positive for amplification product 













-For example, if viral load data is provided, a known amount of viral RNA is purified 
from plasma using the QIAamp Viral RNA Mini Kit and it is transcribed at a theoretical 
concentration of 200 copies per µL using a gene-specific primer with Invitrogen’s 
Superscript III (a reverse transcriptase that has been genetically modified to reduce 
RNase H activity and to maintain cDNA synthesis activity at temperatures (ie. 50-55ºC) 
required to melt template secondary structure). 
-The viral cDNA is then serially diluted to obtain single copy in a two-step “nested” PCR 
procedure. 
-Due to variations in sample integrity, stability (ex. freeze/thaw), and serum components, 
etc., it may be necessary to repeat the PCR reactions at a lower or higher dilution to 
achieve the desired results. 
  
-The resulting positive amplification products are initially subjected to direct DNA 
sequencing in the highly variable V1-V2 regions to pre-test for sequence homogeneity 
(lack of multiple superimposed peaks). 
-To confirm single-genome amplification, the entire envelope gene is sequenced and 
cannot contain any double peaks. 
 
3. Procedure for RNA extraction 
Note: Work with plasma in sterile Biosafety cabinet. 
 
3.1 Use QIAamp Viral RNA Mini Kit following protocol as written in Handbook 
with the following adaptations: 
3.2 Normalize the 140 µL plasma sample to contain equivalent viral copies  (i.e. 
20,000 copies per 140 µL). 
3.2.1.1.1 Increase volume to 140 µL with  PBS.  
3.2.1.1.2 Or, if viral load is too low, concentrate by centrifugation for 1 hr at 17k 
rpm.  Remove supernatant down to 140 µL and resuspend viral pellet.  
3.3 Elute RNA from spin column with 55 µL buffer (stock elution buffer is diluted   













4 cDNA synthesis 
4.1 Reagents and Solutions 
4.1.1 Superscript III Reverse Transcriptase, Cat. No. 18080-044, Invitrogen Corp. 
(components : SSIII RT (200 U/µL), 5X First-Strand Buffer, 0.1 M DTT) 
4.1.2 Sterile, RNase-free water 
4.1.3 10mM dNTP mix 
4.1.4 RNA template (Sec. 6) 
4.1.5 RNaseOUT, Cat. No.  10777-019, Invitrogen Corp. 
4.1.6 20 uM Primer, subtype specific  
4.1.7 RNase H, Cat. No. 18021-014 
 
4.2 Procedure for cDNA synthesis 
Note:perform in RNA-only clean room. Spin down condensate after heat incubation  
A Pipette the following components into a 0.5 ml RNase-free tube: 
µL/tube     [ stock]  [final] 
  8.75  H2O 
  1.25  primer    20 µM 0.25 
  (OFM19or oligo-dT20) 
  5.00  dNTP mix  10 mM each 0.5 
15.00  per tube 
50.00  RNA template      
65.00 total volume 
 
Place tube in 65ºC heat block for 3-5’, remove to ice for 1’. 
 
Add the following components: 
µL/tube   [ stock]  [final] 
 20.00            5x Buffer      5x                    1x 
  5.00             DTT              100 mM                5  
  5.00             RNaseOUT      40 u/µL              2 












35.00             per tube 
 100.00  final volume 
Mix and incubate at 45ºC for 1 hr and then increase to 45ºC for 1 hr. 
Inactivate SSIII RT by heating at 70ºC for 15’. 
To each tube, add 1 µL RNase H, incubate at 37ºC for 20’. 
5 PCR amplification 
Note:  PCR reaction mixes should be made up and aliquoted in an area free of PCR 
amplified or plasmid DNA. 
5.1 Reagents and Solutions 
5.1.1 Sterile H2O, ultrapure 
5.1.2 Subtype C Primers: 
5.1.2.1 OFM19:  5’– GCACTCAAGGCAAGCTTTATTGAGGCTTA 
5.1.2.2 VIF1:      5’– GGGTTTATTACAGGGACAGCAGAG 
5.1.2.3 ENV A:  5’– GGCTTAGGCATCTCCTATGGCAGGAAGAA 
5.1.2.4 ENV N:  5’– CTGCCAATCAGGGAAGTAGCCTTGTGT 
5.1.3 High Fidelity Platinum Taq–Invitrogen 11304. 
5.1.4 dNTPs (10mM each). 
5.1.5 Diluted cDNA template (above) 
5.2 Establish Appropriate Titration 
5.2.1 cDNA Dilutions 
5.2.1.1 Perform serial dilutions of cDNA to obtain <30% positivity. 
5.2.1.2 Proceed to PCR amplification.  If too few/too many positive reactions, repeat 
PCR with lower/higher dilution. 
If viral load is not known, use the PCR conditions in sec. 8.5 to determine the dilution at 












replicates at each dilution of trial serial cDNA dilutions. Select dilution that gave less 
than 30% positives for further SGA study. 
 
If viral load is known and 20,000 viral copies are extracted, determine the dilution at 
which cDNA will yield a single cDNA molecule per reaction by starting out with the 
following dilution: 
 *Select 1:180 dilution for further SGA study. 
 
5.3 First Round Amplification Reaction 
5.3.1 Prepare PCR reaction mix for 1-100 reactions (94 test + 2 negative controls). 
µL/rxn         x 100                                                            [stock]            [final] 
  15.3           1530 dH2O  
    2                200 10X buffer (supplied) 
  0.8                 80 MgS04 (supplied) 
  0.4                 40 dNTPs (10mM each) 
  0.1                 10 Taq (High Fidelity Platinum) 
  0.2                 20                             OFM19                       20µM         0.2 µM  
  0.2                 20                                 VIF                        120µM        0.2 µM  
19.0                 1900 
Add 20 µL to the negative wells. 
1µL cDNA per well. Once the correct cDNA dilution has been determined, add  













 Estimated # 
PCR+/  total 
replicates
 % PCR +
1:20 10  16/16 100%
 1:60 3.3  13/16 81%
 1:180 1.1  4/16 25%













5.3.2 Place in thermal cycler.  Run with following parameters: 
                       ºC Time 
 
              94 2 min 
 
35 cycles        94 15 sec  
55 30 sec  
68 4 min  
 
68 10-20 min  
 
 4  hold  
 
5.3.3 From all positive wells, save remaining first round in 0.5ml tube at -80ºC for 
future envelope cloning. 
 
5.4 Second Round (Nested) PCR Reaction 
5.4.1 Prepare PCR reaction mix for 1-100 reactions (94 test + 2 negative controls). 
µL/rxn      x 100                                                          [stock]                [final] 
  15.3        1530        dH2O  
    2             200        10X buffer (supplied) 
  0.8              80        MgS04 (supplied) 
  0.4              40        dNTPs (10mM each) 
  0.1              10         Taq (High Fidelity Platinum) 
  0.2              20         ENV A                                        20µM              0.2 µM  
  0.2              20         ENV N                                        20µM              0.2 µM  
19.0           1900 
 
5.4.2 Pipette 19 µL to each well of a 96-well plate.  Add 1µL from each of the First 
Round PCR reaction samples to the corresponding well of the nested PCR 












5.4.3 Place in thermal cycler.  Run with following parameters. 
                      ºC Time 
 
             94 2 min 
 
45 cycles        94 15 sec  
55 30 sec  
68 4 min   
 
68 10-20 min  
 
 4  hold  
 
6 Proceed to reaction analysis. 
6.1.1  Agarose Gel Electrophoresis, 3-5 µL sample. Select all positive wells. 
6.1.2 Sequence DNA directly (0.5 – 1µL per sequencing reaction). Store remaining 













D1: Quality and depth coverage assessment of HIV-1 whole genomes assembled from 
sequences obtained from cloned genome amplicons. 
Strain_clone Time post infection Average quality Coverage 
CAP63_F4 34 d 86 4.9 
CAP65_F1 42 d 87.4 6.3 
CAP69 14 d 89.4 7.2 
CAP85_F1 23 d 84.1 5.1 
CAP88_F2 36 d 87.1 5.3 
CAP174 28 d 88.9 6.9 
CAP206_F1 41 d 86.4 6 
CAP210_F1 36 d 88.1 6 
CAP221 14 d 87.8 5.4 
CAP228_F2 53 d 86.5 4.5 
CAP229_F1 48 d 81.6 3.8 
CAP239_F1 36 d 87.8 7.1 
CAP244_F1 58 d 87.7 6.6 
CAP248_F1 62 d 89.7 5.5 
CAP255 54 d 86.9 5.2 
CAP256 42 d 86.6 6.2 












D2: This figure shows the predicted epitope coverage by the SAAVI consensus-based 
Gag immunogen and different valencies of the subtype C Gag mosaic proteins (Fischer et 



















































































































D3: Putative CTL epitopes with evidence of escape 
Gag Peptide HLA Comment 
CAP8 QYMLKHLVWAS A*2301 HIV Immunology Compendium 
DIYKRWIILGLNKIVRM B*0801 HIV Immunology Compendium 
CAP30 ALNP/GLLET A*0201 A2, HIV Immunology Compendium 
SLYNTVATL/YCVHEDT A*0201 A2, HIV Immunology Compendium 
2008 
GHQAAMQMLKE A*0201 A2, HIV Immunology Compendium 
WIILGLNKIVRMYSPVSIL A*0201 A2, HIV Immunology Compendium 
FLQNRPEPT A*0201 A2, HIV Immunology Compendium 
CAP61 VQNAQGQ/MVHQPLSPR A*6602 A*6603, HIV Immunology Compendium 
CAP63 IILGLN/KIVRMYSPVSIL A*0201 HIV Immunology Compendium 
CAP85 NIMMQRGNI B*0801 
CAP239 STLQEQVAM B*5801 HIV Immunology Compendium 
CAP257 KKHYMLKHLVW A*2301 HIV Immunology Compendium 
VRMYSPVSIL/DI A*2301 HIV Immunology Compendium 
Pol HLA Comment 
CAP30 ALTAICEEM A*0201 HIV Immunology Compendium 
SWTVNDIQ/KLVGKLNWA A*0201 A2, HIV Immunology Compendium 
CAP61 HTN/DVKQLTEAV A*6802 HIV Immunology Compendium 
DIVPLTEEA/ELE A*6802 
ELAENREIL/KEPVH A*6802 
CAP63 DIQ/KLVGKLNWA A*0201 A2, HIV Immunology Compendium 
NWRAMAADF A*0201 A2, HIV Immunology Compendium 
IWQLDCTHL/EGKVI A*2301 
WWAGIKQEF/GIPY A*2301 
QAEHL/KTAVQMAVF A*0201 A2, HIV Immunology Compendium 
CAP85 RGRQKVVSL B*0801 B*0801 
CAP206 GPKVKQWPL/TEEK B*0702 B7, HIV Immunology Compendium 
G/KLNWASQIYP A*3204 
WEFVNTPPL B*4403 
SESEIVNQI B*0702 B7, HIV Immunology Compendium 
LIKKE/KVYLSWVPA A*0702 B7, HIV Immunology Compendium 
CAP210 WTVNDIQKL A*6802/ 
B*1510 
B15, HIV Immunology Compendium 
CAP239 PIVLPEKESW B*5801 HIV Immunology Compendium 
SAAVKAACW/WAGIQQEF B*5801 HIV Immunology Compendium 
CAP257 PYQIYQEPF A*2301 HIV Immunology Compendium 
SESELVNQI/IEELIK B*4403 
TKLEGKVIL/VAVHVASGY ?B*1503 B*1510, HIV Immunology Compendium 
MAVFIHNFK/RK A*2902 














Env  HLA Comment 
CAP8 WWIWSSLGF/WML A*2301  
 LWVTVYYGV/PVWK A*2301  
 KD/KKQKVYALF/ A*2301  
 EIMIRSENL B*0801  
 WYIKIFII A*2301  
 RSIRLVNGF B*0801  
    
CAP30 WMLMIYNVV A*0201    
 CSFNATTER/RDKK A*3402  
 VYEREVH/ NVWATHACV A*0201   A2, HIV Immunology Compendium 
 ALFYRPDIV/LLSQND A*0201    
 T/IIVHLNESV A*0201    
 SGGD/LEITTHS/FNCR A*0201   A2, HIV Immunology Compendium 
 SEITGLLLT/RDGGR B*4501    
 LLQYWSREL  A*0201   HIV Immunology Compendium 
    
CAP61 TEN/FNMWKNDMV A*6802   A68, HIV Immunology Compendium 
 CSFNTTTEI A*6802    
 YTNTIYRLL A*6802    
 IR/LVSGFLSLA A*6802    
 SLFDTIAIA/VAE A*6802 A68, HIV Immunology Compendium 
    
CAP63 HFPNKTITF A*2301    
 NYTQTIYQL A*2301    
 LLDSIAITV A*0201   HIV Immunology Compendium 
 RIIEVIQRF A*0201   HIV Immunology Compendium 
    
CAP85 NM/KDNWRSELY A*3002    
 RYLGSLVQY A*3002   HIV Immunology Compendium 
    
CAP206 KPCVKLTPLC/VTLN B*0702  HIV Immunology Compendium 
 WKNDMVDQM B*4403    
    
CAP210 CSFNATTEL A*6802   A2, HIV Immunology Compendium 
 LLNATAIAV/AEAT A*6802   HIV Immunology Compendium 
    
CAP239 VTFDPIPIHY/CAPA A*2902 A29, HIV Immunology Compendium 
 THI/FNCRGEFFY A*2902   A29, HIV Immunology Compendium 
 FSITNWLWY B*5801,  
A*0101   
 
    
CAP244 GMLRNYQQW A*2301    
 KQKEYALFY A*3004    
    
CAP257 YEKEVHNVW B*4403    
 NYTNSIYKL/LEE A*2301    
 D/KWQNLWNWF A*2301    
 KYLGSLVQY A*2902,A*

















Vif  HLA Comment 
CAP8 EWRLRRYSTQVD B*1510 HIV Immunology Compendium 
 KPKKRKPPL B*0801  
    
CAP30 GLADQLIHI/HYF A*0201 A2, HIV Immunology Compendium 
    
CAP61 WRLRR/YSTQVDPGL A*6802    
    
CAP63 SLVKHHMYV A*0201   A2, HIV Immunology Compendium 
 KVG/SLQYLALTA A*0201   A2, HIV Immunology Compendium 
    
CAP206 RTWNSLVKH A*3204    
 KPPLPSVTKL/TEDRWNN B*0702   B7, HIV Immunology Compendium 
    
CAP210 WHLGHGVSIEWRLRKY B*1510   HIV Immunology Compendium 
    
CAP239 VSGKARGWF/YRHHY B*5801 HIV Immunology Compendium 
    
CAP257 TESAIRQAI B*4403    
 
Vpr  HLA Comment 
CAP30 SLGQYIYET A*0201   A2, HIV Immunology Compendium 
    
CAP61 FPRPWLHDL B*4201   HIV Immunology Compendium 
    
CAP63 I/RILQQLLFI A*0201 HIV Immunology Compendium 
    
CAP244 QHIYETYGDTW A*2301    
    
CAP257 WLHSLGQYI A*2902/ 
B*4202  
B*4201, HIV Immunology Compendium 
 
 
Vpu  HLA Comment 
CAP8 MEQLRLLDV/N B*0801  
    
CAP61 IIAVILAIV A*6802   A2, HIV Immunology Compendium 
    
CAP85 AIIVWTITYLEY A*3002    
 




B*1510   
B15, HIV Immunology Compendium 
 
 
Rev  HLA Comment 
CAP63 EALL/LAVRTIKLL A*0201    
 QIHSISERIL A*0201   A2, HIV Immunology Compendium 
    
CAP85 RNRRRRWRA/RQR 
RHI/REISERILS 
B*0801   
















Nef  HLA Comment 
CAP8 EGLI/YSKKRQEIL B*0801   HIV Immunology Compendium 
 KFD/SQLARRHIA B*0801/ 
B*1510   
HIV Immunology Compendium 
    
CAP30 QEEEEEVGFPV B*4501 HIV Immunology Compendium 
    
CAP45 AQEEEEEVGFPV B*4501 HIV Immunology Compendium 
    
CAP61 STNADMAWL A*6802    
    
CAP63 QEEEGVGF/PV B*4501 HIV Immunology Compendium 
 ILDLWVYHT A*0201 HIV Immunology Compendium 
    
CAP85 AQE/EEKEVGFPV B*4501 HIV Immunology Compendium 
 AASQDLGKY A*3002  
 GYFPDWQNY A*3002 HIV Immunology Compendium 
 MAREKHPEF B*0801  
    
CAP210 REVLQ/WKFDSSLAF/ B*1510 B15, HIV Immunology Compendium 
    
CAP239 RPMTYKAAV / 
KAAVDLSFF 
B*5801 HIV Immunology Compendium 
 YTPGPGVRYPL/TFGWC B*4201/ 
B*5801 
B58, HIV Immunology Compendium 
    
CAP244 QEILDLWVY B*4403 Matthews et al., 2008  
    
CAP257 QEILDLWVY B*4403 Matthews et al., 2008 

















Peptide (p49-61) No. of 
sequences with 
mutation 
HLA association Escape 
2 (P1V05) 
QRQIRSISERILSTCLGR 20/20 B*1510 12-16 wks
5 (P2V00) .................. 7/7 
12 (P2V05) .................. 4/4 
16 (P2V07) ...........F...... 1/1 
52 (P3V10) .................. 1/7 
...........F...... 
6/7 






Peptide (p58-75) No. of 
sequences with 
mutation 
HLA association Escape 
2 LQAQEEEEEVGFPVRPQV 4/4 B*4501 5-12 wks
5 .................. 8/8 
12 .......G.......... 3/4 
........X......... 1/4 
16 .......G.......... 1/1 



























2 (P1V00) KIKALTEICEEMEKEGKI 10/10 A*0201 5-11 wks 
5 (P2V01) .................. 3/3   
11 (P2V05) .........K........ 6/7   
  ......K........... 1/7   
29 (P3V10) ......K........... 1/3   
  .........D........ 1/3   
  ......A........... 1/3   
37 (P3V12) ......K........... 1/4   












2 KQLTEAVHKIAIESIVIW 11/11 A*0201  29- 37 wks 
5 .................. 1/1   
11 .................. 7/7   
29 .................. 3/3   
37 .......Q.......... 1/4   
  .....V............ 1/4   














 HLA association Escape 
2 VEALIRILQQLLFVHFRI 11/11 A*0201 5-11 wks 
5 .................. 1/1   
11 ......S........... 4/7   
  ......M...........   1/7   
  ......T........... 1/7   
  .....K............ 1/7   
29 ....V.T........... 1/3   
  ......M........... 1/3   
  ......T........... 1/3   
37 ......M...........  1/5   

























Peptide (p81-101) No. of 
sequences with 
mutation 
HLA association Escape 
2 ..................... 28/30 No 2-11 wks
.....K............... 2/30 
5 ..................... 1/1 
11 ................T.... 3/8 
............G........ 2/8 
...................E. 3/8 

























Peptide (p41-58) No. of 
sequences with 
mutation 
HLA association Escape 
2 RRRRWRARQQQIHKISER 29/30 A*2301 2-11 wks
.K................ 1/30 
5 .................. 1/1 
11 .................. 4/8 
............Q..... 3/8 
..K............... 1/8 


































HLA association Escape 
2 MIGEIKNCSFNATTELRDKK  30/30 
A*2301 
2-5 wks 
5 ...........T........ 1/1   
11 ............S....... 4/8   
  ..............V..... 1/8   
  .................... 1/8   
  ..............A..... 1/8   
  ...................E 1/8   
29 .TE...........A..... 1/29   
  .R.........S........ 4/29   
  .T.........S........ 1/29   
  .R.................. 1/29   
  ................W... 6/29   
  ............S....... 1/29   
  ..............I....Q 1/29   
  ...............I.... 4/29   
  ...........T...I.... 3/29   
  ..............A..... 1/29   
  I..............I.... 2/29   
  ..............V....E 1/29   
  ..E...........A..... 1/29   
  ...........S........ 1/29   
  I................... 1/29   
37 I.............I....Q 1/5   
  I..............I.... 1/5   
  ...............I.... 1/5   
  .R.............I.... 1/5   
  ......X....S........ 1/5 
 
  








2 IRQAHCNISKTQWNTTLE  30/30 No associated HLA 11-29 wks 
5 .................. 1/1   
11 ........X......... 1/8   
29 .................. 16/29   
  .........N........ 2/29   
  ..........P....... 2/29   
  .........E........ 2/29   
  ....Y.....K....... 1/29   
  .............D.N.. 1/29   
  ...............I.. 1/29   
  ..............A... 4/29   
37 .................. 1/4   
  ..........A....... 1/4   
  ..........K....... 1/4   




























Peptide (p389-413)(gp120) No. of 
sequences with 
mutation 
HLA association Escape 
2 FNSTYMPNGIHIPNGASEVITLPCR 30/30 No associated HLA 2-5 wks
5 .......S................. 1/1 



























2 SWSNKSEEDIWGNMTWMQ 30/30 No associated HLA 11-29 wks
5 .................. 1/1 
11 .................. 8/8 






























2 IEEEGGEQDNSRSIRLVS 29/30 A*2301/A*0201 2-11wks 
  
..K............... 
1/30   
5 
.................. 
1/1   
11 
..........N....... 
2/8   
  
...K......N....... 
1/8   
  
.............R.... 
3/8   
  
......G........... 
2/8   
29 
.................. 
16/29   
  
......G........... 
6/29   
  
......G...N....... 
1/29   
  
.......K.......... 
3/29   
  
.......E.S........ 
2/29   
  
.........S........ 
1/29   
37 
.................. 




 Gain of 
glycosylation 











    
 Peptide (p816-833)(gp41) 
 
   
2 LLDSIAITVAEGTDRIIE 30/30 A*0201 2-5 wks 
5 ..N............... 1/1   
        
11 .......I.......... 4/8   
  ........A......... 2/8   
  ..G............... 1/8   
  .......I....R….. 1/8   
29 .......I.......... 16/29   
  .F.....I.......... 1/29   
  ..N....A.......... 4/29   
  .......AA......... 1/29   
  ........A......... 7/29   
37 ........I.........  3/5   
  ........A......... 1/5   































2 GALTSSNTAATNADCAWL 10/11 
  .............X.... 1/11 
5 .................. 1/1 
11 .................. 7/8 
  .........D........ 1/8 
29 .................. 1/3 
  ....N............. 2/3 
37 .................. 2/5 
  .....R............ 1/5 





















 Peptide (p57-73) 
 
   
2 WLEAQEEEEVGFPVRPQV 8/11 
  .........X........ 1/11 
  ........X......... 1/11 
  .......K.......... 1/11 
5 ........G......... 3/3 
11 ........G......... 5/8 
  ........D......... 2/8 
  .......D.......... 1/8 
29 ........D..L...... 1/3 
  ........D......... 2/3 
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